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ABSTRACT OF THESIS
The presence of host disease, such as insulin dependent diabetes mellitus (IDDM) and
chronic hypertension alters the incidence of stroke. Whether these factors also
influence outcome of a cerebrovascular event is less clear. This possibility is even
more obscure in relation to haemorrhagic stroke (ICH), because the presence of
intraparenchymal blood is likely to present an additional factor that could potentially
alter the pathophysiological response to stroke. The processes underlying the
evolution of delayed perihaemorrhagic brain ischaemia, oedema and infarction are still
speculative. The modification of these processes by the presence of cerebrovascular
dysfunction, associated possibly with IDDM or hypertension, could be a contributing
factor for an adverse influence upon outcome. It is also equally intriguing to
hypothesize that host cerebrovascular dysfunction may alter the mechanisms of stroke
evolution, offering an explanation for the failure to translate the spectacular successes
of neuroprotective strategies from animal models of stroke into the clinical
environment.
The aims of this thesis were (i) to investigate whether cerebrovascular dysfunction
linked to a perturbation of nitric oxide (NO)-related control mechanisms, is associated
with IDDM and chronic hypertension; (ii) to assess the extent to which any abnormal
cerebrovascular physiology associated with IDDM and chronic hypertension
contributes to the pathophysiological response to haemorrhagic stroke; and finally (iii)
to determine if endothelin (ET) or neuronally derived NO, which may be implicated in
the development of delayed perilesional ischaemia following ICH in normal animals,
contribute to a potentiated ischaemic burden in ICH associated with IDDM or chronic
hypertension respectively.
In a series of physiological studies, local cerebral blood flow (LCBF) was measured
using the fully quantitative [14C]-iodoantipyrine (IAP) autoradiographic technique, in
areas within the vascular territories of the anterior, middle and posterior cerebral
arteries in spontaneously diabetic (BB) and hypertensive (SHR) rats and appropriate
controls, under basal conditions or following manipulation of NO systems with the
NOS inhibitor A^-nitro-L-arginine methyl ester (L-NAME), the selective neuronal
NOS inhibitor 7-nitroindazole (7-NI) and the NO donor 3-morpholinosydnonimine
(SIN-1). In parallel intracerebral haematoma studies, volumes of significant striatal
oligaemia were measured by computer-based planimetry in the same groups of
animals injected with blood, or silicon oil as a control, and treated with saline, sesame
oil, the non-peptide ETA/ETB receptor antagonist SB209670 or the selective neuronal
NOS inhibitor 7-NI. In the same studies, sections adjacent to those used for
autoradiography were taken for histological analysis, stained with either haematoxylin
and eosin or cresyl violet with luxol fast blue. Differences in blood-brain barrier
(BBB) permeability to a-aminoisobutyric acid (AIB) were measured in the same
groups of animals subjected to experimental ICH, to determine if differences in
permeability contributed to differences in pathology.
The physiological studies revealed that both IDDM and chronic hypertension are
associated with NO-dependent cerebrovascular dysfunction. IDDM is associated with
a reduced basal LCBF, linked to specific perturbation of endothelial NO, but with an
intact NO-related vasodilatory capacity. In contrast, chronic hypertension is
associated with an attenuated NO-associated vasodilatory reserve, in conjunction with
an upregulated neuronal NO system. The haematoma studies revealed that the
presence of intraparenchymal blood, rather than the mass effect, is responsible for the
evolution of delayed perilesional oligaemia, which in turn is exacerbated by the
presence of diabetes mellitus. Finally, although the endothelin antagonist and the
neuronally derived NOS inhibitor resulted in haemodynamic improvement in the non-
diseased animals, both the diabetic and hypertensive rats exhibited resistance to their
beneficial effect.
In conclusion, there is abnormal cerebrovascular homeostasis associated with IDDM
and chronic hypertension resulting in worse outcome following experimental
haemorrhagic stroke. This cerebrovascular pathology results in resistance to
neuroprotection with endothelin antagonists or neuronal NOS inhibitors which are
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effective in otherwise healthy animals. These results are of particular importance since
stroke commonly occurs in patients with assorted "risk" factors that can cause
underlying alterations in cerebrovascular regulation. Extrapolation of the
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Spontaneous intracerebral haemorrhage (ICH) is a common condition and uncertainty
exists regarding optimal therapeutic management (Mendelow, 1991). The initial bleed
may cause limited brain dysfunction, but over the subsequent 24 to 48 hours there
may be progressive deterioration in coma score and neurological deficit (Mayer et al.,
1994). These epiphenomena have been attributed to the development of perilesional
brain ischaemia and oedema (Mendelow, 1993; Yang et al., 1994). The aetiology of
delayed perihaemorrhagic brain ischaemia, oedema and infarction is complex but
relates to the effects of the "mass" lesion on local tissue perfusion pressure and the
release of secondary "toxic" mediators from the haematoma (Nath et al., 1986;
Vanhoutte & Houston, 1985). The occurrence of ICH is commonly associated with
the presence of host risk factors (such as chronic hypertension and diabetes mellitus;
Juvela, 1996), but whether their presence alters the pathophysiological sequelae of
ICH or the efficacy of therapeutic intervention is not known. This hypothesis was
tested in a rodent model of ICH (Nath et al., 1987), with the use of spontaneously
diabetic (BB) and hypertensive rats (SHR). Pathophysiological events such as
perilesional ischaemia and blood-brain barrier (BBB) disruption were measured 24
hours following experimental ICH using fully quantitative autoradiographic
techniques (Blasberg et al., 1983; Sakurada et al., 1978). A 24h delay was used to
allow any putative mediators of vasospasm and BBB disruption released from the
blood clot to act upon the perilesional intraparenchymal cerebrovasculature.
The presence of endothelial dysfunction, affecting mainly extracranial tissues in a
heterogeneous manner, is undoubtedly a complicating factor for both hypertension
and diabetes mellitus (Cohen, 1993; Liischer, 1992). However, the presence of
cerebrovascular dysfunction, if it was established in diabetes mellitus and
hypertension, could be an attractive mechanism for an altered pathophysiological
response following an intracranial haemorrhagic insult. Nitric oxide (NO) plays a
pivotal role in the basal control of vascular tone (Moncada & Higgs, 1993). In the
brain, its role is more complex because NO of non-endothelial origin can affect blood
flow (Faraci & Brian Jr, 1994) and possesses potentially neurotoxic properties
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(Huang et al., 1994). Perturbations of the NO systems have been found in extracranial
tissues of humans and animals with diabetes mellitus and hypertension (Bucala et al.,
1991; Calver et al., 1992). This thesis sets out to test the hypothesis that
cerebrovascular dysfunction complicates diabetes mellitus and hypertension, with
measurement of local cerebral blood flow (LCBF) following manipulation of the
various NO pathways using selective NOS inhibitors and exogenous NO donors, and
employing the same fully quantitative autoradiographic techniques in the rat strains
mentioned above.
Various neuroprotective substances have been used in animal models of occlusive
stroke with spectacular success, but their subsequent use in clinical trials has been
rather disappointing (Hsu, 1993). Some potential neuroprotective agents have also
been evaluated in experimental models of haemorrhagic stroke (Mendelow, 1993;
Sinar et al., 1988). The presence of host "risk" factors has not been taken into
consideration in many of the animal studies, despite the fact that they are present in
most human stroke victims (Juvela, 1996). It is conceivable that these risk factors can
not only affect the outcome, but can also modify the pathophysiological cascades
which are triggered following the pathological insult resulting ultimately in ischaemic
cell death. Therefore, specific therapeutic strategies which take these individual host
factors into account may be more appropriate (Muizelaar, 1996). Along these lines,
antagonists of two putative mediators of ischaemic brain damage (endothelin-1, the
bioavailability of which is promoted by factors released from the blood, Ohlstein et
al., 1991; and neuronal NO, Huang et al., 1994) were tested using the same
haematoma model and quantitative autoradiography, in order to identify any
fundamental differences in the mechanisms that govern the haemodynamic responses
of non-diseased, diabetic and hypertensive animals.
3
1. 2 Spontaneous Intracerebral Haemorrhage (ICH)
J. 2. 1. Incidence
Spontaneous intracerebral haemorrhage (ICH) is common in the United Kingdom (20
new cases per 100000 per year; Mendelow, 1991) and accounts for 10% of all strokes
(Jorgensen et al., 1995). Patients with ICH are younger, with a median age at
presentation of 56 years, than patients with occlusive strokes (Wityk & Caplan, 1992)
who have a median age of 65 years. The incidence of ICH is declining due to better
control of risk factors such as hypertension and more appropriate use of oral
anticoagulation (Furlan et al., 1979). A transient increase in incidence occurred
between 1961 and 1968 due to widespread use of anticoagulants. In the mid '70s a
second increase was noted following the introduction of CT and subsequent
realization that the incidence of ICH had previously been underestimated since many
small haemorrhages had been considered to be thrombotic infarcts (Drury et al.,
1984). African-Americans have a higher risk for ICH, possibly due to a higher
prevalence of hypertension (Broderick et al., 1992). A higher incidence of ICH also
seems to occur in Japan (Tanaka et al., 1982), raising the possibility of a genetic
predisposition to this condition.
I. 2. 2. Mortality andmorbidity
Mortality from spontaneous ICH remains very high (over 50%) and is higher than that
of a similar volume occlusive event (Findley & Weir 1990). This higher mortality is
related to events occurring during the first 48 hours, with 27% of patients dying
during the first day (Fogelholm et al., 1992). In patients surviving this early post-ictal
period however, the mortality becomes similar to that following cerebral infarction
(Franke et al., 1992). Morbidity is also very high. Of the patients surviving an ICH,
49% will be dependent on outside help (Fogelholm et al., 1992). The volume of the
haematoma is one of the crucial factors influencing subacute neurological
deterioration and final outcome (Mayer et al., 1994). Lobar haematomata with
volumes of 40 ml or more are likely to be associated with a delayed deterioration,
most commonly occurring within the first 24 hours of the ictus, unrelated to
haematoma enlargement which invariably occurs within 6 hours after the original
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bleed (Fujii et al., 1994), and carry a worse prognosis. Other factors related to poor
prognosis include location of haematoma, elevated plasma glucose and low Glasgow
Coma Score on admission (Franke et al., 1992; Tuhrim et al., 1995), initial stroke
severity (Jorgensen et al., 1995), old age, intraventricular extension and
hydrocephalus (Fogelholm et al., 1992). The presence of ventricular blood probably
reflects the size of the bleed and may not be independently important. Patients on oral
anticoagulants often have large haematomata, with substantially higher mortality rates
(Hart et al., 1995; Radberg et al., 1991). Similarly, haemorrhages associated with the
use of thrombolytic agents for the treatment of acute myocardial infarction have a
grave prognosis (Kase et al., 1992; Sloan et al., 1995). Haemorrhages occurring from
a pre-existing AVM are frequently non-fatal (Kase, 1995). Markedly elevated blood
pressure on admission adversely affects prognosis (Dandapani et al., 1995).
1. 2. 3. Pathophysiology
Studies addressing the cerebral pathophysiological sequelae following ICH have been
conducted using various animal models. The main bulk of current information arises
from experimental work in rodents, where the temporal evolution of the acute and
subacute pathophysiological events that accompany an ICH have been investigated.
Following experimentally induced ICH, an area of early ischaemia develops in the
perilesional brain parenchyma, possibly due to compression of the microcirculation
immediately surrounding the "mass" lesion, even in the absence of generalized
increase of intracranial pressure (ICP) (Bullock et al., 1984; Kingman et al., 1987;
Nath et al., 1986). No evidence of an acutely raised ICP has been found following
injection of a mass lesion upto lOOpl, which volume for volume is equivalent to a
100ml haematoma in the human brain (Kingman et al., 1988). Gradually, this
compression of the microcirculation around the haematoma settles. This is probably
due to clot retraction (Wagner et al., 1996) and lysis (Masuda et al., 1988) associated
with spatial rearrangements in the brain, so that by 4 hours after the insult the initial
ischaemic zone around the clot has almost disappeared (Nath et al., 1987). There is
also strong speculation that "toxic" metabolites are released from the clot (Vanhoutte
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& Houston, 1985) inducing vasospasm in the intraparenchymai perilesional arterioles
and disruption of the BBB with development of vasogenic oedema (MacKenzie,
1996; Mendelow et al., 1986). Experimental evidence supporting this hypothesis
arises from studies in which an intrastriatal injection of silicon oil (with viscosity
similar to that of blood), induces less acute perilesional oligaemia compared to an
equivalent volume of unclotted arterial blood (Jenkins et al., 1990).
There are reports from clinical studies, where these concepts of perilesional ischaemia
and oedema can be applied to human sufferers of ICH. In these studies it has been
reported that patients with ICH can suffer delayed neurological deterioration in the
absence of rebleeding (Mayer et al., 1994), independent of global ICP elevations
(Papo et al1979) and where the presence of perilesional ischaemia has been
indicated with the use of transcranial doppler (Mayer et al., 1996).
1. 2. 4. Ischaemia associated with ICH
Ischaemic brain injury is a rather complex event and intensive research is being
pursued in an attempt to understand the nature of this process (see Siesjo et al.,
1995). Following cessation of blood flow (CBF) cell death due to energy failure
occurs in the core of an ischaemic lesion (Siesjo, 1992). However, in the zone
surrounding the core, which is perfused by significantly compromised CBF, cells can
remain potentially viable for a variable but limited time, and eventually die (Fisher &
Garcia, 1996). This area of constrained blood supply, where the metabolic demands
are met for a limited period, is termed the "penumbra" (Hossmann, 1994). The
availability of glucose in the presence of ischaemia can result in further compromise of
the brain tissue, because the cells shift to anaerobic glycolysis with subsequent
creation of tissue acidosis. This presents one potential mechanism explaining the
detrimental effects of hyperglycaemia in relation to cerebral ischaemia. The role of
hyperglycaemia in relation to cerebral ischaemia is also covered in the Insulin-
dependent diabetes mellitus section of this thesis.
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Experimental findings support the hypothesis that following the initial "stroke" ictus
(occlusion of an intracranial artery or formation of an intraparenchymal haematoma)
secondary processes evolve, upon an already vulnerable tissue, resulting in the
liberation of excitotoxic neurotransmitters, presumably as a result of neuronal
depolarization or spreading depression originating in the core of ischaemia. Upon
activation of neuronal receptors (mainly the NMDA) abnormally large amounts of
Ca++ enter the cells, with subsequent activation of proteolytic enzymes (Bartus et al.,
1994) and further cell damage.
There is also evidence that an occlusive cerebrovascular event is commonly followed
by subsequent spontaneous reperfusion. Early reperfusion through a previously
occluded artery is obviously essential for the salvage of ischaemically compromised
tissue, but delayed reperfusion has various potentially deleterious effects due to
generation of oxygen-derived free radicals (Kim et al., 1996; Matsuo et al., 1995) and
inflammatory sequelae (Connolly Jr et al., 1996), including activation of microglia
(Gehrmann et al, 1995) and cytokines (Yamasaki et al., 1995). Finally, the as yet ill-
defined role of apoptosis in relation to cerebral ischaemia is currently under intense
investigation (Du etal., 1996).
Ischaemic events associated with ICH may follow a somewhat different pathway
because of the presence of a "mass" lesion compressing the surrounding
microvasculature, with creation of local tissue pressure gradients, and also the
presence of blood with potentially vasospastic properties (Mendelow, 1993).
Interestingly, in vitro studies have also shown that endothelin (ET) production is
induced by blood constituents in a time-dependent manner, and ET itself is a very
potent vasoconstrictor in the cerebrovasculature (Sharkey et al., 1993). There is
additional evidence that haemoglobin quenches nitric oxide (NO) (Martin et al.,
1985), a very potent vasodilator, possibly providing further gravity to the concept of
delayed perilesional ischaemia following ICH. The roles of both NO and ET in
relation to cerebral ischaemia are covered more extensively in the Nitric Oxide
section of this thesis.
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It should also be considered that an analogy to the reperfusion injury of occlusive
stroke might also exist in the perilesional brain following ICH, once the action of the
putative spasmogens resolves. In addition, iron from haeme can catalyze lipid
peroxidation of cellular membranes contributing to the severity of the ischaemic cell
damage (Halliwell & Gutteridge, 1990). Although the brain has all the prerequisite
systems (including astrocytes and microglia) to convert haemoglobin iron to ferritin
and haemosiderin and thus inactivate it (Koeppen et al., 1995), these enzyme systems
may be adversely affected by ischaemia. It is also noteworthy, in relation to the role of
inflammatory mediators upon the evolution of ischaemia following haemorrhagic
stroke, that whole body irradiation (resulting in inactivation of white cells) attenuated
ischaemic damage in the perilesional striatum following intrastriatal microballoon
inflation in the rat (Kane et al., 1990).
Studies evaluating the presence of delayed perilesional ischaemia following
experimental ICH are lacking. A microballoon has been used in the rat to simulate the
"mass" effect of the haematoma, and experiments have been undertaken with the use
of this model addressing the role of surgical intervention in ICH. Perilesional
ischaemia was evident at 24 hours, but animals in which the balloon was deflated 4
hours after the inflation had a much better outcome in terms of haemodynamic
compromise (Nehls et al., 1990). However, the microballoon is devoid of the putative
spasmogens released from a blood clot. In another study, pretreatment with the
calcium antagonist nimodipine improved striatal CBF 4 hours after the production of
an experimental haematoma (Sinar et al., 1988). In collagenase-induced striatal ICH
in the rat (a model of haemorrhagic transformation in an existing infarct), ischaemic
levels of LCBF were observed in the caudate at 24h (Rosenberg et al., 1992).
1. 2. 5. Oedema following ICH
Brain oedema is generally divided into cytotoxic and vasogenic types depending upon
whether the BBB is intact or disrupted (Kimelberg, 1995; Klatzo, 1967). In the
context of ICH, an additional form of oedema should be considered generated by
osmotic stress from the clot products (Yang et al., 1994). This latter form of oedema
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develops probably quite early (~lh) after the onset of the haemorrhage presumably as
a result of clot retraction and release of soluble protein into the parenchymal tissue
(Wagner et al., 1996).
Oedema formation around the haematoma generally resembles, with certain
exceptions, that occurring during focal ischaemia; it presents at 6 to 12 hours
following the ictus and this initial phase results mainly from disruption of BBB
presumably following release from the blood of putative mediators of vasogenic
oedema (Wahl et al., 1988) such as thrombin (Lee et al., 1995; Lee et al., 1996); it
reaches a peak at 24 hours, and remains constant for around 5 days before it starts
subsiding. At 24 hours following the bleed the oedema seems to be a result of direct
cytotoxicity and BBB disruption (Yang et al., 1994).
This temporal evolution of oedema is in contrast to what occurs in occlusive focal
cerebral ischaemia, where the cytotoxic phase of oedema occurs early (Menzies et al.,
1993). A possible explanation for this discrepancy is that factors released in a delayed
fashion from the clot cause vasospasm in the surrounding vessels, contributing to
ischaemia. Studies to test this possibility have not been performed, and in those
reports where the temporal evolution of oedema following experimental ICH was
addressed (Yang et al., 1994), LCBF in the perilesional area was not measured. Total
ipsilateral striatal CBF was however measured, and although a reduction in CBF was
noted at 24 hours compared to earlier time points, it did not reach ischaemic levels
(Yang et al., 1994). Not only did this paradigm fail to measure small, localized areas
of perilesional ischaemia, it also failed to account for any possible reactive hyperaemia
associated with the insult.
I. 2. 6. Potential modifications ofpathophysiology ofICH by "host" riskfactors
Flypertension, insulin-dependent diabetes mellitus (IDDM) and aging (Davis et al.,
1995, Sutherland et al., 1996) are associated with increased incidence and worse
outcome following cerebral ischaemia. Although chronic hypertension is very
commonly associated with ICH and experimental studies have shown that occlusive
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stroke in hypertensive animals is associated with worse outcome (Coyle, 1984), its
association with increased morbidity following ICH is far from clear. In an
experimental study using spontaneously hypertensive rats (SHR), there was a
significantly higher acute mortality in the hypertensive group following striatal
injection of a blood volume of 400pl (Gonzalez-Darder & Duran-Cabral, 1990). In
contrast, studies in humans report that hypertensive patients have worse outcome
following ICH probably because they have larger bleeds (Jorgensen et al., 1995) and
not because the pathophysiological response to the haemorrhage is different from that
of non-hypertensives. Interestingly, studies have also emerged stressing the fact that
inherited alterations of vascular function (manifest in an impairment of endothelium-
dependent vasorelaxation) may, independently of blood pressure, contribute to the
pathogenesis of stroke in hypertensive animals (Volpe et al., 1996). Likewise, IDDM
is associated with worse outcome following occlusive stroke in humans and animal
models, but whether this is true following ICH has not been investigated.
Attempts to translate the spectacular successes of neuroprotective strategies from
animal models of stroke into the clinical environment have, to date, been largely
disappointing. Since most human stroke victims suffer from on-going vascular disease
processes, which might be both actively responsible for the stroke and at least
contribute to the pathology once the stroke has occurred, it is attractive to
hypothesize that their presence may alter the pathophysiological sequelae of
ischaemia. In relation to ICH this association is even more relevant, because if blood
products trigger additional delayed processes (ET production, NO quenching, BBB
disruption by thrombin and other mediators), the presence of "host" cerebrovascular
dysfunction may alter the response. There is evidence of vascular dysfunction
complicating both chronic hypertension and IDDM in extracranial vascular tissues, so,
it is worth investigating whether this may also be the case in the cerebrovasculature.
Additionally, these pathological processes seem to evolve at a time point that the
possibility for neuroprotection becomes more realistic.
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Experimental studies in support of the hypothesis that the presence of background
vascular pathology can modify the pathophysiology of cerebrovascular events, arise
from studies that show opposite patterns of response to reperfusion following
experimental middle cerebral artery occlusion (MCAO) in SHR when compared to
normal rats (Kurokawa & Tranmer, 1995; Selman et al., 1994). In these studies SHR
had a worse outcome following ischaemia/reperfiision compared to permanent
ischaemia, whereas the non-hypertensive animals had a better outcome following
ischaemia/reperfusion compared to permanent ischaemia. The SHR are also resistant
to neuroprotection with excitotoxic neurotransmitter (glutamate) antagonists
following focal ischaemia (Roussel et a/., 1992).
1. 2. 7. Experimental Models ofICH
Experimental models of ICH have been available since the 1960s and commonly
involve the injection of autologous blood into the frontal lobe of anaesthetized dogs,
cats or monkeys (Sussman et a/., 1974; Takasugi et ai, 1985; Whisnant et al., 1963),
and more recently smaller animals (rodents). Rodents have been found to provide a
convenient and suitable model of ICH. They are inbred providing genetic
homogeneity within strains, there is close resemblance of the cerebrovascular anatomy
and physiology to that of higher species, and certain strains are associated with the
presence of background pathology akin to human disease (i.e. the BioBred-BB rat
and the SHR strain).
Several approaches have been developed for the production of ICH in rodents. Most
groups inject autologous arterial blood in the striatum of the anaesthetized animal,
with varying speed to avoid reflux. During the original attempts in Glasgow, blood
was injected under arterial pressure, the whole injection lasting less than lmin (Nath
et al., 1987). In a subsequent modification of this model the blood was introduced in
the form of an infusion rather than an injection with a speed of infusion -lOpl.min"1
(Masuda et al., 1988). In an attempt to overcome the problem of reflux, the group
from Glasgow used a microballoon (Nehls et al., 1988), which could be deflated, to
simulate haematoma removal However, despite the interesting results obtained with
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the microballoon model, the physical characteristics of the balloon were substantially
different from that of a blood clot.
Problems associated with the use of rats for experimental ICH include the fact that the
brains of these animals have very limited amounts of white matter tissue, making it
difficult to simulate the commonly occurring lobar haematomata in humans. In
addition, the small size of the rat brain makes reflux of blood along the needle track
problematic. In an attempt to reduce the backflux of injected blood along the needle
track, the "double injection" model has been recently described. A small amount of
blood is initially injected, followed by an interval of 7min before the final injection is
performed, thus allowing the first injection to clot and block the potential pathways of
backflux (Deinsberger et al., 1996).
In an effort to overcome the problems of introducing exogenous blood, Rosenberg
injected collagenase, a proteolytic enzyme that destroys the vascular wall, into the
striatum of the rat (Chesney et al., 1995; Elger et al., 1994; Rosenberg et al.,
1990a,b; Rosenberg & Navratil, 1994). This is more akin to a haemorrhagic
transformation of an occlusive infarct in the man, rather than a primary ICH. Bleeding
occurred lOmin after the injection, coalescing into a mass lesion around 4 hours, and
at 24 hours there was a narrow band of poorly staining parenchyma surrounding the
clot. The final lesion is a confluent area ofmultiple foci of microscopic haemorrhages.
The temporal evolution of oedema and the presence of delayed (24h) striatal
ischaemia associated with this model, resembles the other rodent models of ICH.
However it must be stressed that with this model the volume of the haematoma is very
extensive, occupying virtually the entire caudate nucleus (Lyden et al., 1997).
The development of a rat strain, the stroke-prone spontaneously hypertensive rat
(SHRSP) was reported by Yamori and his colleagues in 1974, that had very high
blood pressure and a high incidence of stroke. This was derived from the
spontaneously hypertensive rat (SHR) and exhibited an 80% to 90% incidence of
cerebral lesions during the first year of life. However, most of the lesions that develop
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are occlusive rather than haemorrhagic in origin and their incidence also depends on
nutritional factors (Yamori et al., 1984). This, along with the lack of reproducibility in
the spontaneous haemorrhagic lesions, makes this model far from ideal for the study
of spontaneous ICH.
Experiments in larger animals (pigs) have been combined with injection of
thrombolytic agents and clot aspiration at certain time points following the injection of
the blood. The purpose of this was to simulate haematoma evacuation, in an attempt
to ascertain any benefits from surgical intervention (Wagner et al., 1995 & 1996).
Another advantage associated with the use of these animal models is that they have a
comparable volume of white matter to that of the human brain. The disadvantage of
using larger animals is that, appropriate models of spontaneous host diseases, like
chronic hypertension or diabetes mellitus (Muizelaar, 1996), cannot be used.
The use of transgenic animals, is and will undoubtedly continue providing new
insights in relation to cerebrovascular physiology and pathology. It is an area of
scientific research in constant evolution, but since it is currently confined mostly to
mice (Johns et al., 1996; Shuldiner, 1996), it is technically difficult to incorporate
them into studies that address the pathophysiology of ICH.
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1. 3. Insulin-Dependent Diabetes Mellitus (IDDM)
1. 3. J. Pathogenesis and role ofnitric oxide (NO)
Diabetes mellitus is a metabolic disorder associated with functional and structural
abnormalities in a variety of organs and systems of the body. The aetiology of the
disease is still obscure, but the bulk of scientific evidence suggests that immunological
factors play a major role (Pankewycz et al., 1995). The histological evidence of
"insulitis", the presence of islet cell antibodies and of increased levels of "activated" T
lymphocytes provide supportive evidence that the destruction of the pancreatic beta
cells is mediated by autoimmune processes. Current evidence suggests that the release
of highly toxic free radicals (either directly by infiltrating macrophages or secondary
to secretion of cytokines, such as interleukin-1, from activated macrophages) may be
a critical event in the inflammatory destruction of islet /?-cells (Rabinovitch, 1993).
Nitric oxide (NO) has been proposed by several scientific groups as the specific free-
radical species which acts as the primary effector molecule in cytokine-mediated (3-cell
dysfunction (resulting in decreased insulin secretion) and destruction in vitro (Corbett
& McDaniel, 1992; Kroncke et al., 1991; Sjoholm, 1996) and in vivo (Lindsay et al.,
1995; Wu, 1995).
1. 3. 2. General Complications
Diabetes is associated with the development of complications in several tissue organs.
Areas rendered particularly vulnerable include the retina, the kidney and the peripheral
nerves. The presence of both macro- and microvascular changes in relation to IDDM
result in hypertension, accelerated atherogenesis, thrombosis and ischaemia (Colwell,
1991; Tooke, 1995), which can all cause tissue dysfunction. The pathogenic
mechanisms for the evolution of these processes are still rather obscure, with earlier
studies concluding that their appearance is independent of the degree of diabetic
control (Kannel & McGee, 1979; Kroc Collaborative Study Group, 1984), suggesting
that it was the disease process itself which was responsible and not exposure to
hyperglycaemia or insulin treatment. However, more recent work (DCCT Research
Group, 1993; Reichard et al., 1993) suggests a more complex causal relationship
between the disease process and therapeutic intervention.
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1. 3. 3. CNS Complications
Although the cerebral circulation has been found to be subject to pathological change
similar to that found in the periphery (Aronson, 1973; Grunnet, 1963), the effects
upon cerebrovascular physiology were previously thought to be rather subtle, and
often went unrecognized. More recently however, it has become apparent that neither
the brain nor its vasculature are spared from the effects of diabetic pathology (McCall,
1992; Mooradian, 1988), and altered blood/brain transport (Boyle et al., 1995;
Gjedde & Crone, 1981; McCall et al., 1982), cerebral blood flow (Grill et al., 1990;
Macleod et al., 1994; Tallroth et al., 1993), and brain metabolism, as well as effects
on neurons and glia, are all associated with the disease process.
Diabetic patients are at higher risk of developing stroke, both occlusive and
haemorrhagic (Juvela, 1996; Lavy et al., 1973; Stegmayr & Asplund, 1995).
Epidemiological studies reveal that the presence of the disease process seems to also
alter the outcome following stroke (Jorgensen et al., 1994). The complexity of
functional and structural derangements associated with IDDM make it difficult to
study the pathophysiological mechanisms responsible for the increased vulnerability of
the diabetic brain to ischaemia.
1. 3. 4. Role ofhyperglycaemia in the CNS complications
Hyperglycaemia is commonly associated with IDDM and in extracranial tissues seems
to be correlated with the extent of vascular complications (Dahl-Jorgensen et al.,
1994; DCCT Research Group, 1993) although a direct cause-and-effect relationship is
not evident in all the tissues. Its presence is also associated with exacerbation of
ischaemic cell damage in animal models of cerebral ischaemia (Duverger &
MacKenzie, 1988; Nedergaard & Diemer, 1987), with very few contradictory results
(Kraft et al., 1990).
In severe ischaemia, acute hyperglycaemia potentiates brain lactic acid production and
increases tissue acidosis (Smith et al., 1986). The increased H" generation leads to a
sustained rise in intracellular CaT+ with all the detrimental effects that this carries. This
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scenario occurs while cerebral blood flow (CBF) is reduced to a point where glucose
delivery becomes limiting for glucose phosphorylation and subsequent glycolysis
(Siesjo et al., 1993). However, under less severe ischaemia, glucose phosphorylation,
rather than glucose delivery and blood-brain barrier transport, is the limiting factor.
Hyperglycaemia under these conditions will not affect brain lactate generation, but
can still be associated with worsened brain damage, unrelated to acidosis potentiation
(Hoffman et al., 1990; Warner et al., 1995). In some animal studies of occlusive
stroke (Wagner et al., 1992), but not others (Nedergaard et al., 1988),
hyperglycaemia was also associated with more depressed CBF in the area supplied by
the occluded middle cerebral artery, as well as delayed blood flow recovery following
reperfusion (Kittaka et al., 1996).
Recent studies have also revealed that hyperglycaemia is associated with an increase
in endothelin (ET) concentration in cultured endothelial cells in vitro (Yamaguchi et
al., 1990), a decrease in adenosine production following ischaemia and reperfusion in
vivo (Hsu et al., 1991), and with increases in inflammatory cell adhesion molecules
(ICAM-1) in vitro (Baumgartner-Parzer et al., 1995a). These may offer potential
explanations for the potentiated cerebrovascular sequelae of ischaemia. In vivo studies
in extracranial tissues have also raised the possibility that ET may be responsible for
some of the microvascular abnormalities associated with drug-induced diabetes
(Cameron et al., 1994). However, contradictory reports of down-regulation of ET-1
receptors in the kidney in association with activation of protein kinase C (PKC)
(Awazu et al., 1991) and resistance to ET-l's biochemical actions induced by
elevated glucose (De La Rubia et al., 1992) have also emerged. High plasma glucose
levels are also associated with apoptosis in cultured endothelial cells (Baumgartner-
Parzer et al., 1995b).
1. 3. 5. Role ofoedema in the CNS complications
One of the potential mechanisms for the increased susceptibility of diabetics to brain
injury is a "leaky" BBB associated with the disease. Certainly, in extracranial tissues
of humans, IDDM is associated with increased vascular permeability, even at early
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stages of the disease (Parving, 1976, Viberti, 1983). In vitro studies showed that
vascular permeability was modestly increased in the brains of streptozotocin (STZ)-
induced diabetic rats (Wautier et al., 1996) but studies in BioBred (BB) rats revealed
a relative resistance of brain to the increased vascular permeability, which was
nevertheless present in extracranial tissues (Williamson et al., 1987). However, in
vivo studies in STZ rats showed a very subtle increase in BBB permeability in the
hypothalamus of the diabetic animals (Lorenzi et al., 1986), as well as selective
extravascular escape of albumin into the cerebral cortex (Oztas & Ktigiik, 1995;
Stauber et al., 1981). In contrast, another study employing the same model of drug
induced diabetes failed to reveal any increase in BBB permeability associated with the
disease (Bradbury et al., 1991).
In the context of experimental (Dietrich et al., 1993; Warner et al., 1987) and human
(Berger & Hakim, 1986) cerebral ischaemia, acute hyperglycemia worsens acute BBB
injury, but interestingly chronic hyperglycaemia may generate adaptive processes to
counter this effect (Sieber et al., 1994).
I. 3. 6. Role ofendothelial dysfunction in the CNS complications
Microvascular pathology is commonly associated with IDDM. Evidence of endothelial
dysfunction, i.e. the presence of abnormal vascular responses to agonists exerting
their action via endothelial intermediates in the absence of structural abnormality, is
present in various extracranial tissues (Cohen, 1993; Oyama et al., 1986; Poston &
Taylor, 1995). This suggests altered bioactivity of either vasodilators (endothelium-
derived NO, prostacyclin, endothelium-derived hyperpolarizing factor) or
vasoconstrictors (prostaglandin, endothelin). Potential mechanisms for this
dysfunction include alterations in the polyol pathway, increased production of oxygen-
derived free radicals (Cameron & Cotter, 1995) and protein kinase C, alterations in
Na+, K+-ATPase (Xia et al., 1995) and production of advanced glycosylation end
products (AGE) (Bucala et al., 1991), all associated with the disease process.
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The presence of abnormal endothelial function in the brain of diabetics is not well
established, but indirect evidence suggests that this may indeed be the case.
Pathophysiological effects of the disease upon the cerebral circulation are manifest in
an impaired autoregulatory response to alterations in systemic blood pressure
(Bentsen et al., 1975; Kastrup et al., 1986), altered C02 reactivity even in young
patients who lack structural vascular complications (Griffith et al., 1987), impaired
cerebrovascular reactivity to lidocaine (Kastrup et al., 1990) and acetazolamide
(Rodriguez et al., 1993), and regionally distributed cerebral blood flow decreases in
animal models (Duckrow et al., 1987; Harik & LaManna, 1988; Jakobsen et al.,
1990), all being processes in which the endothelium may play an important role.
In the STZ-induced animal model of diabetes there is clear evidence, from both in
vitro and in situ (cranial window) studies, of impaired cerebrovascular responsiveness
to a variety of vasoactive compounds including ADP (Mayhan, 1989), serotonin
(Mayhan, 1989; Rosenblum & Levasseur, 1984), /^-adrenoceptor agonists (Mayhan,
1994), and acetylcholine (Mayhan et al., 1991). Studies performed in vivo showed a
reduced effect of muscarinic agonists upon blood flow, which was regionally variable
(Pelligrino et al., 1992). Interestingly however, the STZ rat model does not appear to
display the same reduced cerebrovascular C02 reactivity found in humans (Pelligrino
& Albrecht, 1991), although even in that model the CBF response to acute
hypoglycaemia was attenuated in the diabetic animals. Moreover, in the STZ model,
and contrary to findings in human sufferers of the disease, autoregulation is preserved
(Rubin & Bohlen, 1985). It should be pointed out that the endothelial dysfunction in
STZ-treated rats is rather complex especially in peripheral vascular beds, where in
vivo studies have reported that the pressor response to an inhibitor of NO synthase
(L-NAME) was attenuated (Kiff et al., 1991a) whilst vasodilator responses to
acetylcholine (which establishes some of its vasoactive effects through stimulation of
NO release) remained intact (Kiff et al., 1991b).
The potential presence of cerebrovascular dysfunction in IDDM would be of
particular importance not only in relation to the physiological control of cerebral
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circulation, but also because some of these endothelial mediators (NO, ET and
prostaglandins) have recently been implicated in the pathophysiology of stroke
(Barone et al., 1995; Huang et al., 1994; Warso & Lands, 1983). Recent evidence
suggests that there is selective depression of endothelium-dependent dilatation in the
cerebrovasculature during experimental cerebral ischaemia (Rosenblum & Wormley,
1995), rendering the presence of endothelial dysfunction under physiological
conditions an even more important factor that could complicate the responses of the
host to ischaemia.
1. 3. 7. Role ofstructural changes, biochemical and metabolic abnormalities in CNS
complications
The disease is also associated with structural changes in the cerebrovasculature of
both humans (Johnson et al., 1982) and animals with drug-induced diabetes (Moore et
al., 1985; Mukai et al., 1980). Interestingly, the expression of collagen IV and
fibronectin in endothelial cells increases and the activity of enzymes involved in
collagen synthesis is enhanced under high-glucose conditions. This effect of
hyperglycaemia persists for several weeks after restoration of normoglycaemia (Roy
et al., 1990). Increased atherosclerosis has also been reported in association with
STZ-induced diabetes (Kunjathoor et al., 1996).
Reduction in the density of cerebral cortical microvessels has also been reported in
STZ rats (Jakobsen et al., 1987). The presence of rheological abnormalities, such as
increased viscosity, hyperlipidaemia, decreased red blood cell deformability and
increased procoagulant activity is also common in IDDM. An increase in plasma
viscosity (Barnes et al., 1977) and increased adhesion of platelets to endothelial cells
(MacMillan et al., 1978; Wautier et al., 1981) may contribute to cerebrovascular
dysfunction in diabetes. Interestingly, the haemorrheological changes associated with
experimental diabetes reveal regional variations (Sutera et al., 1992). Further
experimental work has also shown that tissue plasminogen activator is downregulated
in diabetic but not acutely hyperglycaemic rats following middle cerebral artery
occlusion (MCAO), possibly linked to delayed restoration of CBF during reperfusion
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(Kittaka et al., 1996). Delayed metabolic recovery (Sutherland et al., 1992) as well as
slower recovery of ion homeostasis (Tyson et al., 1996) after reperfusion, has also
been observed in spontaneously and drug-induced diabetic rats following forebrain
ischaemia.
In the aetiology of diabetic neuropathy, metabolic alterations such as decreased myo¬
inositol levels (secondary to an increase in sorbitol formation), decreased Na+, K+-
ATPase (Greene et al., 1987; Ver et al., 1995) and Ca2 -ATPase (Janicki et al., 1994)
activity, mitochondrial dysfunction and altered calcium signaling (Levy et al., 1994),
have been reported. Whether similar abnormalities exist in the diabetic brain is not
clear. It should also be mentioned that contradictory reports have been published
regarding the potential role of decreased Na+, Kf-ATPase activity and decreased myo¬
inositol in the diabetic microvessels (Mooradian et al., 1994; Sussman et al., 1988).
With respect to the potential role of metabolic alterations in relation to the excessive
production of free radicals in diabetes, which can in turn be responsible for vascular
damage, in vitro and in vivo evidence exists of a link between diacylglycerol (DAG)-
PKC activation and production of free radicals, induced by hyperglycemia in
extracranial vascular smooth muscle cells (VSMC) (Kunisaki et al., 1996).
1. 3. 8. Role ofadvanced glycosylation endproducts (AGE) in CNS complications
The development of AGE in diabetes (Brownlee et al., 1988) has rather complex
effects (Cameron & Cotter, 1996; Kihara et al., 1991), both haemodynamic but also
directly cytotoxic. The haemodynamic effects are manifested primarily by the
quenching of endothelial NO by subendothelial AGE, resulting in reduction in its
bioactivity (Bucala et al., 1991). However, studies have also shown that AGE are
directly cytotoxic in the cerebral tissue (Zimmerman et al., 1995). AGE-proteins and
peptides may enhance tissue damage by binding to AGE-specific receptors on
macrophages, endothelial cells (Schmidt et al., 1995) and other cell types including
VSMCs (Schmidt et al., 1996), to mediate capillary leakage, cytokine production,
enhanced procoagulant activity on the endothelial surface and increased generation of
reactive oxygen intermediates (Vlassara & Bucala, 1996). Their potential involvement
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in the vulnerability of the diabetic brain to exacerbated cerebral ischaemia is very
probable, but whether their precise role is haemodynamic or cytotoxic is far from
clear.
1. 3. 9. Animal models ofdiabetes mellitus
The most commonly used model of the disease is the STZ-induced diabetic rat. The
development of diabetes in this model involves an autoimmune component, with
elevated endogenous NO participating in that action (Lukic et al., 1991; Tanaka et
ai, 1995). However, the existence of other mechanisms for the diabetogenic function
of STZ, such as the direct release ofNO from the nitroso moiety of STZ (Turk et al.,
1993) complicate the interpretation of the pathogenesis of diabetes in this model.
Animals with STZ-induced diabetes are not dependent on exogenous insulin for
survival, despite the presence of severe hyperglycaemia and malnutrition, and are
ketosis-resistant (Pelligrino et al., 1989). In an attempt to create an animal model with
plasma glucose levels more closely related to those of diabetic subjects, some
investigators have administered nicotinamide prior to the injection of STZ, which
results in a milder form of diabetes (Pugliese et al., 1989). Additionally, in most
studies with STZ, the duration of diabetes is rather short. This makes it impossible to
address the effects of AGE, which need at least 6 to 8 weeks to develop, in the
evolution of any observed complications. Interestingly, treatment with insulin reverses
the abnormalities found in peripheral tissues (Kihara & Low, 1995) and the brain
(Bdmont & MacKenzie, 1995; Warner et al., 1992), indicating that this could be best
described as a model of hyperglycaemia rather than diabetes per se. Finally, and
probably most importantly, studies have shown that STZ has no diabetogenic effect in
human /Tcells (Eizirik et al., 1994). Similarly, alloxan damages pancreatic /Tcells by
an oxidative mechanism and it has been used in a context similar to that of STZ, but
again the same problems regarding the lack of any diabetogenic effect in human (3-
cells occur in this model too (Eizirik et al., 1994).
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Diabetes has also been induced in larger animals (dogs) following pancreatectomy. In
this model the vascular pathology associated with the disease does not develop until 2
to 3 years of poorly controlled diabetes have elapsed (Sieber et al., 1993 & 1994). It
is evident therefore, that it is used as a model of hyperglycaemia rather than diabetes
mellitus by most groups.
The BioBred (BB) rat strain provides an attractive model for the study of juvenile-
onset IDDM. The involvement of genetic and immune aetiological factors in the
pathogenesis of the disease (Crisa et al., 1992; Lee, 1994), and especially the
dependence on exogenous insulin for prevention of ketoacidosis together with the
development of diabetic complications in a variety of organs (Marliss et al., 1982),
represent a condition more akin to the human disease process than that afforded by
models of drug-induced diabetes (Eizirik et al., 1994). Pathological changes in the
retina, kidneys and peripheral nerves have been observed as early as 3 weeks
following the onset of diabetes (Baird, 1989). There is no detectable circulating
immunoreactive insulin (Baird, 1989) and endothelial dysfunction has been described
in extracranial tissues of the diabetic animals (Kappagoda et al., 1989; Lindsay et al.,
1997; Meraji et al., 1987).
The transgenic mouse studies have provided insights into fundamental questions of
how immune tolerance is established and broken down, delineating the potential
effector mechanisms involved in autoimmune destruction associated with the
pathogenesis of IDDM. However, transgenic technology has not yet produced models
which have been so comprehensively characterized as for example the BB rat strain
(Lipes & Eisenbarth, 1990). Moreover, the size of mice is prohibitive for the study of
the associated central nervous system complications.
22
1. 4. EssentialHypertension
1. 4. 1. Pathogenesis ofHypertension
Chronic hypertension is characterized by altered haemodynamic balance, in particular
increased peripheral vascular resistance (Pickering, 1936). The precise mechanisms
for the raised peripheral resistance are not clear, with neural (e.g. sympathetic nervous
system and neuropeptide Y), circulating (e.g. angiotensin II, noradrenaline and
vasopressin) and local factors (e.g. nitric oxide, endothelin-1 and prostaglandins)
potentially contributing to the increased vascular tone (Shepherd, 1990). Within the
vascular wall, structural and functional alterations may also occur (Folkow, 1990).
The endothelium has a strategic anatomical position that allows it to regulate the
function of both VSMCs and circulating blood cells (platelets, monocytes). The
release by the endothelium of various mediators that effect either contraction
(endothelin and certain prostaglandins) or dilatation (NO, prostacyclin and
endothelium-derived hyperpolarizing factor) of the underlying VSMC, makes an
imbalance between those opposing influences an attractive pathogenetic mechanism of
the disease, as well as a source for its associated complications (Luscher, 1994).
1. 4. 2. Role ofNitric Oxide (NO) in the pathogenesis ofhypertension
Although it has been proposed that an impaired release of endothelial vascular
relaxing factors might underlie the pathogenesis of chronic hypertension (Luscher &
Vanhoutte, 1986; Snyder, 1995; Taddei et al., 1996; Woodman, 1995), the
involvement of NO in the aetiology of the disease process remains controversial.
Studies in hypertensive human subjects have shown that there is abnormal NO activity
associated with hypertension (Calver et al., 1992; Panza et al., 1990), but divergent
results have also emerged (Angus & Lew, 1992; Cockroft et al., 1994). In
experimental animal models of chronic hypertension, there is increasing evidence that
endothelium-dependent relaxation is heterogeneously affected (Luscher, 1992), with
normal function maintained in the renal and coronary arteries (Kelm et al., 1995;
Nava et al., 1995; Tschudi et al., 1991), but impaired function in aorta, mesenteric,
carotid and cerebral circulation (Crespo et al., 1996; Cuevas et al., 1996; Dohi et al.,
23
1990; Luscher & Vanhoutte, 1986). These observations could explain not only
contradictory experimental observations (Dominiczak & Bohr, 1995), but also the
selective vulnerability of certain tissues, such as the brain, to hypertensive
complications. Interestingly, recent findings of a reduced release of endothelial NO
from aged aorta but not from aged pulmonary artery in response to agonists, is
consistent with the hypothesis that elevated BP may cause a reduction in the
production of endothelially derived NO (Tschudi et al, 1996a). Overall, there is no
clear consensus as to whether NO synthesis is impaired in human hypertension and, if
it is, whether the defect is primary or secondary (Benjamin & Vane, 1996).
1. 4. 3. Role ofendotheliti (ET) in the pathogenesis ofhypertension
The exact role of endothelin (ET) in the pathogenesis of hypertension is rather
obscure, with experimental findings supporting its role only in fulminant forms or at
discrete stages of the disease (see Rubanyi & Polokoff, 1994). In experimental models
of hypertension the information available is equally conflicting. In the spontaneously
hypertensive rats (SHR) chronic blockade of ET-1 did not alter MABP (Li &
Schiffrin, 1995). In contrast, ET has been shown to play an enhanced role in
deoxycorticosterone acetate (DOCA)-salt hypertension (Schiffrin et al., 1995). It is
also probable that it may possess a modulating role since subthreshold concentrations
of ET have a potentiating effect on vasoconstriction induced by other agonists in
hypertensive rats (Dohi et al., 1992).
J. 4. 4. Hypertensive complications
The vasculature contributes both as a regulator of peripheral vascular resistance and
as a target of high blood pressure. Alterations induced by hypertension in certain
vascular beds are crucial events in the development of complications such as
myocardial infarction and stroke (Doyle, 1992).
1. 4. 5. Hypertensive complications affecting the CNS
The brain is particularly vulnerable to complications associated with chronic
hypertension and both the incidence (Whisnant, 1996) and severity of cerebrovascular
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ischaemia (Coyle, 1984) are increased in human sufferers with the disease. The same
applies to haemorrhagic stroke, where hypertension is a factor that increases the
prevalence of this pathology (Juvela et al., 1995; Juvela, 1996). However, recent
clinical studies have questioned the association between hypertension and worse
outcome following intracerebral haemorrhage and have raised the possibility that
hypertensive subjects simply have larger strokes (Jorgensen et al., 1995). In
experimental models of the disease, the outcome following occlusive (Grabowski et
al., 1988) and haemorrhagic stroke (Gonzalez-Darder & Duran-Cabral, 1990)
together with the response to neuroprotective agents (Roussel et al., 1992) are
influenced by the presence of hypertension.
1. 4. 6. Role ofvascular dysfunction in the CNS complications
The presence of cerebrovascular dysfunction has been examined as a potential
explanation for the vulnerability of the brain to hypertensive complications. Early in
vitro investigations identified a decrease in NO-mediated activity in cerebral blood
vessels taken from SHR (Malinski et al., 1993b; Miyata et al, 1990). Subsequent
examination of the basilar artery in situ showed that L-NAME, a non-selective NOS
inhibitor, induced greater constriction in hypertensive rats (Kitazono et al., 1995), an
observation which suggests rather surprisingly that basal release of NO might be
somewhat enhanced in SHR over that in WKY controls. In vivo studies confirmed
that the cerebrovascular response to NO inhibition with L-NMMA was greater in
SHR (Izuta et al., 1995), although no significant difference in LCBF was found in
SHR and WKY treated with nitro-L-arginine (L-NA).
Cerebrovascular dysfunction associated with hypertension is most probably
multifactorial. Studies using pial arteries from hypertensive rats have identified altered
dilator responses which appear to involve vasoconstrictor prostanoids (Mayhan et al.,
1988; Mayhan, 1992b; Yang et al., 1991a) and altered responses to bradykinin,
possibly related to an abnormal production of hydrogen peroxide (Yang et al.,
1991b). There is also recent evidence that NO and prostanoid pathways are not
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independent of each other because in situ studies have shown that prostaglandin-
induced pial arterial vasodilatation is related to NO production (Armstead, 1995).
Enhanced responses of the basilar artery to activation of ETB receptors, independent
of NO or prostanoid pathways (Kitazono et al., 1995), as well as impaired responses
of the same vessel to activation of ATP-sensitive potassium channels (Kitazono et al.,
1993) have also been observed in hypertensive rats. The same group also found that
the mechanisms responsible for the impaired responses of the basilar artery in SHRs
(Mayhan, 1990) are not the same as those responsible for the attenuated responses of
the pial vessels in the same sub-strain. This observation is not surprising, since it has
been shown that the cerebrovascular control mechanisms differ fundamentally
between large conduit (basilar artery) and smaller resistance (small pial and
intraparenchymal) vessels (Faraci, 1991; Iadecola et al., 1994a). Several research
groups have also reported enhanced intravascular generation of superoxide radicals in
extracranial vascular beds of hypertensive animals (Grunfeld et al., 1995; Nakazono et
al., 1991), with all the potential detrimental functions they can convey, including
inactivation ofNO and peroxidative damage to cell membranes (Halliwell, 1994).
1. 4. 7. Roles ofaltered white cell andplateletfunction in hypertensive complications
There is evidence for enhanced adhesiveness of monocytes onto endothelial cells in
the cerebrovasculature of SHR, associated with altered expression of adhesion
molecules by the endothelium (McCarron et al., 1994a&b). The exact mechanism is
unclear and there is a possibility that increased shear stress, associated with the
increased vascular resistance, could be a factor for the stimulation of the endothelial
cells (Alexander, 1995). Another potential explanation is that NO, being a possible
paracrine mediator regulating adhesion of leukocytes to the vascular endothelium
(Kubes et al., 1991), is inactivated by superoxide anion, which may be increased in
hypertension (Grunfeld et al., 1995, Tschudi et al., 1996b).
Platelets from hypertensive patients and animals are more reactive to stimuli that
induce platelet aggregation (Vlachakis & Aledort, 1979). In addition, they release
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more serotonin (Biondi et al., 1986), adhere more readily to vascular endothelium
(Hazama et al., 1979), have a decreased survival time (Okuma & Yamori, 1976), and
have augmented turnover as compared to platelets from normotensive patients and
animals (Yamanishi et al., 1985). Thus, platelet dysfunction during chronic
hypertension could be contributing to the vulnerability of the brain to ischaemia.
1. 4. 8. Role of vascular structural changes associated with hypertension in CNS
complications
Morphological analysis of cerebral vessels has been reported in the SHR strain, which
is the most commonly used animal model of essential hypertension. It seems that in
those cerebral blood vessels which are largely responsible for the control of LCBF, no
structural differences have been found between normotensive (WKY) rats and SHR
(Lin et al., 1990a). It is obviously possible that subtle changes might go undetected in
these rather small vessels, but in the larger intracranial vessels, structural changes have
been reported in the same model of hypertension (Folkow, 1990; Harper & Bohlen,
1984). It has also been reported that structural changes appear even before frank
hypertension has been established (Folkow, 1990).
Even if structural alterations play a role in the vascular dysfunction described in
chronic hypertension, these changes in the vessel wall could not alone provide
sufficient explanation for the preferentially impaired responsiveness to certain
vasoactive agents whereas responsiveness to others is not affected (Calver et al.,
1992). If structural cerebrovascular changes were the sole determinant of vascular
dysfunction in hypertension, it might be expected that the responses to all vasoactive
agents (constrictor and dilator) would be affected in a non-specific manner (Folkow
1990; Harper & Bohlen, 1984). This is certainly not the case, and the current
literature appears to support the concept of hypertension-induced functional changes
in combination with structural changes in the cerebrovasculature (Winquist & Bohr,
1983).
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1. 4. 9. Role ofoedema in CNS complications
Increased vascular permeability has been reported in extracranial (Tedgui et a/., 1995)
and cerebral (Nag, 1993) vascular beds of spontaneously hypertensive rats under
physiological conditions. It is speculated that the endothelial cytoskeleton involved in
blood-brain barrier (BBB) integrity is altered in hypertension (Nag, 1992). Under
pathological conditions and following experimental middle cerebral artery occlusion
(MCAO), hypertensive animals have significantly more brain oedema, as compared to
normotensives (Olsson et al., 1989). It seems possible therefore, that increased BBB
permeability resulting in enhanced oedema may account for a worse outcome of
hypertensives following stroke.
1. 4. 10. Animal models ofchronic hypertension
The main bulk of information regarding both the pathogenesis of hypertension and the
mechanisms underlying the hypertension-associated complications has been derived
from the spontaneously hypertensive rat (SHR), which is a variant of the Wistar
strain. As also stated in the Spontaneous Intracerebral Haemorrhage section of this
thesis, a stroke-prone SHR sub-strain (SHRSP) has also been developed and studied
extensively.
It appears that the brain renin-angiotensin system plays a role in the development and
maintenance of hypertension in the SHR model. Brain angiotensin (Ang II) levels are
higher, and the pressor response to intracerebroventricular administration of Ang II is
augmented as is norepinephrine turnover in the anteroventral third ventricle
(Tsukashima et al., 1996) of SHR. Conflicting data exist regarding the bioactivity of
NO in this model, but the weight of evidence suggests that it may be overactive in
SHR (Dominiczak & Bohr, 1995) but surprisingly enough, depressed in SHRSP
(Dominiczak & Bohr, 1995; Fozard & Part, 1991). Angiotensin infusion has been
used experimentally to analyze cerebrovascular responses to acute hypertension (Kelly
et al., 1994b), and direct infusion of Ang II via osmotic minipumps to rats has also
been used as a model of chronic hypertension (Simon & Abraham, 1995).
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In an attempt to reproduce a situation akin to the human renovascular hypertension,
the "one kidney one clip" (1K1C) model has been developed, in which a unilateral
nephrectomy is combined with a placement of an occluding vascular clip to the
contralateral renal artery. There is indirect evidence for preserved or even increased
basal influence of NO upon vascular tone in extracranial tissues in this model of
hypertension, which depends upon the duration of the condition (Dubey et al., 1996).
NO bioactivity seems to be increased at 2 weeks after the onset of hypertension but
returns to normal levels at 5 weeks. Basal NO activity may be reduced after that time-
point, either as a secondary adaptation of the system to the hypertensive environment
or endothelial cell damage caused by a prolonged increase in blood pressure.
The Sabra rat develops hypertension following deoxycorticosterone acetate (DOCA)-
salt treatment (Ben-Ishay et al., 1987). The susceptibility of this strain to hypertension
results probably from a decrease in NO generation (Rees et al., 1996). Interestingly,
sodium loading in this model results in defective excretion by the kidneys, a function
which is mediated in part at least by NO (Lahera et al., 1991). In contrast, sodium
loading in the SHR results in increased sodium excretion, providing indirect evidence
that in the SHR NO production may be adequate to preserve renal function.
Selective breeding and genetic selection has produced the San Juan hypertensive rat,
which is associated with presence of endothelial dysfunction (Crespo et al., 1996), but
with advancing molecular genetics transgenic animals have also been developed,
expressing the murine Ren-2d renin gene, with severe hypertension (200-260mmHg).
In this model, the adrenal glands show remarkable overexpression ofmRNA encoding
renin (Mullins et al., 1990). They exhibit high plasma aldosterone concentrations,
reduced renal renin production and low plasma renin activity.
The existence of a large variety of models of chronic hypertension indicates the
complexity of the condition and the lack of a single ideal one. More importantly, the
pathogenetic mechanisms of the disease and the role of NO in this context in
particular, seem to differ dramatically between different models. It is of interest that
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human studies have reached equally conflicting results when the peripheral vascular
responsiveness of chronically hypertensive subjects was measured (Calver et al.,
1992; Cockroft et al., 1994). It would seem reasonable to suggest that essential
hypertension is an heterogeneous condition and despite the large amount of
experimental work, it is likely that diverse conclusions will continue to be reached.
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1. 5. Nitric Oxide
I. 5. 1. General
Nitric oxide (NO) is a ubiquitous molecular mediator involved in a wide variety of
biological processes in several organ systems (Moncada & Higgs, 1993). It is
synthesized from the amino acid L-arginine by a family of enzymes, the nitric oxide
synthases (NOS). L-citrulline is also produced, which can in turn be converted to L-
arginine, a process that prevents depletion of intracellular substrate for NO production
(Hecker et al., 1990). NO is freely diffusible, with a short half-life and is a highly
reactive chemical species that is difficult to measure in vivo (Iadecola et al., 1994a).
Therefore, studies on the role of NO have most often utilized agen's that inhibit the
activity of NO synthases or agents that generate NO. More recently, the biological
functions of NO have been clarified considerably by the use of mice with various
forms of NOS inactivated through gene knockouts created by homologous
recombination (Huang et al., 1993; Huang et al., 1995; MacMicking et al., 1995).
To date, three isoforms of NOS have been identified. Two of them, the endothelial
(eNOS, Type III) and the neuronal (nNOS, Type I), are constitutively expressed.
They are calcium-dependent and release NO phasically from various cells (including
the endothelium, neurons, peripheral nerves, glial cells and others). The third isoform,
inducible (iNOS, Type II), is calcium-independent, is induced by certain cytokines and
leads to a potentiated production of NO. It is released by cells of the macrophage-
monocyte lineage and other cells too (including those present in the vascular wall) and
acts upon mitochondrial respiratory-chain enzymes as well as nuclear DNA-
synthesizing enzymes in the target cells by binding to their iron-sulphur centers
(Garthwaite & Boulton, 1995). NO also inhibits NOS providing a feedback system to
protect the body from an excess of the product (Buga et al., 1993).
1. 5. 2. Cardiovascularphysiological role ofNO
It is rather intriguing that the discovery of endothelium-derived relaxing factor
(EDRF) (Furchgott & Zawadzki, 1980) was probably a result of scientific curiosity,
since the biological significance of the direct effect of acetylcholine upon the vascular
31
endothelium is of questionable physiological importance. The quest to identify the
EDRF led to the discovery of an enzyme, nitric oxide synthase, that generates nitric
oxide from the amino acid L-arginine (Moncada & Higgs, 1993). NO is one of several
EDRFs including PGI2 and EDHF (Palmer et al., 1987). It acts via activation of
guanylate cyclase in VSMC and subsequent increase in cGMP.
In VSMC, cGMP causes relaxation through various putative mechanisms such as
activation of cGMP-dependent protein kinase (cG-PK) and activation of large
calcium-dependent potassium channels which leads to membrane hyperpolarization
and closure of voltage-sensitive calcium channels. This pathway seems to operate also
in the cerebrovasculature, where cAJVIP has a similar action (Paterno et al., 1996).
There is recent evidence that NO can directly activate potassium channels in the
VSMC (Bolotina et al., 1994), independently of cGMP or cAMP generation.
Basal release of NO by the vascular endothelium (from eNOS) is responsible for
regulation of blood flow and blood pressure (BP). Interestingly, recent findings
suggest that non-endothelial sources of NO are also involved in maintaining blood
pressure (Huang et al., 1995; Sander et al., 1995), the role of which may differ
between species (Okamura et al., 1996). It is clear though that eNOS knockout mice
are hypertensive providing strong evidence for a basal secretion of endothelium-
derived NO (EDNO) (Huang et al., 1995), under normal conditions. The NO-
dependent vasodilator tone seems to be maintained through the activation of
endothelial cells by stimuli such as pulsatile flow (Cooke et al., 1990; Hutcheson &
Griffith, 1991; Noris et al., 1995) and shear stress (Liischer & Vanhoutte, 1990).
EDNO also participates in the general homeostatic control of the vasculature by
inhibiting aggregation of platelets (Radomski et al., 1987), interaction of leukocytes
with vessel walls and proliferation of smooth-muscle cells (Garg & Hassid, 1989).
Interestingly, there is an interplay between the vasodilatory effects of NO and
adenosine (Smits el al., 1995), as well as NO and the cyclooxygenase pathway
(Garthwaite & Boulton, 1995; Salvemini et al., 1993), which is of obscure
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physiological significance. There is also evidence that Ang II plays a role in the
hypertension maintained by chronic, but not acute NOS inhibition (Melaragno & Fink,
1996). Recent studies have also raised the possibility that Ang II promotes NO
production via stimulation of non-angiotensini (ATi) receptors and activation of local
kinin production (Gohlke et al., 1996). This interaction between various paracrine
mediators shows that it is futile to attribute vascular homeostasis to a single molecule.
Along these lines, during chronic but not acute NOS inhibition, other homeostatic
mechanisms including possible upregulation ofNOS appear to be activated to restore,
at least partially, cerebral blood flow towards normal levels (Kelly et al., 1995c).
As stated above, NO produced by Type I NOS can be released from nitrergic nerves
in the adventitial layer of peripheral vessels and probably the cerebrovasculature
(Okamura et al., 1996). NO from this particular source may be involved in the
regulation of BP, but its significance may vary across animal species (Okamura et al.,
1996). It is also possible that NO released from these nerve terminals may induce
vasoconstriction because NOS inhibition in eNOS knockout mice causes hypotension
(Huang et al., 1995), the nNOS knockout mice are prone to hypotension when
exposed to anaesthesia (Huang et al., 1994) and supervision of pial vessels with NOS
inhibitors in eNOS mutant mice causes vasodilatation (Huang et al., 1996).
1. 5. 3. Role ofNO in cerebrovascular regulation
The finding that the rat cerebellar cells stimulated with A-methyl-D-aspartate
(NMDA) released an EDRF-like material, established the existence of an NO pathway
in the brain (Garthwaite et al., 1988). Neuronal excitation leads to elevations in
cGMP in cerebellum, cerebral cortex, striatum, hippocampus and other brain areas.
The function of this cGMP is unclear. It is speculated that it activates specific
channels that lead to an inward current of sodium and calcium with subsequent
depolarization of the neurone. cGMP may also activate cG-PK in the same way that it
does in VSMC, activate or inhibit phosphodiesterases, and activate ADP ribosyl
cyclase with subsequent calcium release. NO might also regulate cyclooxygenase-2
(inducible) in the brain (Garthwaite & Boulton, 1995). Studies have also shown that
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activation of AMPA and kainate receptors is associated with NO production in the
cerebellum (Southam et al., 1991). Although these findings provide evidence that NO
functions as a signaling molecule in the brain, it must be stressed that NO is
fundamentally different from the concept of the classical neurotransmitter, since it
spreads out from its site of production to influence many tissue elements - neuronal,
glial, and vascular - that are not necessarily in close anatomical juxtaposition, it is not
stored in vesicles, there is no known re-uptake mechanism (Paakkari & Lindsberg,
1995) and the tissue volume in which NO can exert physiological effects is probably
equal to a sphere of diameter 1000pm (Garthwaite & Boulton, 1995).
Although this information could explain a cerebrovascular role for NO secondary to
its effect upon metabolic activity, and has also been suggested that NO plays a central
role as a mediator responsible for flow-metabolism coupling in response to activation
of NMDA receptors (Ayata et al., 1996; Faraci & Breese, 1993),it is surprising that
NOS inhibition reduces basal LCBF without affecting resting cerebral glucose use
(Kelly et al., 1994b). More surprising even was the finding that inhibition of neuronal
NOS similarly reduced basal LCBF with minimal effects upon cerebral glucose use
(Kelly et al., 1995b). It seems therefore very likely that NO produced from both
endothelial and non-endothelial sources has a pivotal role in the regulation of resting
cerebral blood flow, independent of its potential role as a neuromodulator. Although
it could be argued that non-endothelial NO might be of more importance in the
regulation of LCBF, studies have shown that NO continues to provide dilator tone in
cerebral penetrating arterioles after all possible neuronal sources of NO have been
removed (Kimura et al., 1994).
There is evidence that NO plays a role in the cerebrovascular responses to
hypercapnia possibly of a "permissive" (perhaps by maintaining resting levels of
cGMP in the VSMC) rather than a directly vasodilatory nature (Iadecola et al.,
1994b). Its role in hypoxia-induced vasodilatation is probably minor, and adenosine
plays a more important role (Iadecola el a/., 1994a). Reports of a potential role in the
increase in CBF following hypoglycaemia in piglets (Ichord et al., 1994) have been
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followed by contradictory studies in rats (Horinaka et al., 1997). There is also
evidence that NOS inhibition may determine the upper limit of pressure autoregulation
(Kelly et al., 1994b).
1. 5. 4. Role ofNO in cerebral ischaemia
The formation ofNO is increased in brain after induction of focal and global cerebral
ischaemia (Malinski et al., 1993a; Tominaga et al., 1993). This could be viewed as an
appropriate homeostatic response to ischaemia. However, the role of NO is rather
complex, with initial studies of experimental ischaemia reaching rather contradictory
results (Dawson et al., 1992; Iadecola et al., 1994a; Kuluz et al., 1993; Nowicki et
al., 1991).
The haemodynamic, and platelet and leukocyte antiaggregatory effects ofNO (Zhang
et al., 1994) presenting acutely after the onset of ischaemia, mediated mainly by
eNOS (Lo et al., 1996) and in part by nNOS, are beneficial in reducing infarct size.
However, as stated earlier, NO can inhibit iron-containing enzymes and alter DNA
synthesis (Garthwaite & Boulton, 1995). Following reperfusion, it may also react with
superoxide anion to produce peroxynitrite (Halliwell, 1994). Peroxynitrite can cause
lipid peroxidation of cellular membranes (Beckman, 1991). It can also lead to
irreversible nitration of critical tyrosine residues, which could disrupt cellular
communication and integrity (Beckman et al., 1994). Finally it can cause aggregation
of platelets and reverse the action of endogenous inhibitors of aggregation, including
NO and prostacyclin. Its formation under certain conditions can explain how, and
under what circumstances, the same molecule (NO) may seemingly produce both
physiological and pathological effects (Radomski, 1995). Another potentially
detrimental effect of NO is that it may form hydrogen peroxide at subphysiological
levels of L-arginine or tetrahydrobiopterin (Cosentino & Katusic, 1995). The sources
of this NO are not absolutely clear but several studies using selective nNOS inhibitors
or nNOS-knockout mice (Huang et al., 1994; Yoshida et al., 1994; Zhang et al.,
1996b), point towards a pathogenetic role for nNOS. Recent studies, extending the
experiments with the eNOS deficient mice have provided further evidence for a
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beneficial role of EDNO and a detrimental role of neuronally derived NO following
experimental focal cerebral ischaemia (Huang et al., 1996). One important feature
regarding the detrimental role of NO in cerebral pathophysiology is the large amount
of NO that is produced, and the redox state of the tissue exposed to NO. When the
redox state of the tissue favours the production of NO , neurotoxicity occurs
mediated by peroxynitrite, whereas when NO" is produced instead, neuroprotection
results linked to S-nitrosylation of NMDA receptor thiol groups and subsequent
downregulation of the NMDA receptor (Lipton et al., 1993).
Although it seems from the above that the detrimental effects of NO produced by
nNOS are at least partially linked to glutamate excitotoxicity (Dawson et al., 1991;
Lin et al., 1996), its precise role in the NMDA-mediated toxicity in vivo is rather
complex, depending on the NMDA dose and on the participation of haemodynamic
mechanisms secondary to NMDA exposure (Globus et al., 1995). It is also of interest
that hypoxia (probably in relation to generation of oxygen radicals) impairs the
NMDA-induced dilatation of pial arterioles in the rat (Bari et al., 1996). Interestingly,
neurons that release NO seem themselves to be resistant to its cytotoxic actions (Koh
eta/., 1986).
NO produced following induction of iNOS has a detrimental effect in experimental
focal cerebral ischaemia (Iadecola et al., 1997; Zhang et al., 1996a). Induction of
iNOS (which is present in astrocytes, microglial cells, endothelium and VSMC)
presents following experimental occlusive stroke. However the temporal
characteristics of this phenomenon differ between permanent and temporary
occlusion. Earlier studies reported that iNOS was not induced for the first 24h after
the onset of permanent ischaemia (Iadecola et al., 1995), but recent studies found that
in focal ischaemia associated with reperfusion, the induction of iNOS starts much
earlier (during the first 24h) and the cell type (vascular) in which it is expressed is also
different (Iadecola et al., 1996) from that in permanent ischaemia (inflammatory).
Therefore, a contributory role of iNOS in ischaemic brain damage is probable.
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With particular relevance to the presence of intracranial blood, haemoglobin (Hb)
inactivates NO. NO reacts with the ferrous iron in the haeme group, an effect that also
depends on the degree of glycosylation of Hb (Angulo et al., 1996). This quenching
towards NO effect of Hb has been investigated as a potential contributing factor for
the pathogenesis of vasospasm following SAH (Hongo et al., 1988; Kim et al., 1989),
although contradictory results have also emerged (Yoshimoto et al., 1995). However,
it must be stressed that in SAH the vasospastic arteries are large calibre vessels and
the mechanisms governing EDRF function might be different to those of the
intraparenchymal vasculature (Faraci, 1991; Hino et al., 1996). Another issue relating
to the presence of intracranial blood is that haemin, a prominent breakdown product
of haemoglobin, activates iNOS in VSMC in vitro in a time-dependent manner
(Suzuki et al., 1995). Despite the ever-increasing number of studies, the role ofNO in
cerebrovascular regulation and in the pathophysiology of cerebral ischaemia is far
from clear and a considerable degree of controversy remains.
1. 5. 5. Role ofNO in oedemaformation
Experimental evidence reveals that NO of both constitutive and inducible origin plays
a role in the formation of oedema in extracranial tissues (Hughes et al., 1990; Ialenti
et al., 1992; Mayhan, 1993). NO may also be involved in the regulation of BBB under
physiological conditions (Janigro et al., 1994) and also in the disruption of BBB
following ischaemia (Chi et al., 1994; Zhang et al., 1995). It also seems likely that the
neuronal NO is responsible for this effect, since an association between glutamate and
BBB disruption has also been found recently (Mayhan & Didion, 1996).
1. 5. 6. Endothelin (ET): Interaction with NO and its role in ischaemia
The discovery of the endothelin (ET) oligopeptide family by Yanagisawa and his
colleagues in 1988 was of great interest, in view of their profound vasoconstrictor
potency. Their potential contribution to the maintenance of basal vascular tone has
received considerable attention (Haynes & Webb, 1994; Hirose et al., 1995), but
initial enthusiasm regarding a contributory role in the pathogenesis of hypertension
(Webb & Haynes, 1993) and ischaemia (Clozel et al., 1993) has somewhat subsided
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(Patel & McCulloch, 1996), although some rather interesting findings have come to
light with respect to the links between the NO and ET pathways (Boulanger &
Luscher, 1990; Schini et al., 1991). However, in support of endothelin's essential role
for life, mice lacking the ET-1 gene cannot survive due to respiratory and craniofacial
anomalies (Kurihara et al., 1994).
Endothelin-1 is generated from a precursor polypeptide, proendothelin-1, through the
action of endothelin-converting enzyme (ECE), a membrane-bound neutral
metalloprotease inhibited by phosphoramidon (Fukuroda et al., 1990). Endothelin-1
binds to at least two receptors (Haynes & Webb, 1993): the ETA receptor appears to
be the major receptor causing vasoconstriction in arteries (by increasing intracellular
calcium in VSMC) as well as mitogenesis, the ETB receptor mediates release of
endothelium dependent vasodilator substances (including EDNO, which can in turn
block the conversion of preproendothelin to proendothelin, Kurihara et al., 1994;
Rubanyi & Polokoff, 1994; Vanhoutte, 1994). The ETB receptor also mediates
vasoconstriction in some vessels (Noguchi et al., 1993). In support of an interplay
between NO and ET in the cardiovascular regulation, acute hypertension after
inhibition of NOS is attenuated by ETA/ETB receptor antagonism (Banting et al.,
1996), and mice heterozygous to ET-1 gene disruption have elevated blood pressure,
compared to wild-type animals (Kurihara et al., 1994).
ET is a potent vasoconstrictor of cerebral arteries both in vivo and in vitro, with long-
lasting effects. Exogenously administered ET results in extensive vasoconstriction and
causes tissue damage similar to that observed following ischaemia in rat, cat and dog
brain (Kurosawa et al., 1991; Robinson et al., 1991; Sharkey et al., 1993). ETs could
also be directly cytotoxic to neurons and glia, independent of their haemodynamic
effects. Both ET-1 and ET-3 increase [Ca2+]i in cultured glia and neuroblastoma cells
(Marsault et al., 1990; Yue et al., 1990). They also stimulate the release of excitatory
amino acids (Lin et al., 1990b). In models of focal cerebral ischaemia tissue levels of
ET start to rise after 4h, and are significantly increased by 24h (Barone et al., 1994).
ET-receptor antagonists reduce infarct volume following middle cerebral artery
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occlusion in rats (Barone et al., 1995) and cats (Patel et al., 1996), although
contradictory results have also emerged from the same group (McAuley et al., 1994).
The presence of intraparenchymal blood following haemorrhagic stroke has further
implications, in relation to the role of endothelin in the potential development of
delayed perilesional ischaemia. Factors released from the blood (most probably the
platelets) promote the bioavailability of ET in a time-dependent manner in vitro
(Kurihara et al., 1989; Ohlstein et al., 1991). In support of this hypothesis, and in
studies addressing the role of ET in the development of vasospasm following SAH,
haemoglobin has been found to be responsible (amongst other factors) for arterial
spasm by stimulating the synthesis/release of ET-1 from cultured endothelial cells
(Ohlstein & Storer, 1992).
1.5. 7. Potential mechanisms ofNO dysfunction in IDDM
Conflicting data have been reported from in vitro experiments on the effects of
hyperglycaemia, in which the production of NO is increased via amplification of
agonist-induced Ca++ response in endothelial cells (Graier et al., 1993; Wascher et al.,
1994), and in vivo experimental studies, where reduced NO in peripheral tissues
associated with diabetic complications has been reported (Elliott et al., 1993; Taylor
et al., 1995; Way & Reid, 1995). In contrast to the in vitro findings, acute
hyperglycaemia does not affect NO mechanisms in humans in vivo (Houben et al.,
1996).
Potential mechanisms contributing to altered NO bioavailability in IDDM include
increased synthesis/release of sorbitol via the polyol pathway (Sredy et al., 1991), or
exacerbated generation of oxygen-derived free radicals (Hattori et al., 1991; Keegan
et al., 1995) and reduced L-arginine availability (Mans et al., 1987; Matsunaga et al.,
1996; Pieper & Peltier, 1995; Wascher et al., 1996). Upregulation of the polyol
pathway associated with diabetes or hyperglycaemia can influence the bioavailability
of NO through at least two mechanisms (Otter & Chess-Williams, 1994). This
pathway consumes NADPH which is essential, first for the action of NOS, and second
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for the action of glutathione reductase (Loven et al., 1986) which is responsible for
the production of the free radical scavenger glutathione (GSH).
Contradictory results have also emerged from studies of the cerebrovasculature
(Mayhan et al., 1996), where responses of pial vessels to superfusion with NOS
inhibitors was preserved in drug-induced diabetic rodents, using in situ methodology.
Some groups also report that the production of NO is increased in the peripheral
tissues of diabetic animals, especially in the early stages of the disease, and are
responsible for the pathogenesis of diabetic complications (Corbett et al., 1992;
Komers et al., 1994; Tilton et a/., 1993; Williamson et al., 1993). In order to explain
these contradictory reports, it should be noted that important regional (conduit vs
resistance vessels) differences exist between the mechanisms that contribute to
cerebrovascular dysfunction associated with diabetes (Mayhan, 1992a) together with
differences between extra- and intracranial vascular beds (Mayhan et al., 1996).
Alterations of protein kinase C (PKC) activity associated with diabetes (Inoguchi et
al., 1994) can explain a reduction in NO bioactivity, since PKC is known to
phosphorylate and inhibit endothelial and brain NOS (Bredt et al., 1992; Hirata et al.,
1995). However, the interplay between NO and PKC is rather complex and recent
studies have reported that cGMP can also inhibit the production of PKC, which in
turn can elicit directly vasoconstriction to the VSMC (Nishizawa et al., 1996).
Nonenzymatic glycosylation of long-lived proteins occurs in diabetes mellitus and
aging (Eble et al., 1983; Monnier et al., 1984). Bucala and his colleagues have
proposed that the formation of advanced glycosylation products in the subendothelial
collagen associated with diabetes, quenches and inactivates NO before it can act upon
the VSMC (Brownlee et al., 1988; Bucala & Cerami, 1992; Bucala et al., 1991).
Although the presence of a perturbed NO pathway in the aetiology of experimental
diabetic neuropathy is evident, resulting from synergistic interactions between polyol
pathway/nitric oxide and essential fatty acid/cyclo-oxygenase systems (Cameron et
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al., 1996), the characterization ofNO dysfunction in the diabetic brain is not clear to
date. There is more clear evidence of impaired cerebrovascular responsiveness
associated with abnormalities of the cyclo-oxygenase pathway in drug-induced
diabetes (Mayhan et al., 1991). This might be relevant to NO, because the effects of
prostaglandins in the cerebrovasculature are mediated by both cAMP and cGMP, and
the cGMP production is NO dependent (Armstead, 1995). Another observation of
relevance to NO is that Ang II has been implicated in the pathogenesis of diabetic
complications in the periphery, because ACE inhibition improved the regulation of
vascular tone in the mesenteric bed of diabetic rats (Olbrich et al., 1996). NO in turn
has a regulatory role in modulating some of the Ang II effects (Ho et al, 1995).
1. 5. 8. Insulin andNO
Insulin-induced vasodilatation in extracranial tissues, independent of its effect on
plasma glucose, is probably mediated by NO production (Scherrer et al., 1994;
Trovati et al., 1995). The possible mechanism is through activation of the Na+-K+
pump at the endothelial surface (Tack et al., 1996), which results in cell
hyperpolarization and influx of Ca due to electrogenic driving force. Calcium
channels in the endothelium are primarily voltage independent, but in contrast,
hyperpolarization of VSMC would result in closure of voltage-dependent Ca"
channels. There is also recent evidence that NO may be a novel effector of the insulin
signaling pathways involved in glucose metabolism (Zeng & Quon, 1996). This
concept is supported by studies in healthy humans suggestive of a physiological link
between endothelial nitric oxide synthesis and insulin sensitivity (Petrie et al., 1996).
Hyperinsulinaemia is associated with an increase in cerebral blood flow (CBF),
independent of blood glucose level (Kerr et al., 1993). Despite all of these reports, a
recent study from SokolofFs laboratory provided evidence against a direct role of
insulin to raise CBF, or a role ofNO in the increased CBF following hypoglycaemia in
awake animals (Horinaka et al., 1997).
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1. 5. 9. NO and hypertension
There is an extremely large body of experimental and clinical work regarding the role
of NO in both the pathogenesis of hypertension and its associated complications with
conflicting results depending on the species/models, tissue and duration of the disease.
This work has been reviewed in the Essential Hypertension section of this thesis.
I. 5. 10. Concluding remarks
NO is a most extensively investigated molecule, and it is impossible to present all the
information available regarding its physiological and pathological functions. The
purpose of this introduction was to include only those facts which are relevant to the
work presented in this thesis.
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1. 6. Aims and objectives
The aims of this thesis are (i) to investigate whether cerebrovascular dysfunction
linked to a perturbation of NO-related control mechanisms is associated with IDDM
and chronic hypertension (ii) to assess the extent to which any abnormal
cerebrovascular physiology associated with IDDM and chronic hypertension
contributes to the pathophysiological response to haemorrhagic stroke, and finally (iii)
to determine if ET or neuronally derived NO, which may be implicated in the
development of delayed perilesional ischaemia following experimental ICH in normal







The experiments presented in this thesis represent two discrete, but related studies:
firstly, an investigation of the physiology of the cerebrovascular endothelium, and
secondly an investigation of the pathophysiology of ICH.
In the physiological studies, local cerebral blood flow (LCBF) was measured using the
fully quantitative [14C]-iodoantipyrine (IAP) autoradiographic technique, in areas
within the vascular territories of the anterior, middle and posterior cerebral arteries in
spontaneously diabetic (BB) and hypertensive (SHR) rats and appropriate controls,
under basal conditions or following manipulation of NO systems with the NOS
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inhibitor N -nitro-L-arginine methyl ester (L-NAME), the selective neuronal NOS
inhibitor 7-nitroindazole (7-NI), the NO donor 3-morpholinosydnonimine (SIN-1) and
the non-peptide ETA/ETB-receptor antagonist SB209670 [(+)-(l5',2/?,36)-3-(2-
carboxymethoxy-4-methoxyphenyl)-1 -(3,4-methylenedioxyphenyl)-5-(prop-1 -yloxy)
indane-2-carboxylic acid]. Electron and light microscopy using the periodic acid schiff
(PAS) stain were used to identify any structural vascular abnormality in the diabetic
vessels which might reflect cerebrovascular responses to the above pharmacological
agents. Finally, whole blood viscosity and plasma L-arginine levels were obtained in
the diabetic and non-diabetic controls to further elucidate the mechanisms responsible
for cerebrovascular dysfunction associated with IDDM.
In the parallel intracerebral haematoma studies, volumes of striatal oligaemia were
measured by computer-based planimetry in the BB and SHR groups of animals
injected with blood, or silicon oil as a control. Rats carrying the burden of ICH were
treated with saline, SB209670, sesame oil or 7-NI. In the same studies, sections
adjacent to those used for autoradiography were examined histologically, stained with
either haematoxylin and eosin or cresyl violet with luxol fast blue. Differences in
blood-brain barrier (BBB) permeability to a-aminoisobutyric acid (AIB) were
measured in the parallel groups of animals subjected to experimental ICH, to
determine if the presence of IDDM or chronic hypertension were associated with
alterations in permeability. In all groups of animals, volumetric analysis of the mass
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lesion was performed ex vivo using tissue planimetry. Intracranial pressure (ICP) was
also measured in pilot experiments, to ensure that the volume of blood injected into
the striatum (50pl) did not induce global cerebral perfusion pressure (CPP)
reductions.
All of the experimental methods used in this thesis, as well as the animal models,
represent established procedures which have been previously validated and described
in detail in the scientific literature.
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2. 1. Animals
All experiments were performed using adult male rats, weighting between 230 and
495 g. Diabetic animals and their controls were purchased from the British Diabetic
Association BB (Edinburgh) U.K. Resource Unit. Hypertensive animals and their
controls were purchased from Charles River. All animals had free access to food and
water until the day of the experiment and environmental control (room temperature,
light/dark cycle) was maintained throughout.
2. 1. 1. Spontaneously diabetic BioBred rats
The BB/E colony consists of two lines derived by selectively breeding for and against
diabetes. In the high-incidence diabetes-prone (DP) main line, the incidence of IDDM
is 50-60%, and the age at onset of diabetes is 96 ± 18 days (mean ± s.d.). In the
diabetes-resistant (DR) subline, the incidence of diabetes is < 1%. Animals from the
DR subline were used as controls for diabetes, and were age-matched to the diabetics
used in the experiments presented in this thesis.
Both DP and DR rats were maintained at 20°C on a 12h light/dark cycle and fed rat
and mouse Number 1 Expanded Feed (Special Diet Services, Witham, U.K.). Animals
were weighed twice weekly from 40 days of age. Failure to gain weight, or loss of
weight, was taken as an indication of the possible onset of diabetes, and such rats
were tested for glycosuria. If glycosuria was detected, the blood glucose
concentration was measured from a sample obtained by tail-tipping. A blood glucose
concentration >324mg.df1 is invariably associated with ketonuria, weight loss and the
absolute requirement for daily injection of insulin. These variables constituted the
criteria for classifying an animal as having IDDM. The diabetic animals were
maintained on a single subcutaneous injection of medium-acting insulin (U40 Bovine
Ultralente insulin, NOVO), the injection given at 9.00 am each morning in the
subcutaneous tissue of the neck. The exact dosage (2.4 to 11 units), was specifically
titrated for each individual animal to prevent ketoacidosis and weight loss. Blood
glucose concentration and body weight were measured three times per week in each
diabetic animal and the insulin dose adjusted accordingly. This protocol is in
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accordance with those employed by other groups using animals from BB colonies
elsewhere (Hall etal., 1996).
In those rats in which haematomata were induced, the daily insulin injection was given
4h prior to the intracerebral injection of blood or silicon oil. On the final day of
experiments, all diabetic rats were injected with insulin 4h prior to the measurement of
LCBF or BBB permeability. This time interval was chosen to allow the insulin time to
act, and normalize the plasma glucose
Some of+he diabetic complications, such as the appearance of advanced glycosylation
endproducts develop only after approximately 6 weeks of established diabetes (Bucala
& Cerami, 1992). The diabetic animals used for all the experiments were between 18
and 36 weeks old and had a duration of diabetes between 8 and 20 weeks. The
processes of aging are themselves associated with endothelial dysfunction, therefore
older animals were not used. As mentioned earlier, the DR rats used as controls were
age-matched to the diabetic animals.
In a further group of diabetic animals long lasting sustained release insulin implants
(SRI1, Mollegaard, Denmark) were used, instead of the daily dosing regimen
described above. These implants deliver a basal dose of insulin continuously, thereby
preventing periods of hyperglycaemia, eliminating the large diurnal fluctuations in
plasma glucose concentrations, and achieving a better overall glycaemic control. The
insulin implants are in the form of rods (7x2mm) consisting of a 17% powder
admixture of Bovine insulin compressed into a pellet with 83% palmitic acid. The
insulin release rate is approximately 2 units per day per implant for 6 weeks. The sites
of implantation were subcutaneous in the neck region or in the sternal area. Because
the diabetic animals used in this study had a duration of disease of over 8 weeks, a
new rod was implanted at 6 weeks. This protocol of continuous subcutaneous insulin
infusion (CSII) was employed in an attempt to create a model of diabetes with more
effective metabolic control.
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2. 1. 2. Hypertensive rats
The hypertensive animals used in the experiments outlined in this thesis were from the
spontaneously hypertensive strain (SHR). Hypertension presents before the age of 6
weeks in this animal strain. The rats were purchased from Charles River at the age of
10 to 14 weeks, and used for experiments 4 weeks later, having become re-
acclimatised to their new surroundings. The age of the SHR rats at the time of
experimentation was between 14 and 18 weeks. There was no dietary supplement in
these animals.
WKY animals were used as controls. These were purchased from the same supplier at
the same age, were age-matched to the SHRs at the time of experimentation and
housed in the same way as the SHRs.
2. 2. Production ofexperimental ICH
Experimental intracerebral haemorrhage was produced by injecting blood from a
donor rat into the right caudate nucleus of recipient animals using stereotactic
procedures.
2. 2. 1. Donor
The donor of the blood was a syngeneic animal from each of the groups examined. In
a series of preliminary experiments, it was established that the response to
experimental ICH in diabetic or DR rats was independent of the source of blood, i.e.
whether the donor was a diabetic or DR and the recipient diabetic or DR.
Subsequently, all donors were DR, thus eliminating the blood variable from the
treatment effect. Similarly, it was found that the same occurred with the SHR and
WKY groups, where the response to the experimental ICH was independent of the
source of blood. Therefore all donors in these studies were from the WKY group.
Donor animals were anaesthetized with intraperitoneal pentobarbitone (45-60mg.
kg"1). A 15cm long PE50 cannula (Portex polythene tubing i d. 0.58mm, e.d. 0.96mm)
was inserted in the right femoral artery and kept patent by connecting it to a syringe
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(1.0ml) containing heparinized saline (lOIU.mr1), the whole procedure taking place
near the stereotactic frame where the recipient of the haematoma was to be placed.
0.2ml of blood was withdrawn from the arterial cannula into the heparinized syringe.
A further 50pl of unheparinized arterial blood was withdrawn, with a small bubble of
air separating the blood from the saline, into a 30cm length cannula tubing graduated
in 25 pi steps and filled with saline. The other end of the 30cm long cannula was
connected by way of a three-way tap to a 20ml syringe containing saline.
2. 2. 2. Recipient
The recipient animal was anaesthetized with pentobarbitone (30-45mg.kg_1) injected
intraperitoneal^. Depth of anaesthesia was assessed by lack of movement of the
animal upon exertion of stimuli in the lower limb paws. The scalp was shaved and
cleaned with an antiseptic swab, containing 5% chlorhexidine. The animal was placed
prone in a stereotactic frame, restrained by use of ear bars and an incisor bar set at
0mm, according to Paxinos and Watson (1986). A thermal blanket was placed under
the torso of the animal and a rectal probe was also inserted, ensuring that, with
appropriate adjustments of the heat source, the temperature of the animal remained at
37°C. Oxygen, at 4 litres per minute, was administered via a face mask. The scalp was
infiltrated with 1% lignocaine hydrochloride, incised longitudinally along the midline
and retracted. The bregma was identified. Using a 1mm diameter burr cleaned with
5% chlorhexidine a burrhole was made 3.5mm to the right of the midline, on the
coronal suture, while the skull was continuously irrigated with normal saline. The
underlying dura was identified, and incised with the tip of a 25G needle (e.d. 0.5mm).
The needle (25G) which was connected to the cannula tubing containing the 50pl of
blood was cleaned with alcohol, air dried and placed on the stereotactic frame. It was
introduced into the burrhole and initially lowered to a depth of 6mm below the dura,
but subsequently withdrawn to a depth of 4.5mm, creating a "pocket" of 1.5mm
below the tip of the needle.
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In preliminary experiments, 25 pi of blood was injected in the right caudate nucleus of
control animals for 24 and 48h. The animals were sacrificed by decapitation and the
brains were removed intact and immersed in 10% formalin for 24h. Coronal sections
were cut and processed routinely into paraffin wax, from which 5 micron (p) sections
were cut and stained with haematoxylin and eosin (H+E). No perilesional structural
abnormality was evident in any of these groups, so in the subsequent procedures 50pl
of blood or silicon oil was injected in control, diabetic and hypertensive rats and the
animals sacrificed at 24h. Perilesional cell damage of variable extent between
treatments and groups was evident, so this volume, which is also more realistic in
being equivalent to a 40-50ml lesion in the human brain (Kingman et al., 1988), was
used for all the subsequent experiments.
In determining the mode of injection, two parameters were found in preliminary
experiments to be important for reproducibility of the lesions: the rate of the injection
and the time interval between the withdrawal of the blood from the donor and its
injection into the striatum. Initially the method used was to inject the blood under
lOOmmHg pressure generated by a saline column connected by a three-way tap to the
tube containing the blood (Nath et al., 1986). The injection was normally complete
within 20sec. However, the reproducibility was poor using this method because of
variable backflux of the blood, especially when the injection was performed within a
short time after the withdrawal of the blood from the donor. It was also found during
these preliminary experiments that, if the blood was left for 2min in the collection tube
before it was injected, the occurrence of backflux was greatly reduced. Therefore, the
protocol for the experiments presented in this thesis was as follows; the donor blood
was drawn into the injection apparatus, left in the tube for 2min, and then injected
over lmin. The needle was left in situ for another 5min and then withdrawn, the
burrhole sealed with sterile bonewax and the wound sutured with 4/0 silk. The animal
was removed from the stereotactic frame and placed in an incubator, set at 37°C until
it regained consciousness. Thereafter, it was placed in an individual cage, and allowed
free access to food and water for 24h, at which point the final experiment for the
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measurement of LCBF, BBB permeability or histopathology was performed (see
appropriate sections).
2. 2. 3. Controlsfor ICH - Silicon oil injection
In a group of animals, 50pl of inert silicon oil was injected in order to differentiate the
effects of the blood products from the effects of the "mass" lesion. The silicon oil was
of similar viscosity to blood (7.6 centipoise at 37°C) and was kindly provided by
Professor Gordon Lowe from the University of Glasgow. The oil has the same flow
rate as blood, and when injected around the pial vessels of a cat, no vasoconstrictive
or dilatating effects are observed (Jenkins et al., 1990). The oil was injected into the
animals in exactly the same way as the blood. However, in preliminary experiments, it
was noted that if the needle was withdrawn 5min after the completion of the injection,
there was considerable backflux (presumably due to lack of clotting of the oil).
Therefore, the needle was withdrawn much more slowly, at a rate of 1 mm every 5min.
Since the original depth at the start of the injection was 4.5mm, the procedure lasted
for 25min. The animals were treated afterwards in the same way as those injected with
blood, and were allowed to recover for 24h prior to further experimental
manipulation.
2. 3. Surgicalpreparation forfinal experiment
Rats were initially placed in a perspex chamber into which an anaesthetic gas
composed of 5% halothane in a nitrous oxide: oxygen mixture (70%: 30%) flowed for
induction of anaesthesia. Once the animals became unconscious, they were removed
from the box, placed supine on an operating bench, and anaesthesia maintained with
1.5-2% halothane in the same nitrous oxide: oxygen mixture delivered by a face mask.
Both lower limbs were immobilized with adhesive tape and the skin over both groins
shaved and cleaned with antiseptic solution. The femoral vessels were exposed
bilaterally through small incisions in the skin overlying the pelvic muscles, proximal to
the femur. Polyethylene cannulae (Portex, external diameter 0.96mm, internal
diameter 0.58mm), 15cm in length and filled with heparinized saline (lOIU.mf1), were
inserted approximately 3cm into both femoral arteries and veins. The cannulae were
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secured with fine suture material, the wounds infiltrated with local anaesthetic
(lignocaine hydrochloride, 2%) and sutured (Ethicon, W586) closed. Externally, the
wounds were covered with gauze pads soaked in lignocaine. The lower torso was
enveloped in a surgical stocking (Tubigrip, size E), and a plaster cast (Gypsona) was
applied loosely around the hindlimbs and lower abdomen. With the rat in prone
position, the plaster cast and hindlimbs of the animal were taped to a weighted block
for purposes of restraint and support, and a rectal thermometer was inserted. Core
temperature of around 37°C was maintained with the use of a heating lamp.
Anaesthesia was terminated and the animals were allowed to regain consciousness. A
recovery period of at least 2h were allowed to elapse, prior to further manipulation or
injection of isotopes or pharmacological agents. During this recovery time and
subsequent experimental procedures, arterial blood pressure was monitored and/or
recorded from one of the arterial femoral cannulae using Macintosh, MacLab 4e
Chart. Body temperature was displayed continuously.
In the subgroup of animals to be treated with 7-nitroindazole (7-NI), an
intraperitoneal cannula (PE 50) was inserted via a trocar into the abdominal space,
secured with suture at the insertion site, and led caudally to lie with the femoral
cannulae, to which it was also secured.
2. 4. Measurements ofphysiological variables
After the end of the recovery period from anaesthesia, 100-150pl of arterial blood
was withdrawn for the measurement of pH, p02, pC02, base excess, bicarbonate,
plasma glucose and haematocrit. Mean arterial blood pressure (MABP), heart rate and
core temperature were also noted just prior to the initiation of subsequent LCBF or
BBB permeability experiments. In the groups of animals in which an acute injection or
infusion of a pharmacological agent was performed (i.e. L-NAME, 7-NI, SIN-1 or
SB209670), these physiological parameters were measured prior to the drug injection
(or infusion) and again just prior to the LCBF experiment.
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2. 5. Measurement of local cerebral bloodflow (LCBF)
Local cerebral blood flow (LCBF) was measured using the fully quantitative [14C]-
iodoantipyrine autoradiographic technique (Sakurada et al., 1978).
Rats already supported on the weighted blocks were positioned under a guillotine.
One femoral venous cannula was connected to a syringe containing 50gCi of the
freely diffusible tracer [14C]-iodoantipyrine (Tocris Cookson, specific activity
55mCi.mmor') diluted in 0.5ml of normal saline. One arterial femoral cannula was
secured to a metallic block to facilitate subsequent sampling.
The tracer was infused over a 45sec period on a "ramp" schedule, i.e., the rate of
infusion was continuously accelerating so that the arterial tracer concentration would
rise steadily and be highest at the end of experiment. Thus, the possibility of reaching
a steady-state arterial tracer concentration, or of the arterial concentration falling at
any stage of the experiment was avoided. During administration of the isotope, blood
was allowed to flow freely from the arterial cannula that was secured on the metallic
block. Timed samples (16 to 18) were collected intermittently onto preweighed filter
discs (Whatman AA, 13mm, Merck) held flat in polystyrene auto-analyzer cups
(automatic assay type, 14mm, 1.5ml, Merck) held around the perimeter of a perspex
wheel (12cm diameter). The sequence of all drops, emanating from the arterial
cannula, including the numbered ones collected on the discs, was called out and
recorded on audiotape.
At the end of the infusion (around 45sec after the onset), the animal was decapitated
by guillotine. To avoid equilibration of the isotope in the brain structures or reduction
in arterial concentration, the animal was decapitated just before the tracer infusion
ended. Because of the time lag inherent in the sampling cannula, care was taken to
obtain a blood sample after the decapitation, in order to estimate as accurately as
possible (without the need for extrapolation), the amount of isotope present in the
brain at the instant of death. The brain was dissected intact, and frozen in pre-cooled
isopentane (-45 °C) within 2 to 3 min of death to prevent diffusion of the isotope. The
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frozen brain was transferred onto dry ice. A layer of approximately 3mm M-l
embedding matrix (Lipshaw) was allowed to freeze on the top of a 13mm object
holder, the matrix being held in place by a collar of masking tape. Another few drops
of matrix were put on the frozen surface and the brain, cerebellum down, placed into
the liquid matrix. Solid C02 was crumbled over the brain and liquid matrix to ensure
rapid freezing. The brain, now held in an upright position, was brushed free of excess
C02, dipped quickly in a small reservoir of matrix and returned immediately to be
covered in crumbled C02. The frozen brain was left for 5-10min before being either
stored in a small self-sealing, labeled polythene bag at -70°C until required, or being
transferred to a cryostat at -22°C for sectioning.
In the preliminary experiments performed in the WKY and SHR animals, there was a
tendency for the blood pressure to fluctuate and sometimes to drop considerably
during the haemorrhaging necessary for the collection of blood samples. In these
groups the protocol was modified as follows; the infusion period was reduced from 45
to 30sec, and although the same amount of isotope was infused, by careful crimping
of the sampling cannula, the flow rate of arterial blood was reduced (40-48 drops per
minute instead of 60-64 drops per minute employed in the diabetic and non-diabetic
BB groups). With this modification, MABP remained steady during each experiment.
MABP and time of death were read from recorded computer trace (Macintosh,
MacLab 4e). In the recording of physiological parameters, the MABP measures that
were included were those obtained at the exact time of death.
The filter discs were returned quickly to the appropriate scintillation vials in which
they had been preweighed, capped tightly to prevent evaporation, and then reweighed.
Hydrogen peroxide (0.4ml, 30% w/w, Sigma) was added to bleach the blood, and
reduce the possibility of colour quenching. The vials were left at room temperature
for 2h to allow completion of bleaching, and then 10ml of liquid scintillant (Picofluor,
Packard) was added. The vials were placed in a cold room at 4 °C for 24h to allow
elution of isotope into the scintillation fluid and then placed in a liquid scintillation
analyzer (Tri-Carb 1600TR, Packard). Each sample was counted for two minutes
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over each of three cycles, and the mean d.p.m. (disintegrations per minute minus
background) of each sample used for the subsequent calculations.
The timing of the numbered samples and the total number of drops, from the start of
the isotope infusion, were noted from the audiotaped record of the experiment. From
mean sample weight (corrected to volume by the specific gravity of blood, 1.05) and
the number of drops issuing from the cannula, the cannula flow rate could be
calculated and lag-time for blood to pass through the cannula determined. This was
necessary because blood sampled from the catheter is delayed relative to that in the
brain by the amount of time it takes to flow through the catheter (lag-time). A
correction for this lag-time, which varies from animal to animal, can be determined
from the flow rate (number of drops/ min x volume/ drop) and the volume of the
catheter.
2. 6. Measurement ofblood-brain barrier (BBB) Permeability
Blood-brain barrier (BBB) permeability was measured using the fully quantitative
[14C]-a-aminoisobutyric acid (AIB) autoradiographic technique (Blasberg et al.,
1983). The AIB method is excellent for measuring moderate to large increases in
BBB permeability, since this amino acid (molecular weight 104 daltons) has a low rate
of transport across normal brain capillaries (carrier-mediated, the same that mediates
flux of neutral amino acids) and undergoes rapid concentrative uptake by brain cells
(Blasberg et al., 1983).
The production of the haematoma 24h prior to these experiments, the surgical
preparation of the animal, and the measurement of the physiological variables have
been described in sections 2. 2., 2. 3. and 2. 4. respectively. MABP was continuously
monitored before and during the experiment until the animal was dead and core
temperature measured by a rectal thermometer throughout. The isotope, 40pCi
dissolved in 0.7ml of normal saline, was injected intravenously over a period of 30sec.
Timed arterial blood samples (100-150pl over l-2sec) were taken by allowing arterial
blood to flow from the open cannula into a heparinized centrifuge tube (Beckman
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EHF-26). The exact times of starting and stopping each collection were noted. The
first sample coincided with the beginning of the injection (Osec), and then at 15sec
intervals until 60sec. Subsequent samples were taken at progressively longer intervals
(2, 3, 5, 7.5, 10, 15, 20, 25 and 30min), to make 14 samples in total. The animal was
killed with an overdose of barbiturate immediately after the last sample. The exact
time of the animal's death was noted. The brain was dissected and prepared for
cryostat sectioning as described in section 2. 5.
The arterial blood samples were centrifuged for lmin (Beckman microfuge E) and
0.02ml aliquots of the plasma were withdrawn, placed in plastic vials (Pico-prias
6.5ml, Packard) containing 0.5ml of distilled water, and 5ml of liquid scintillant
(Picofluor 40) were then added. Liquid scintillation analysis was performed as
described in section 2.5.
2. 7. Preparation of tissuefor autoradiography
Brains which had been stored at -70°C were transferred to a cryostat at -22°C and 30
to 45min were allowed to elapse before the brains were sectioned.
2. 7. 1. Protocols to generate LCBF autoradiogramsfrom physiological studies
Semi-serial brain sections (20 microns thick) were cut starting at the olfactory bulbs
and ending at the medulla oblongata. The first three consecutive sections in every 13
were mounted on glass cover slips and dried on a hotplate (90 °C). The other 10
sections were discarded, apart from the diabetic and non-diabetic (DR) groups treated
with saline (for measurement of basal blood flow). In those groups, sections from
several brain areas were mounted onto poly-L-lysine - coated glass slides and stained
with periodic acid schiff (PAS, see 2. 10. 3.) in order to investigate whether any
significant deposition of advanced glycosylation end-products was evident in the
subendothelial layer of the diabetic animals. The cover slips were glued onto thin
cardboard (20x25cm), together with a set of 8 [14C]-containing (40-1069 nCi.g*1),
methylmethacrylate plastic standards (Amersham), precalibrated for 20 micron brain
sections. Sections and standards were exposed to X-ray film (Kodak SB-5) in light-
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tight cassettes stored at 4°C for seven days. At the end of the exposure period,
cassettes were brought to room temperature. The films were developed, under red
safety light (Kodak GBX-2 filter) conditions, for 5min in LX-24 developer (Kodak,
1:4 with tap water), washed quickly in water to remove excess developer, fixed for
2x5min in UNIFIX (Kodak, 1:4 with tap water) then washed in running tap water for
15min before being hung up to dry at room temperature.
2. 7. 2. Protocols to generate LC.BF and BBB permeability autoradiograms from
haematoma studies
In these studies, sectioning of the brain was performed in largely the same way as
described before. However, when the beginning of the clot was noted at the anterior
part of the caudate nucleus, the frequency with which sections were collected onto
coverslips was increased to three brain sections in every 8. All intervening sections
were mounted on glass slides (coated with poly-L-lysine to avoid dislodging of the
section during the staining procedure) and stained with haematoxylin and eosin or
luxol fast blue with cresyl violet, in order to correlate directly the blood flow or BBB
permeability in autoradiograms with these neuropathological slides in each individual
animal. Once the haematoma had ended, the frequency of collection was reduced and
the protocol was again as described previously.
In the BBB permeability protocol, brain sectioning started at the anterior caudate and
ended at the end of the globus pallidus. Initially the first three consecutive sections out
of every 13 serial sections were mounted on glass coverslips and dried on a hotplate
(90°C). However, when the haematoma was encountered, a protocol similar to that
used for the LCBF studies was adopted.
The cover slips were processed in the same way as described in section 2. 7. 1., apart
from the BBB permeability autoradiograms, which were exposed to X-ray film
(Kodak SB-5) and kept in light-tight cassettes at 4°C for twenty days. In preliminary
experiments the films were left in the cassettes for ten days, but the radioactivity was
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found to be too low for provision of reasonable discrimination from the background
of the film.
2. 8. Analysis ofautoradiographic images
Quantitative densitometric analysis of all autoradiographic images was performed
using a computer-based image analysis system (Quantimet 720, Cambridge
Instruments).
2. 8. 1. Analysis ofautoradiograms ofLCBFfrom physiological studies
The images on the X-ray film were analyzed by quantitative densitometry (Quantimet
720, Cambridge Instruments), relative to the precalibrated standards. The optical
densities of the plastic 14C standards were measured before and after the measurement
of the optical densities of the brain structures. The mean of these two values for each
standard was entered in the computer. This procedure was carried out to avoid errors
associated with measurements of optical density consistency. In all the experiments
analyzed, the difference between the two values obtained for each standard was less
than 10%. For each region of the brain which constituted an area of interest, twelve
optical density readings were made bilaterally on six consecutive sections in which the
structure could be anatomically defined by reference to a stereotactic atlas (Paxinos &
Watson, 1986). The mean optical density of these 12 measurements was used to
calculate the tissue 14C concentrations. The size of the measuring frame varied
depending upon the brain region to be analyzed. For the caudate nucleus, a frame of
50 square picture points (pixels, 500 pixels representing a distance of 15mm) was
used; 20 square pixels were used for globus pallidus, 10 square pixels were used for
nucleus accumbens, lateral geniculate and hypothalamus and 5 square pixels were
used for parietal cortex, subcortical white matter and the hippocampal structures. The
size of the measuring frame was maintained constant for the same region in different
animals. Blood flow was calculated using the appropriate operational equations.
Tracer concentrations in arterial blood samples were taken from the liquid scintillation
analyzer as described previously (section 2.5.). These d.p.m. together with the blood
drop weights and corresponding collection times were entered into a computer.
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Knowing the specific gravity of whole blood (1.05) (Sakurada et al., 1978), and the
drop weight, the sample volume was calculated. The computer then calculated the
best fit between the optical densities and the known 14C concentrations. Using a
specifically designed computer programme, in which the partition coefficient (the ratio
of the solubility of the diffusible tracer in the brain tissue to that in the blood) was
considered to be 0.8 (Sakurada et al., 1978), the calculation of the CBF was
determined for the corresponding tissue 14C concentrations of the tracer (Sakurada et
al., 1978) from the equation
T
Ci(7) = CAUK(T4,d/ , where Ci(7) equals the tissue concentration of the
chemically inert diffusible tracer in a homogeneous tissue at a given time, T, after the
introduction of the tracer into the circulation; A, equals the tissue:blood partition
coefficient; CA is the concentration of the tracer in the arterial blood; t equals the
variable, time; and K equals a constant that incorporates within it the rate of blood
flow in the tissue. The constant K is defined as follows K = wF/WA where FAV equals
the rate of blood flow per unit mass of tissue and m equals a constant between 0 and 1
that represents the extent to which diffusion equilibrium between blood and tissue is
achieved during passage from the arterial to the venous end of the capillary. In the
absence of diffusion limitations or arteriovenous shunts, m = 1.
2. 8. 2. Calculation ofstriatal ischaemia from LCBF autoradiograms in haematoma
studies
In this method of analysis, volumes of striatal tissue with blood flow below
predetermined thresholds were derived for each animal. These thresholds (15, 25, and
BSml.lOOg'Vmin"1), represent widely acceptable values for the ischaemic penumbra in
the rat (Ginsberg & Pulsinelli, 1994; Hossmann, 1994). It is understood that in the
original study by Astrup, Siesjo and Symon in 1981 the actual CBF values for the
penumbra were lower. However it seems that in the rat, because of a higher metabolic
rate (Nilsson & Siesjo, 1976; Siesjo, 1992; Sokoloff et al., 1977), these CBF values
are higher. Moreover, as was found in this work, these CBF thresholds corresponded
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very closely to the area of neuropathological evidence of ischaemic injury obtained
from adjacent sections to those used for autoradiography.
A preliminary analysis of the autoradiograms was conducted to measure the optical
densities of the eight [14C]-containing standards. It was also necessary to include a
measure of the background optical density of each film, and this represented zero
[14C] concentration. Using the blood data for the individual animal to which the film
related, and Sakurada's operational equation (1978), blood flow values were derived
which corresponded to the optical densities of the standards. The operational equation
was then reversed to derive by an interactive process, optical densitv values which
corresponded to the chosen blood flow thresholds.
The image analyzer was calibrated to absolute units of length. In most experiments
500 picture points (i.e. the units which comprise a video image) were equivalent to
15mm, and optical density thresholds were set, which had previously been calculated
to correspond with the predetermined blood flow thresholds. Using a light-pen linked
to a computer mouse, the perimeter of the striatum containing the haematoma (or
silicon oil) was delineated, and the area within the boundary was calculated by the
computer. The computer then generated the area of striatum within the boundary
which had an optical density below each of the three thresholds, expressed both as
percentage of total striatal area and also in absolute units of area, i.e. mm2. These
measurements were conducted over three consecutive sections, and the mean values
derived for this level of striatum. Volumes (in mm') of striatal tissue in which blood
flow was below the same thresholds were derived by repeating the above procedures
at all levels of the brain in which the haematoma was present. Volumes were
calculated from the measured areas, using the known distance between each of the
levels (100pm).
2. 8. 3. LCBF measurements in areas distant to the mass lesion
LCBF was also measured in areas distant to the haematoma/silicon oil injection (i.e.,
contralateral caudate nucleus). The procedure employed was similar to that described
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in section 2. 8. 1., with the exception that only 6 instead of 12 optical readings were
made on the same side (left, opposite the mass lesion) on six consecutive sections, for
each brain structure studied.
2. 8. 4. Analysis ofAIB (BBB permeability) autoradiograms
Analysis of the images on the X-ray film was performed using the same computer-
based densitometer described above (section 2. 8. 1). Tissue tracer concentrations
were derived by densitometric analysis relative to the precalibrated 14C-containing
standards. Because the optical densities of "normal" tissues were so low, the optical
density of the film background (tracer concentration - zero) was included. Three
consecutive images containing the haematoma were analyzed separately at each brain
level using a measurement area of 5 square pixels, and the mean optical density
obtained from these three readings. The area ofmeasurement was defined as that with
the most obvious AIB concentration in the lesioned caudate. At each brain level the
optical density of the contralateral non-lesioned striatum was also measured, in order
to obtain an index of concentrations of AIB accumulated in normal tissue in each
animal. Permeability to AIB was calculated using the appropriate operational
equation;
Ki = FVf [1 - exp(-/TS7AIV)], where K\. blood-to-brain transfer rate constant; F: blood
flow; Vf. fraction of the whole blood flowing through the capillaries that is involved in
the blood-brain transfer process of AIB (1 - haematocrit); P: permeability; S: surface
area, (see Blasberg et al., 1983) using the timed arterial concentrations of the tracer
taken from the liquid scintillation analysis as described previously (section 2. 6 ).
2. 9. Calculation ofstriatal volume ofhaematoma or silicon oil
The coverslips containing the sections of the lesioned (with blood or silicon oil)
animal brains were placed on the densitometer. The volume occupied by blood or
silicon oil, excluding that in overlying cortex or adjacent white matter, was derived by
planimetry. Areas of haematoma or silicon oil, and the caudate nucleus (in mm2) were
delineated at each brain level and volumes (in mm3) calculated from these areas with
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knowledge of the distance between brain levels (100pm). Striatal haematoma or
silicon oil was expressed as percentage of the volume of the whole caudate nucleus.
2.10. Neuropathology
All the staining procedures were performed in the Department of Neuropathology at
the Western General Hospital, using standard histological techniques (Bancroft &
Cook, 1994; Cox, 1982; Stevens, 1982).
2. 10. 1. Haematoxylin and eosin (H+E)
The sections (20p thick) were initially placed in water for 30sec (to wash off any
excess poly-L-lysine) and then stained in haematoxylin solution for 1.5min. They were
then washed in water, and "blued" in tap water to which 5-10ml saturated aqueous
lithium carbonate was added. They were again washed in water and then stained in
eosin solution for 2min, washed in water and eosin fixed in tap water with 5-10ml
potassium alum added, for lOsec. Finally, the sections were washed, dehydrated,
cleaned and mounted.
The haematoxylin solution was prepared as follows: 3g of haematoxylin powder was
dissolved in 20ml of absolute alcohol, with the aid of gentle heat. This was added to
2000ml of distilled water and oxidized by adding 0.4g sodium iodate. lOOg potassium
alum was added as a mordant. The mixture was boiled for 2min, allowed to cool and
finally 2ml acetic acid was added to 100ml of the solution before use.
The eosin solution was prepared from two solutions, the first containing 5% eosin L
in distilled water and the second containing a saturated solution of eosin ethyl in 95%
alcohol. Two volumes of the first solution were mixed with one volume of the second
solution and the resultant solution was ready for use.
With this method nuclei appear blue and cytoplasm, connective tissue, red blood cells
and muscle appear pink.
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2. 10. 2. Luxolfast blue with cresyl violet (LFB)
The sections (20p thick) were placed in water for 30sec and then stained in luxol fast
blue (lg, dissolved in 5ml of 10% acetic acid and 1000ml of alcohol and filtered
before use) for 30min. They were afterwards washed in water and differentiated in
0.1% lithium carbonate for a few seconds, followed by 70% alcohol for 20-30sec.
This procedure was repeated until the required degree of differentiation was achieved.
The sections were again washed in water and counterstained with 0.1% cresyl violet
for 2min. Finally, they were washed, dehydrated, cleaned and mounted. With this
method myelin is stained deep blue and neuronal cell bodies (Nissl substance) are
purple.
2. 10. 3. Periodic AcidSchiff (PAS) Stain
One of the effects of long-standing hyperglycaemia is the non-enzymatic glycosylation
of long-lived tissue proteins. This process also occurs with aging. With the PAS stain
it is sometimes possible to visualize this deposition of glycogen and periodate reactive
carbohydrates (appearing magenta) in the bodily tissues. Brain sections of the diabetic
animals used for autoradiographic measurement of basal LCBF (section 2. 7. 1.) were
examined, with non-diabetic (DR) brain sections of animals used for measurement of
basal LCBF serving as controls.
The sections were initially washed with water for 30sec. They were then put to 1%
periodic acid for 2-3min. They were afterwards washed well in running water for 5-
lOmin. Schiffs reagent (0.5M in water at 20°C, Sigma) was added for 2-3min. They
were again washed well in running water for 5-10min. Then, it was counterstained
lightly in haematoxylin (prepared as described in section 2. 10. 1.). Following that
they were differentiated in acid alcohol and "blued" in lithium carbonate. Finally, they
were washed, dehydrated, cleared and mounted.
2. 10. 4. Electron microscopy (EM) ofmicrovessels in diabetic and DR rats
For these studies, the animals were anaesthetized with pentobarbitone (30-45mg.kg"1)
and the right femoral artery and vein were cannulated in the same way described in
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section 2. 2. 2. The arterial cannula was used to monitor the MABP continuously and
for withdrawal of blood for physiological measurements.
Initially, 2ml of heparin (2000IU) was injected through the right femoral vein.
Subsequent to that a thoracotomy was performed and the pericardium opened. The
apex of the left ventricle was incised and a cannula was introduced into the ascending
aorta. The cannula was clamped in the ascending aorta. The atria were subsequently
opened. 50ml of sodium phosphate buffer (0.1M) at room temperature was rapidly
perfused transcardially in order to clear the intravascular space from the blood. Care
was taken to keep the MABP between 100 and 160mmHg, by adjusting the rate of
perfusion. Afterwards, transcardiac perfusion of 300ml of a solution containing 0.2%
gluteraldehyde and 4% parformaldehyde in 0.1M sodium phosphate buffer was
performed.
After the end of the perfusion the brain was dissected intact and immersed in perfusate
for 24h at 4°C to ensure complete fixation. Previous studies performed by others in
this laboratory using the same perfusion fixation technique, have revealed that there
were sometimes perfusion artifacts in the brain parenchyma (dark neurons) when the
brain was left in the perfusate for more than 4h. However, no artifacts relating to the
structure of the vessels have ever been noted.
The brain was finally cut in gross coronal blocks 2mm apart, and specimens of tissue
(1mm') were taken from the cortex, the basal ganglia, the hippocampus and the white
matter. The tissues were processed using standard approaches for EM by Dr James
Ironside, Consultant Neuropathologist in Western General Hospital, Edinburgh.
2. 11. Analysis ofneuropathological sections
As already described, most of the neuropathological sections that were analyzed were
obtained from frozen tissue, so the criteria set by Brown & Brierley in 1968 regarding
the microscopic appearance of ischaemic/hypoxic cell damage could not be used in
these studies. As an alternative approach, the area of striatal tissue in which pallor and
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cell loss was evident in the lesioned brains was calculated in each section with the use
of the densitometer, in the same way that the volume of striatal blood or silicon oil
were analyzed (section 2. 9.). The boundary of this area was sharply demarcated in
the haematoxylin and eosin and luxol-fast blue sections from the adjacent normal brain
tissue. This procedure was undertaken primarily to study to which extent the CBF
thresholds set for the calculation of striatal ischaemia (section 2. 8. 2.) corresponded
to presence of structural abnormality. This analysis was conducted "blind" to either
animal strain or treatment group.
2. 12. Drugs (L-NAME, 7-NI, SIN-1, SB209670)
7-NI and SB209670 were used in experiments investigating both physiology and
pathology. In contrast, L-NAME and SIN-1 were only used in relation to physiology.
G
2. 12. 1. N -nitro-L-arginine methyl ester (L-NAME)
The non-selective NOS inhibitor L-NAME (Sigma) was dissolved in saline at a
concentration of 30mg.mf1. It was injected at a dose of 30mg.kg"' i.v. over 30sec and
LCBF was measured 20min later. MABP and core temperature were monitored
constantly and the rest of the physiological parameters were measured before the
injection of L-NAME and before the measurement of LCBF. The control animals
were injected with an equal i.v. volume of saline.
L-NAME, at the dose used in the experiments presented in this thesis has been
previously shown to reduce LCBF significantly by 15min post-injection and the effect
is maintained stable for at least 3h (Kelly et al., 1994b; Macrae et. al., 1993).
2. 12. 2. 7-nitroindazole (7-NI)
The selective nNOS inhibitor 7-NI (Lancaster Synthesis) was dissolved in sesame oil
on a hot-plate at 70°C at a concentration of 12.5mg.ml"1. It was injected fast i.p. at a
dose of 25mg.kg"1 and LCBF was measured 40min later. MABP and core temperature
were monitored constantly and the other physiological parameters were measured just
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before the injection and before the LCBF measurement. The control animals were
injected i.p. with the same volume of sesame oil, at the same temperature.
In the experimental ICH studies, the same dose was injected i.p. 30min after the
induction of the haematoma, while the animals were under the influence of the
anaesthetic.
7-NI is selective for neuronal NOS in vivo (Moore et al., 1993a,b) and at the dose
used in the experimental procedures outlined in this thesis, produces significant
reductions in LCBF (Kelly et al., 1995b). Doses of 7-NI higher than that used here
have been shown to produce further reductions in cerebral blood flow in normal rats
(Kelly et al., 1995b; Wang et al., 1995), but they may also produce anomalous focal
hyperaemia (Kelly et al., 1994a; 1995b). In the haematoma studies, the dose of 7-NI
and the timing of the injection relative to the induction of the haematoma were chosen
on the basis of reports of a neuroprotective effect in a rat model of focal cerebral
ischaemia (Kelly et al., 1994a).
2. 12. 3. 3-morpholinosydnonimine (SIN-1)
The NO donor compound SIN-1 (donated by Cassella AG) was dissolved in saline at
a concentration of 250pg.ml"1 or 62.5pg.mf1. It was infused i.v. over 20min using an
infusion pump set at a rate of 1 .Smg.kg'Vh"1 in the diabetic and non-diabetic groups,
and at a rate of l.Bmg.kg^.h"1 or 0.54mg.kg"'.h"1 in two groups of WKY and SFIR.
MABP and core temperature were monitored constantly throughout this infusion
period. Equal volumes of saline (-40 or 48pl.min"1) were infused in the control
animals.
In a series of preliminary studies, it was found that an i.v. infusion of SIN-1 at 1.8mg
kg"1 h"1 for 20 to 30 min completely blocked the expected cardiovascular and
cerebrovascular effects of subsequent i.v. injection of L-NAME (30mg.kg_1),
indicating saturation by exogenous NO. However, when this dose was used in the
SFIR, it produced a reduction in MABP very close to the lower limit of pressure
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autoregulation reported for this sub-strain (Barry et al, 1982; Harper & Bohlen,
1984). Therefore, a second lower dose (0.54mg.kg"1.h"1) was also used for the SHR,
which produced similar magnitude of reduction in MABP in WKY and SHR.
2. 12. 4. SB209670
The ET-antagonist SB209670 (donated by Dr Ohlstein, Smith-Klein Beecham
Pharmaceuticals, King of Prussia) was dissolved in saline at a concentration of
lOmg.mf1. It was injected i.v. in the physiological studies at a dose of lOmg.kg"1 over
30sec. LCBF was measured 20min later. MABP and core temperature were
monitored throughout this period. The rest of the physiological parameters were
measured before the injection and before the LCBF measurement. Because both the
mode of administration and vehicle were similar to that of L-NAME, the same saline
controls were used. SB209670 is a non-peptide endothelin antagonist, so delivery
across BBB was not of concern (Ohlstein et al., 1994).
For the haematoma studies, SB209670 was administered i.p. at the same dose
(lOmg.kg"1), starting 30min prior to the haematoma induction and continuing every 6h
for 24h. The last i.p. injection was administered 2h prior to the LCBF experiment.
Control animals received i.p. injections of saline. Barone and his colleagues reported
neuroprotection with the use of a very similar ET antagonist in 1995, and the protocol
employed in the haematoma studies was based on that report.
2. 13. High performance liquid chromatography (HPLC) for L-arginine
The aminoacid analysis of plasma was kindly performed by Mr Douglas Thompson, at
the Department of Clinical Neurosciences in the Western General Hospital. Briefly,
the procedure was as follows:
Venous blood (200pl) was obtained by tail-tipping from awake diabetic and non-
diabetic animals. The blood specimens were placed in individual heparinized tubes and
centrifuged at 10.000 rpm for lOmin. lOOpl of the supernatant plasma was placed into
polythene vial and stored at -20°C for 5 days. Each specimen was then brought to
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room temperature and 30pl of that plasma together with 70pl of methanol (to
precipitate the proteins) were vortex-mixed for lmin in a polythene vial. The mixture
was then centrifuged at 10000 rpm for 10 min. lOpl of the supernatant was removed
and mixed with 70pl of borate buffer (accq-tag kit) and then, 20pl of accq-tag reagent
was added and vortex mixed for 10 sec. 30pl of that mixture was placed in an
autosampler vial and loaded in an autosampler tray, and lOpl was injected into the
accq-tag column for aminoacid analysis using the Waters HPLC system (Waters
Corporation, Milford, Massachussets).
2. 14. Whole blood viscosityfor the BB rats
IDDM is associated with increased viscosity in humans. Several studies have raised
the possibility that raised viscosity may be associated with alterations in blood flow
and predisposition to cerebrovascular occlusion (see appropriate section in
Introduction). Therefore, whole blood viscosity was measured in groups of diabetic
and non-diabetic BB rats.
Venous blood (1.5ml, obtained by tail-tipping in awake animals, 30min after the daily
injection of insulin in the diabetic rats) was introduced into a heparinized tube and
taken to the Royal Infirmary of Glasgow, where Professor Gordon Lowe measured
the blood viscosity in each animal, relative to standard fluids of known viscosity.
2. 15. Measurement ofglycosylated haemoglobin
Glycosylated haemoglobin values were determined from some diabetic animals and
non-diabetic BB controls in order to assess the degree of metabolic control achieved
with the insulin treatment. These measurements were performed by Dr Mark Lindsay,
at the Metabolic Unit of the Western General Hospital.
Briefly, blood samples were obtained by tail tipping in awake rats using heparin as an
anticoagulant. The samples were centrifuged for 5min at 10,000 revs.min'1 and the
plasma collected for glucose determination (Beckmann Glucose Analyser 2). The
remaining red blood cells were washed three times in 0.9% sodium chloride and
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incubated overnight at room temperature with an equivalent volume of saline. The
cells were then centrifuged and the supernatants discarded. The resulting packed cells
were haemolyzed by the addition of three volumes of a 1:10 dilution of haemolyzing
reagent (0.1% saponin and 0.05% EDTA in distilled water, Ciba Corning Diagnostics
Corp., Palo Alto, CA.) After vortex mixing for 15sec the haemolyzed cells were spun
at 10,000 revs.min"1 for 5min and lpl of the resulting haemolysate was applied to
individual sample wells on an electrophoretic plate (Ciba Corning glycosylated
haemoglobin citrate agar gel electrophoresis film). The rat haemoglobin components
were separated by electroendosmosis using 0.1M citrate buffer (pH 6.3) under 60V
for 40 min. The percentage ofglycosylated haemoglobin was determined by automatic
scanning densitometry on a Corning 720 fluometer/densitometer using a 420 nm filter.
2. 16. Assessment ofphysiological status during the induction ofhaematoma
All haematoma recipients were expected to survive for the following 24h and for
ethical and practical reasons these rats could not be fully instrumented. As
physiological status at the time of haematoma induction could seriously influence the
final outcome (Bileviciute et a/., 1995), a series of experiments were performed using
exactly the same protocols outlined in section 2. 2., but in which the animals were
cannulated to allow physiological variables to be measured.
Animals were anaesthetized with Pentobarbitone (30-45mg.kg_1). The right femoral
artery was cannulated as described above. Following that, continuous MABP
monitoring was initiated and arterial blood was taken for estimation of arterial blood
gases and plasma glucose. The animals were placed on the stereotactic frame as
described previously (on a thermal blanket, an oxygen mask delivering 4 litres of
oxygen per minute and with a rectal thermometer in situ) and 50pl of blood was
injected in the striatum using the protocol already described. Arterial blood gas
measurements were repeated 30min after the injection of the blood, and then the
animals were sacrificed with an overdose of barbiturate.
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2. 17. Measurement of intracranialpressure (ICP)
ICP was measured at the time of the haematoma induction in two pilot experiments,
since extensive relevant information is already available in the literature (see
Introduction) The results of these experiments are therefore not presented in the
Results section, but are only briefly considered in the Discussion
The rats were initially prepared in the same way as for induction of the haematoma. A
burr-hole was made in the left posterior corner of the bregma. A 24G sprott spinal
needle with side port, the side with the opening placed medially, was secured on the
stereotactic apparatus and lowered until the tip touched the brain. The output of the
needle was connected through a fluid link to external strain gauge transducer which
was zeroed at the level of the earbars to atmospheric pressure. The constant infusion
method was employed, with the infusion pump delivering 5ml.h'1 "mock" CSF while
the needle was lowered slowly into parenchyma in 1mm increments observing the
intraparenchymal pressure on a chart recorder. The needle was lowered progressively
to a maximum depth of 4mm from the dural surface, until a step drop in pressure was
observed. This was taken to be the point at which the needle entered the ventricle. At
that point the constant infusion was stopped and the ICP returned to physiological
levels in approximately lOmin. After that time point, the haematoma was induced as
described in section 2. 2. The animal was finally sacrificed with an overdose of
barbiturate 45min later. ICP was recorded constantly throught the experiment.
2. 18. Statistical analysis
Physiological and LCBF data (presented as mean ± standard error of mean) were
analyzed by Student's / test with Bonferroni correction (Wallenstein el a/., 1980)
applied to allow multiple pair-wise comparisons between appropriate groups
(maximum number of comparisons = 3). Differences in the LCBF responses to L-
NAME, 7-NI and SIN-l treatment between the rat sub-strains were analyzed by
Mann-Whitney U-test (Jennrich et al., 1990). Acceptable levels of significance were
set at P < 0.05 for all statistical tests. The number of animals in each treatment group





General conduct of the experiments
Physiology ofcerebrovascular endothelium
There were no unexpected physiological consequences of drug treatments in the
diabetic and DR groups used in the quantitative autoradiographic studies of
cerebrovascular dysfunction. The use of intensified insulin treatment in BB/E rats did
however present problems. One third of the animals originally included in this
protocol died during the intensive treatment regime, possibly due to hypoglycaemia.
Nonetheless, satisfactory data were acquired from the remaining two thirds which
survived.
Experimental ICH
The preliminary experimental ICH studies performed in diabetic and non-diabetic rats,
with injections of 25 pi of blood showed no detectable histopathological changes at
24h. Increasing survival time to 48h did not alter the outcome. In contrast, 50pl
injections resulted in clearly discernible changes in tissues surrounding the haematoma
with survival periods of 24h. In a single diabetic rat subjected to ICH during these
preliminary studies, presence of fibrinoid necrosis was visible in a striatal microvessel
close to the haematoma. This volume (50pl) was used for the main experimental
procedures. Of the diabetic rats used in this study, 20% died after the induction of the
haematoma, and before the LCBF or BBB permeability experiment for reasons
unrelated to the anaesthesia. A seizure was witnessed in one of these animals just
before it died, but most of them were found dead in cages the morning after the
experimental ICH.
The experimental ICH studies in the SHR and WKY rats posed certain problems. The
silicon oil injections in the SHRs were invariably associated with endogenous
bleeding, and it was impossible to differentiate the differential influence of the blood
constituents from that of the mass effect.
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3. 1. Physiological studies with pharmacological manipulation in diabetic and
control animals
3. 1. 1. Physiological variables
In the control (saline or sesame oil-treated) animals, there were no significant
differences in any of the physiological parameters measured, including plasma
glucose, between non-diabetic and insulin-treated diabetic rats (Tables 1, 2 and 3).
Although there were some effects of the drug treatments, physiological variables (with
the exception of MABP) were within the physiological range for rat. Body weights
were not significantly different between non-diabetic and diabetic groups in any of the
studies presented in this thesis (mean weight in both sub-strains was ~400g, data not
shown).
The physiological variables of the CSII-treated diabetic rats and the conventionally-
treated diabetic animals used as controls are presented in Table 4. No significant
differences were found in any of the parameters measured, including plasma glucose.
Glycosylated haemoglobin and haematocrit values were measured only in the CSII-
treated rats.
In the animals treated acutely with L-NAME, there were no differences in the
physiological parameters between non-diabetic and diabetic rats (Table 1). MABP
was significantly higher in both non-diabetic (+24%) and diabetic (+37%) groups,
compared to the saline-treated animals of the same sub-strain. The pattern of rise in
MABP following i.v. administration of L-NAME differed between individual animals,
being sometimes abrupt and more gradual in other occasions, but always lasting
between 2 and 5min before reaching a plateau, which was invariably sustained until
the measurement of LCBF, 20min after the injection. Heart rate was lower in the L-
NAME treated non-diabetic (-26%) and diabetic rats (-19%), compared to the saline-
treated animals of the same sub-strain, although this was not significant (Table 1).
In the groups treated with 7-NI, heart rate was significantly lower in the diabetic
animals (-29%), compared to the non-diabetic rats (Table 2). In the control groups,
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heart rate was again lower (-15%), although not significantly, in the diabetic animals.
Heart rate in the 7-NI - treated diabetic group was also significantly lower (-40%)
compared to the diabetics treated with sesame oil (Table 2). In the non-diabetic rats,
there was also a trend, though not significant for the 7-NI - treated rats to have lower
heart rate (-30%) compared to controls. In contrast to the L-NAME findings, MABP
was not different between 7-NI treated and control animals of any sub-strain.
Following infusion with SIN-1, arterial p02 and body temperature were significantly
lower and pH, plasma bicarbonate and base excess significantly higher in the diabetic
group, compared to the non-diabetic animals (Table 3). In the non-diabetic animals
treated with SIN-1, temperature was significantly higher compared to the animals
treated with saline (Table 3). In the diabetic groups, pH and base excess were
significantly higher and pC02 significantly lower in the SIN-1 - treated rats, compared
to those treated with saline (Table 3). MABP was lower in both non-diabetic (-20%)
and diabetic (-16%) rats treated with SIN-1, compared to the saline-treated animals of
the same sub-strain, although this difference was not statistically significant.
There were no significant differences in the physiological variables between the saline
and SB209670-treated diabetic animals (Table 1). A modest (+11%) non-significant
increase in heart rate was observed in the SB209670-treated rats (Table 1).
Whole blood viscosity was significantly higher in the diabetic animals (4.622 ± 0.174
mPa.s, n = 5) compared to the non-diabetic group (3.840 ± 0.132 mPa.s, n = 6).
Haematocrit did not differ between the same groups (45.4 ± 2.7 % in the diabetics vs
45.2 ± 1.3 % in the non-diabetics).
Plasma L-arginine levels were similar between groups (94.0 ± 2.4 pmol.f1 in the non-
diabetic and 93.8 ± 6.7 gmolT1 in the diabetic, n = 4 in each group).
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3. I. 2. LCBFmeasurements with pharmacological manipulation
LCBF was measured in areas chosen to represent brain regions in the vascular
territories of the anterior, middle and posterior cerebral arteries. In control saline or
sesame oil-injected diabetic rats, mean LCBF was reduced in all 10 brain areas
measured when compared to non-diabetic controls (Tables 5, 6 & 7). However, the
extent of these reductions in LCBF were regionally heterogeneous, ranging from -
14% in parietal cortex (not significant) to -31% in striatum (P < 0.05). The reductions
were statistically significant in six of the areas examined, and these were
predominantly sub-cortical (striatum, globus pallidus, lateral geniculate, corpus
callosum, hippocampal fields CA 2&3 and dentate hilus; Tables 5, 6 & 7; Figures 1, 2
& 3). Taking each diabetic animal individually, there was no correlation between the
extent of LCBF reduction and either duration of diabetes or plasma glucose status at
the time of the experiment.
In the intensively treated (with CSII) diabetic rats, LCBF measurements (Table 8)
were restricted to those grey matter areas where significant differences were
previously encountered between saline-treated non-diabetic and diabetic animals. No
significant differences were observed between the two groups (conventionally-treated
vs CSII-treated), but LCBF was higher in 3 out of the 5 areas examined in the CSII-
treated group (striatum, +17%; lateral geniculate, +12%; globus pallidus, +9%; vs
conventionally-treated animals). No differences were found in the hippocampal fields
CA 2&3 and dentate hilus (Table 8). Within the CSII-treated group, no correlation
was found between glycosylated Hb (8.8 ± 0.6%), or plasma glucose and LCBF in
any of the brain areas examined (Figure 4).
L-NAME treatment produced reductions in LCBF throughout the brain in non-
diabetic animals (Table 5). Only in parietal (-16%) and cingulate areas of cortex
(-18%) and in nucleus accumbens (-25%) did the effects of L-NAME fail to reach
statistical significance. Elsewhere, significant (P < 0.05) reductions in LCBF were
measured, ranging from -26% in the striatum to -40% in lateral geniculate (Table 5).
In contrast, L-NAME treatment had no significant effect upon LCBF in diabetic rats,
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FIGURE 1
Local cerebral blood flow (ml.lOOg '.min ') measured with quantitative [14C]-
iodoantipyrine autoradiography, in four functionally diverse brain regions of




















NON-DIABETIC DIABETIC NON-DIABETIC DIABETIC
Data are presented as mean ± s.e. mean (n = 6 in saline-treated groups, n = 4 in
L-NAME treated groups)
§: significant difference between non-diabetic and diabetic rats receiving the
same treatment (P < 0.05)
#: significant difference between saline and L-NAME treated rats of the same
sub-strain (P < 0.05)
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FIGURE 2
Local cerebral blood flow (ml.lOOg '.min ') measured with quantitative [14C]-
iodoantipyrine autoradiography, in four functionally diverse brain regions of
non-diabetic and diabetic BB rats, 40min after i.p. injection of sesame oil
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Data are presented as mean ± s.e. mean (n = 4 in each group)
§: significant difference between non-diabetic and diabetic rats receiving the
same treatment (P < 0.05)
#: significant difference between sesame oil and 7-NI treated rats of the same
sub-strain (P < 0.05)
78
FIGURE 3
Local cerebral blood flow (ml.lOOg \min') measured with quantitative [14C]-
iodoantipyrine autoradiography, in four functionally diverse brain regions of
non-diabetic and diabetic BB rats, 20min after the onset of i.v. infusion of saline
















NON-DIABETIC DIABETIC NON-DIABETIC DIABETIC
Data are presented as mean ± s.e. mean (n = 4 in each group). Note the
differences in scale along Y axis between the top right (parietal cortex) and the
rest of the graphs.
§: significant difference between non-diabetic and diabetic rats receiving the
same treatment (P < 0.05)
#: significant difference between saline and SIN-1 treated rats of the same sub¬
strain (P < 0.05)
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FIGURE 4
Individual local cerebral blood flow (LCBF, ml.lOOg'.min"1) values in CSII-
treated diabetic rats (n = 7), measured in the brain areas where significant
reductions were observed under basal conditions in the conventionally-treated







































































LCBF was measured with quantitative [14C]-iodoantipyrine autoradiography, is
presented on the Y axis of both graphs and plotted against glycosylated
haemoglobin values (HbAi) from each individual animal (X axis, top graph) or
plasma glucose values measured in each individual animal at the time of the
LCBF experiment (X axis, bottom graph). No correlation between LCBF in any
of the five brain areas measured and HbAi or plasma glucose was found. The
lines in each graph are computer-generated simple curve fits (Cricket Graph,
Macintosh) for each individual brain region.
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with the exception of hypothalamus (Table 5, Figure 1), when compared to the saline-
treated (diabetic) group. Modest non-significant decreases in LCBF were observed,
between -2% in striatum and dentate hilus of hippocampus and -20% in lateral
geniculate and corpus callosum. A comparison of the L-NAME effects between non-
diabetic and diabetic rats revealed a significant difference in the cerebrovascular
response to this non-selective NOS inhibitor. The median reduction in LCBF was
-31.5% in the non-diabetic and -12.5% in the diabetic group (P = 0.004, Mann-
Whitney U-test). In contrast to the significant differences in blood flow between the
saline treated non-diabetic and diabetic groups, there were no significant differences in
LCBF between the groups treated with L-NAME, possibly reflecting an already
reduced basal LCBF in the diabetic rats.
Following treatment with 7-NI there were significant reductions in LCBF in all areas
examined in the non-diabetic animals, compared to sesame oil-treated rats (Table 6,
Figure 2). This reduction in LCBF ranged between -33% in parietal cortex and -55%
in hypothalamus. In contrast to the effects of L-NAME, 7-NI treatment in the diabetic
animals resulted in significant reductions in LCBF in 9 out of the 10 brain areas
examined (Table 6, Figure 2). The reductions ranged between -24% in striatum and
-53% in hypothalamus. The median reduction in LCBF was -50% in the non-diabetic
and -35.5% in the diabetic animals (P = 0.014, Mann-Whitney U-test).
In one of the diabetic animals treated with 7-NI, focal hyperaemia was observed
unilaterally in the cortex, and in the hippocampus and thalamus on the opposite side
(Figures 5 and 6). This phenomenon has been described previously in normal (non-
diabetic) rats, but only at higher 7-NI doses (Kelly et al., 1995b).
SIN-1 infusion resulted in increases in LCBF in the non-diabetic animals in all but one
(corpus callosum) brain areas, compared to the saline-infused rats (Table 7, Figure 3).
However, these increases were statistically significant only in parietal cortex (+42%),
nucleus accumbens (+33%), lateral geniculate (+20%) and dentate hilus of
hippocampus (+26%). In the rest of the areas examined, the increases in LCBF ranged
81
Figure 5: Blood flow (IAP) autoradiogram from a diabetic animal injected acutely with 7-NI
(25mg.kg1). Coronal section obtained at the level of caudate nucleus. Note focal hyperaemia in the
cortex on the left side. Grey scale on the right represents relative optical densities, which can be used
to calculate blood flow (see Methods).
Figure 6: Blood flow (IAP) autoradiogram from the same animal shown in Figure 5. Coronal section
taken at the level of thalamus. Note contralateral hyperaemia in the hippocampus (mainly CA2 and
CA3 layers) and thalamus, in relation to the left sided cortical hyperaemia.
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between +8% in striatum and +21% in cingulate cortex and hypothalamus (median
increase: +20.5%). In the diabetic animals SIN-1 produced increases in LCBF in all
but one (hypothalamus) area (Table 7, Figure 3). These increases reached statistical
significance in seven brain areas (parietal cortex, +100%; cingulate cortex, +31%;
striatum, +31%; globus pallidus, +24%; nucleus accumbens, +39%; lateral geniculate,
+37%; and dentate hilus of the hippocampus, +52%; Table 7). The median increase in
LCBF in the diabetic group was +31% (P = 0.0413, Mann-Whittney U-test vs non-
diabetic). Although globally the response to SIN-1 was greater in diabetics, LCBF
was significantly higher in the striatum and globus pallidus of the SIN-1 treated non-
diabetic rats, compared to the diabetic animals (Table 7, Figure 3).
SB.209670 treatment was confined to the diabetic rats, in order to test whether an
increased ET activity was responsible for the reduced basal LCBF in these animals.
However, non-significant changes in LCBF were observed in the SB209670-treated
rats, compared to the saline-treated diabetic rats (Table 5, Figure 7). Modest, non¬
significant increases in LCBF were observed in 5 out of the ten areas examined,
compared to the saline-treated animals. These ranged between +6% in parietal cortex,
globus pallidus and nucleus accumbens and +13% (almost significant) in the striatum.
LCBF was similar in 3 areas (hypothalamus, lateral geniculate and dentate hilus of the
hippocampus) and showed modest non-significant reduction in 2 areas (cingulate
cortex, -16%; and corpus callosum, -9%).
There was no correlation between LCBF increases following SB209670
administration and regions that had significant reductions in basal LCBF amongst
diabetic animals (Table 5).
3. 2. Electron microscopy results
The potential presence of subendothelial glycosylation products associated with
1DDM, as already mentioned in the Introduction, could have contributed to the
LCBF results, by quenching the endothelially derived NO and therefore reducing its
vasodilatory capacity. Electron microscopy (EM) was used to study the
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FIGURE 7
Local cerebral blood flow (ml.lOOg '.min') measured with quantitative |14CJ-
iodoantipyrine autoradiography, in four functionally diverse brain regions of























Data are presented as mean ± s.e. mean (n = 6 in saline-treated and n = 4 in
SB209670-treated animals)
No significant differences were found between saline-treated and SB209670-
treated rats
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intraparenchymal microvessels predominantly in the areas where basal LCBF was
significantly lower in the diabetic rats (e.g. striatum, hippocampus), compared to their
non-diabetic controls. However, neither abnormal thickening nor differences in the
density of the basement membranes were observed in the diabetic cerebrovasculature,
when compared to vessels obtained from the non-diabetic controls (n = 2, in each
group). Characteristic vessels from striatum of both diabetic and non-diabetic rats are
shown in Figures 8 & 9.
3. 3. Periodic acid schiff (PAS) staining in diabetic brains
The frozen brain sections studied were obtained from the animals used for the basal
LCBF measurements (section 2. 7. 1.). No differences in vessel wall PAS staining
were found between the diabetic and the non-diabetic animals in any of the brain areas
(n = 4, in each group). In particular, no evidence of vascular endothelial basement
membrane thickening or deposition of PAS-positive material was seen in the diabetic
animals in comparison with the controls. These brain sections and the EM
photographs, were examined by Dr James Ironside.
In summary, these results indicate that local cerebral blood flow is compromised in a
regionally heterogeneous manner in the diabetic BB rats under physiological
conditions, associated with reduced endothelial NO bioactivity. This perturbation in
the endothelial NO system does not result from reduced substrate (L-arginine)
availability or structural microvascular abnormalities, and is possibly unrelated to
development of subendothelial AGEs in the cerebrovasculature.
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Figure 8: Electron microscopic appearance of a microvessel (capillary) in the caudate nucleus of a
non-diabetic rat. There is a red cell in the lumen of the vessel. (Print magnification x!6000).
Figure 9: Electron microscopic appearance of a capillary in the caudate nucleus of a diabetic rat. Not
withstanding the difference in magnification, there was no measurable difference in the thickness or
density of the basement membrane of this vessel, compared to that shown in Figure 8. (Print
magnification x28086). There is a platelet in the lumen of the vessel.
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3. 4. Physiological studies with pharmacological manipulation in hypertensive and
control animals
3. 4. 1. Physiological variables
MABP and heart rate were significantly higher in the control (saline and sesame oil-
treated) SHR rats compared to the WKY groups with the same treatment (Tables 9,
10, and 11). In addition, haematocrit was also significantly higher in control SHR rats
compared to WKY (Table 9). Body weights were not significantly different between
WKY and SHR groups in all studies presented in this thesis (mean weight was ~290g
in WKY and ~260g in SHR, data not shown).
L-NAME treatment resulted in significant increases in MABP in both WKY (+27%)
and SHR (+18%)(Table 9). Despite the greater increase in MABP in WKY following
L-NAME, MABP in SHR remained significantly higher than in WKY. Heart rate in
SHR was not significantly affected by L-NAME (-18%), but decreased (-27%) in
WKY and as a result, was significantly lower than in SHR (Table 9).
Treatment with 7-NI had no significant effect upon MABP in either WKY or SHR,
and as a result significant differences in blood pressure found in control rats of these
sub-strains were maintained (Table 10). In SHR treated with 7-NI, a non-significant
reduction in heart rate (-20%) was observed, compared to sesame oil-treated rats
(Table 10).
The lower dose of SIN-1 (O.Sdmg.kg'Vh"1), resulted in a significant reduction in
MABP in SHR (-18%). Although reductions of similar magnitude were also found in
WKY (-20%), these were more variable and not significant (Table 11). With these
parallel decreases in MABP in both sub-strains, the significant difference in blood
pressure found in control rats was maintained. In addition, heart rate was significantly
higher in the SIN-1 - treated SHR compared to the WKY with the same treatment
(Table 11).
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Following the higher dose of SIN-1 (l.Smg.kg'Vh"1), the reductions in MABP in
WKY (-21%) were of a magnitude similar to that found with the lower dose. In
contrast, the higher dose of SIN-1 produced a more marked reduction in MABP in
SHR (-42%) so that the differential, evident in control rats of these sub-strains, was
no longer evident (95 ± 6mmHg in WKY vs 104 ± 5mmHg in SHR) (Table 11).
There were no significant differences in any of the physiological variables between the
saline and SB209670-treated hypertensive animals (Table 9). A modest (-7%) non¬
significant decrease in heart rate was observed in the SB209670-treated rats (Table
9).
3. 4. 2. LCBFmeasurements with pharmacological manipulation
Basal LCBF in control WKY and SHR rats was broadly similar between the two sub¬
strains. Only nucleus accumbens had significantly higher blood flow in the control
SHR. This result was consistent, whether the rats were treated with i.v. saline (Table
12) or sesame oil (Table 13).
Following injection of L-NAME in the WKY group, there was a global tendency
towards decreases in LCBF (with the exception of cingulate cortex) ranging between
-12 and -46% (median= -20%). LCBF was significantly reduced (compared to saline-
treated animals) in seven out of the thirteen brain areas examined (corpus callosum,
nucleus accumbens, hypothalamus, hippocampal fields CA2 and CA3, molecular layer
and dentate hilus; Table 12 & Figure 10).
Similarly, in the L-NAME-treated STIR group there was a global trend towards
reductions in LCBF ranging between -9 and -46% (median= -22%), which reached
acceptable levels of significance in the cingulate cortex, nucleus accumbens,
hypothalamus, hippocampal fields CA2 and CA3, molecular layer and hilus of the
dentate gyrus (Table 12 & Figure 10). There were no significant differences in the




Local cerebral blood flow (ml.lOOg'.min ') measured with quantitative [14CJ-
iodoantipyrine autoradiography, in four functionally diverse brain regions of
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Data are presented as mean ± s.e. mean (n = 6 in saline-treated WKY group, n =
5 in saline-treated SHR group, n = 4 in L-NAME treated groups). Note the
differences in scale along Y axis between the top right (parietal cortex) and the
rest of the graphs.
#: significant difference between saline and L-NAME treated rats of the same
sub-strain (P < 0.05)
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Following the intraperitoneal injection of 7-NI in SHR (Table 13), significant
reductions in LCBF (ranging between -36 and -59%; median= -47%) were found in
all brain areas examined, when compared to the appropriate sesame oil-treated group
(Table 13 & Figure 11). Although the response to 7-NI in the WKY group was
qualitatively similar, significant reductions in LCBF were limited to eleven out of the
thirteen brain areas examined (Table 13 & Figure 11). However, throughout the brain,
the response to 7-NI was less marked in the WKY group (ranging between -15 and -
45%; median= -26%; P = 0.0001 Mann-Whitney U-test) when compared to SHR, and
in seven brain areas (parietal cortex, striatum, globus pallidus, nucleus accumbens,
hypothalamus, lateral geniculate and hilus of the hippocampal dentate gyrus) the
decreases in LCBF were significantly greater in the SHR group (Table 13 & Figure
11).
Following treatment with the lower dose of SIN-1 (O^mg.kg'fh" ) there were
significant increases in LCBF in all but five brain areas (parietal cortex, corpus
callosum, hypothalamus, hippocampal fields CA1 and CA2) in the WKY group (Table
14 & Figure 12). Significant effects ranged from +22% in striatum, to +60% in
cingulate cortex (median= +29%). In contrast, in the SHR group there were
significant effects upon LCBF in only two brain regions (cingulate cortex and globus
pallidus; Table 14 & Figure 12). In the rest of the brain areas examined, the effects of
this lower dose of SIN-1 upon LCBF were less marked than in the WKY (median
increase = +12%, P = 0.0378 vs WKY, Mann-Whitney U-test).
Following intravenous infusion of the higher dose of SIN-1 (1.8mg.kg"1.h~1) there
were significant increases in LCBF in all but three brain areas (corpus callosum,
globus pallidus and hypothalamus) in the WKY group (Table 14 & Figure 12).
Significant effects ranged from +34% in hippocampal field CA2 and striatum, to
+80% in cingulate cortex (median increase was 45%, in comparison to the saline-
infused WKY). The CBF values in most of the brain areas examined were higher
compared to those obtained following treatment with the lower dose of SIN-1 (Table
14 & Figure 12). In contrast, in the SHR group there were no significant effects of
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FIGURE II
Local cerebral blood flow (ml.lOOg'.min ') measured with quantitative [14CJ-
iodoantipyrine autoradiography, in four functionally diverse brain regions of
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Data are presented as mean ± s.e. mean (n = 5 in WKY treated with sesame oil,
n = 4 in all other groups). Note the differences in scale along Y axis between the
top right (parietal cortex) and the rest of the graphs.
§: significant difference between WKY and SHR rats receiving the same
treatment (P < 0.05)
#: significant difference between sesame oil and 7-NI treated rats of the same
sub-strain (P < 0.05)
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FIGURE 12
Local cerebral blood flow (ml.lOOg '.min ') measured with quantitative [14C]-
iodoantipyrine autoradiography, in four functionally diverse brain regions of
WKY and SHR rats, 20min after the onset of i.v. infusion of saline (40pJ.min'),
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Data are presented as mean ± s.e. mean (n = 5 in WKY rats treated with saline,
n = 4 in all other groups) Note the differences in scale along Y axis between the
top right (parietal cortex) and the rest of the graphs.
§: significant difference between WKY and SHR rats receiving the same
treatment (P < 0.05)
#: significant difference between saline and SIN-1 treated rats of the same sub¬
strain (P < 0.05)
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this higher dose of SIN-1 upon LCBF in any region of the brain. In this group, LCBF
ranged from -13% in hypothalamus to +28% in corpus callosum (median increase =
6%; P = 0.0001 vs WKY, Mann-Whitney U-test; Table 14 & Figure 12). A
comparison of LCBF between WKY and SHR groups treated with the higher dose of
SIN-1 revealed significant differences in six of the thirteen brain areas examined
(parietal cortex, cingulate cortex, lateral geniculate, hippocampal field CA1, molecular
layer and hilus of the dentate gyrus) (Table 14 & Figure 12). Although there were no
significant differences between the effects upon LCBF of the two doses of SIN-1 in
SHR, the values obtained following treatment with the higher dose of SIN-1 were
generally lower in most of the areas examined (Table 14 & Figure 12).
SB209670 treatment resulted in non-significant changes in LCBF, compared to the
saline-treated hypertensive rats (Table 12 & Figure 13). Modest, non-significant
increases in LCBF were observed in seven out of the thirteen areas examined,
compared to the saline-treated animals. These ranged between +20% in parietal
cortex and CA1 layer of the hippocampus, +15% in striatum and globus pallidus and
+9% in lateral geniculate, cingulate cortex and corpus callosum. Finally, modest non¬
significant reductions in LCBF were observed in 2 areas (hypothalamus -22% and
dentate hilus of the hippocampus -9%) associated with SB209670 treatment (Table
12 & Figure 13).
In summary, these results indicate that although local cerebral blood flow is not
compromised in the SHR under physiological conditions, the NO-dependent
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Data are presented as mean ± s.e. mean (n = 5 in saline-treated and n = 4 in
SB209670-treated animals)
No significant differences were found between saline-treated and SB209670-
treated rats
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3. 5. LCBF 24h after induction of experimental ICH in diabetic and control
animals
3. 5. 1. Physiological variables
The physiological variables of the animals used to assess the effect of the anaesthetic
during the induction of the haematoma are outlined in Table 15. There were no
pathological derrangements of arterial blood gases or MABP measurements in either
the diabetic or non-diabetic animals. Interestingly, MABP was elevated post-induction
of haematoma, not significantly though, in both groups, compared to pre-induction of
the mass lesion (Table 15).
Heart rate was significantly lower in the diabetic animals injected with blood or silicon
oil, compared to the non-diabetic rats receiving the same insult (Table 16). Arterial
pH, body temperature, plasma bicarbonate and base excess were also significantly
lower in the diabetic animals injected with silicon oil compared to the non-diabetic
animals with the same mass lesion (Table 16). The temperature of the diabetic animals
injected with silicon oil was also significantly lower to that of the diabetic animals
injected with blood (Table 16).
3. 5. 2. Volume ofhaematoma/silicon oil
The volume occupied by the mass of blood or silicon oil (measured exclusively in the
striatum) and estimated post mortem by planimetry, was not significantly different
between groups. In non-diabetic rats, 10 ± 2.5% of total striatal volume was occupied
by blood post mortem (Figure 15), compared to 8.5 ± 2.5% in diabetic rats (Figure
14). In non-diabetic rats injected with silicon oil, 7.5 ± 3% of total striatal volume was
occupied by the injectate, compared to 7.0 ± 1.5% in diabetic animals.
3. 5. 3. Volume ofstriatal oligaemia
The volume of striatal tissue with LCBF less than 15ml. 100g"'.min"1 was not
significantly different between groups, whether injected with blood or silicon oil
(Table 17 & Figure 16). Although the mean value for diabetic animals injected with
blood (1.91 ± 0.90 mm') was considerably higher than in either the same sub-strain
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Figure 14: Unstained coronal section from an individual diabetic rat brain showing presence of
blood in the right caudate nucleus. Arterial blood (50|il) was injected 24h prior to the measurement
of local cerebral blood flow (see Methods). Figures 17 & 19 are from sections obtained from the same
animal.
Figure 15: Unstained coronal section from an individual non-diabetic rat brain showing presence of
blood in the right caudate nucleus. Arterial blood (50pl) was injected 24h prior to the measurement
of local cerebral blood flow. Figures 18 & 20 are from sections obtained from the same animal.
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FIGURE 16






































Volumes of striatal oligaemia (mm3) with blood flow between thresholds of 0-15, 15-35 and
0-35ml.l00g"1.min~\ in non-diabetic rats with haematoma or silicon oil injection, top graph; and diabetic
rats with haematoma or silicon oil injection, middle graph. The response of non-diabetic and diabetic
rats to haematoma alone is summarized in the bottom graph. LCBF was measured with quantitative
[14C]-iodoantipyrine autoradiography, 24h after induction of haematoma or silicon oil injection. Data are
presented as mean ± s.e.mean (n=6 in groups with haematoma, n=5 in groups with silicon oil injection).
Note the differences in scale along Y axis of non-diabetic and diabetic animals (top and middle graphs)
#: significant difference between non-diabetic rats with haematoma or silicon oil injection (P < 0.05)
*: significant difference between diabetic rats with haematoma or silicon oil injection (P < 0.05)
§: significant difference between non-diabetic and diabetic rats with haematoma (P < 0.05)
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injected with silicon oil (0.12 ± 0.04 mm3) or in non-diabetic rats injected with either
blood ( 0.11 ± 0.05 mm') or silicon oil (0.57 ± 0.37 mm), the co-efficient of variation
[standard deviation / mean] was close to 100%. It is also likely that part, or in the
case of silicon oil all (Figures 21 & 22) of the tissue with this level of ischaemia is
occupied by the mass lesion itself. As this is largely similar between groups,
differences in the effects of the mass lesion upon the perilesional flow are likely to be
obscured. Another consideration is that in the case of silicon oil the mass was typically
spherical, whereas in the case of blood ,it traversed along those tissue planes with
least resistance resulting in interdigitations of parenchyma (Figures 14 & 15).
The volume of striatal tissue with LCBF less than 35ml. lOOg'Vmin"1 was significantly
larger in diabetic animals injected with blood (4.55 ± 1.30mm3) than in either diabetic
animals injected with silicon oil (0.31 ± 0.08mm3) or non-diabetic animals injected
with blood (0.75 ± 0.15 mm"; Table 17 & Figure 16). Upon comparison of the
iodoantipyrine autoradiograms with the neuropathological slides from the adjacent
brain sections, it was evident that these areas of severe oligaemia correlated closely to
areas with evidence of tissue damage (pallor and cell loss; Figures 17, 18, 19 & 20).
No difference in the volume of oligaemia was observed between non-diabetic animals
injected with blood or silicon oil (0.75 ± 0.41mm3).
For reasons explained above striatal tissue with blood flow thresholds between 15 and
35ml. lOOg'Vmin"1 was also measured, in an attempt to identify presence of significant
hypoperfusion in an area purely perilesional, since part of the tissue with LCBF values
less than 35ml.l00g"1.min"1 would have been occupied by the haematoma or silicon
oil. Striatal tissue with blood flow between 15 and 35ml.l00g"1.min"1 was significantly
larger in the diabetic animals injected with blood (2.64 ± 0.44 mm3) compared to non-
diabetic animals injected with blood (0.64 ± 0.10 mm") or diabetic animals injected
with silicon oil (0.19 ± 0.06 mm"; Table 17 & Figure 16). Interestingly, the volume of
tissue within these thresholds was significantly larger in the non-diabetic animals















Figure 17: Colour-coded IAP autoradiogram from a diabetic animal injected with blood (50pl) in the
right caudate nucleus. Note the area of dense striatal ischaemia (white colour) surrounded by a zone
of significant oligaemia (purple and dark blue colour). The caudate lateral to the oligaemic rim has
hyperaemia (green colour) relative to the contralateral non-lesioned striatum. The colour scale on the
right represents relative optical densities.
Figure 18: IAP autoradiogram from a non-diabetic animal injected with 50pl blood in right striatum.
Note that the area of the caudate with significant hypoperfusion is smaller than that of the animal in
Figure 17. There is presence of hyperaemia in the lesioned striatum (green colour) relative to the
contralateral side.
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Figure 19: Coronal brain section stained with haematoxylin and eosin, obtained from the same
animal and adjacent to that shown previously in Figure 17. Note an area of tissue damage in the right
striatum clearly demarcated from the surrounding normal parenchyma, corresponding closely to the
area of oligaemia evident on the autoradiogram of Figure 17.
Figure 20: Coronal brain section stained with cresyl violet and luxol-fast blue, obtained from the
same animal and adjacent to that shown in Figure 18. Note an area of tissue pallor in the right
striatum clearly demarcated from the surrounding normal parenchyma, corresponding closely to the
area of hypoperfusion evident on the autoradiogram of Figure 18.
100
Figure 21: Colour-coded IAP autoradiogram from an animal with right-sided intrastriatal injection
of 50pl silicon oil. The area occupied by the silicon oil has no detectable blood flow (green colour in
the striatum similar to the colour of the background) and is surrounded by a thin zone of
hypoperfusion (yellow colour) located mainly in the superomedial aspect of the striatum. The colour
scale on the right side represents relative optical densities.
Figure 22: Coronal section obtained from the same animal and adjacent to that shown in Figure 21,
stained with cresyl violet and luxol-fast blue. Note the area of the right striatum occupied by the
silicon oil, surrounded by an area of pallor, clearly demarcated from the surrounding normal tissue,
and corresponding to the area of hypoperfusion visible in Figure 21.
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Although it is appreciated that the selection of blood flow threshold at 15ml.
100g"1.min"1 representing tissue potentially occupied by the haematoma or silicon oil
was somehow arbitrary, the results obtained with flow between 15 and 35ml. lOOg"
Vmin"1 were rather robust and reinforced by the manifestation of similar differences
between groups when thresholds between 15 and 25ml. 100g"1.min"1 or between 25
and 35ml. 100g"'.min"1 were estimated (Table 17). In one diabetic animal there was
clear evidence of striatal oligaemia and tissue damage, despite the fact that the
haematoma was contained within ventrolateral white matter, with no evidence of
blood within the striatum itself. This animal was excluded from the quantitative
analysis of striatal oligaemia described above.
In summary, these results show that the volume of perilesional striatal oligaemia, 24h
after experimental ICH, was influenced by the presence of intraparenchymal blood and
that the presence of diabetes mellitus exacerbated the extent of this oligaemia.
3. 5. 4. Presence ofhyperaemia
Presence of hyperaemia was observed in the lesioned striatum just lateral to the area
of oligaemia (Figures 17 & 18), when compared to blood flow in the contralateral
striatum (ranging between +27 and +116 % in the diabetics injected with blood, +25
and +113 % in the non-diabetics injected with blood and +23 and +82 % in the silicon
oil-injected groups). Hyperaemia was also observed in the overlying cortex in 2 out of
the 6 diabetic animals injected with blood (Figures 23 & 24). The extent of this
hyperaemia was not influenced by the presence or not of diabetes (with the exception
of cortical hyperaemia) or by the presence of blood or silicon oil.
3. 5. J. LCBF remote from the haematoma or silicon oil
LCBF was measured in structures contralateral to the haematoma or silicon oil. The
blood flow in the contralateral striatum of the diabetic animals injected with blood was
significantly lower compared to the non-diabetic rats with the same mass lesion (89 ±
7 vs 120 ± Sml.lOOg'Vmin"1). Similarly, blood flow in the contralateral globus pallidus
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Figure 23: IAP autoradiogram from a single diabetic rat with right-sided intrastriatal injection of
blood. Ipsilateral striatal and cortical hyperaemia were observed, surrounding the hypoperfused area
in the striatum. This phenomenon was observed in only 2 out of 6 rats in this group. Grey scale in
the right side represents relative optical densities, which can be used to calculate blood flow (see
Methods).
Figure 24: Coronal brain section stained with cresyl violet and luxol-fast blue, obtained from the
same animal and adjacent to that shown in Figure 23. No evidence of structural abnormality in the
hyperaemic areas seen in Figure 23.
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was significantly lower in the diabetic group (64 ± 4 vs 77 ± 2ml. 100g"'.min"1 in the
non-diabetic animals injected with blood).
In the silicon oil injected groups, similar patterns of significant differences were
obtained. Striatal blood flow was 92 ± 3ml.l00g"1.min"1 in the diabetics and 123 ±
3ml.l00g"1.min"1 in the non-diabetics. Blood flow in the globus pallidus was 49 ±
5ml.lOOg'Vmin"1 in the diabetics and 78 ± 2ml.l00g"1.min"1 in the non-diabetics.
Obviously, these LCBF findings were expected on the basis of the earlier presented
results in the studies of cerebrovascular physiology.
3. 6. Effects ofhaematoma upon BBB permeability
3. 6. 1. Physiological variables and volume ofhaematoma
Physiological parameters did not differ between groups, apart from the temperature
being significantly reduced in the diabetic group compared to the non-diabetic animals
(Table 18).
Haematoma volume lying exclusively in the striatum and measured post mortem by
planimetry was not significantly different between groups (9 ± 2.5% of total striatal
volume in both non-diabetic and diabetic groups) and was similar to that found in the
LCBF studies.
3. 6. 2. Unidirectional transfer constant for AIB
Visual inspection of the autoradiograms showed that extravasation of the isotope was
limited to the tissue surrounding the haematoma. Quantification of the films revealed
that there was no significant difference in the calculated K, for AIB between diabetic
and non-diabetic animals in either the lesioned or contralateral striatum (7.66 ±
1.29ml.g"1.min"1.10° in the diabetic and 6.00 ± 0.55ml.g"1.min"1.10"3 in the non-diabetic
animals in the lesioned side and 2.17 ± OJSml.g'Vmin"1.10° in the diabetic and 2.05 ±
0.29ml.g~1.min~1.10"' in the non-diabetic animals in the contralateral side; Figures 25 &
26). The area of tissue pallor in the neuropathological slides taken from adjacent
sections was generally larger than the area of isotope accumulation (Figures 27 & 28).
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Figure 25: AIB autoradiogram from a non-diabetic animal with intrastriatal injection of 50jil blood.
Isotope extravasation was confined to the area surrounding the blood clot. There is also isotope
extravasation in the pial surface and the choroidal ventricular surface.
&
mmw
Figure 26: AIB autoradiogram from a diabetic rat injected with 50gl blood. Note the similar pattern
and intensity of isotope extravasation to that shown in Figure 25.
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Figure 27: Coronal brain section stained with cresyl violet and luxol-fast blue, from the same animal
and adjacent to that shown in Figure 25.
Figure 28: Coronal brain section stained with cresyl violet and luxol-fast blue, from the same animal
and adjacent to that shown in Figure 26.
106
3. 7. Haemodynamic effects of the endothelin antagonist SB2096 70
3. 7. 1. Physiological variables and volume ofhaematoma
In SB209670-treated non-diabetic and diabetic groups, plasma bicarbonate and base
excess were significantly higher compared to the saline-treated animals (Table 19).
Arterial pH was also significantly higher in the non-diabetic animals treated with
SB209670 compared to the saline-treated animals of the same sub-strain.
MABP, measured at the time of the iodoantipyrine experiment, was considerably
lower in the diabetic animals treated with SB209670 (98 ± 6mmHg) compared to the
MABP of the diabetic animals with saline treatment (116 ± 9mmHg) (Table 19). This
16% difference did not reach statistical significance though. There were no differences
in MABP between non-diabetic rats with saline (117 ± 2mmHg) or SB209670
treatment (115 ± 4mmHg).
The volume occupied by the haematoma in the striatum, measured post mortem by
planimetry, was not significantly different between groups. In the non-diabetic
animals, it occupied 11 ± 2.5% of the striatum in the saline-treated and 10 ± 2.5% in
the SB209670-treated groups, whereas in the diabetic animals it occupied 9 ± 2.5% of
the striatum in the saline-treated and 10 ± 2.5% in the SB209670-treated animals.
3. 7. 2. Volume ofstriatal oligaemia
The volume of striatal tissue with LCBF less than 15ml.l00g"'.min"1 was not
significantly different between groups, treated with saline or SB209670 (Table 20 &
Figure 29). Although the mean value for non-diabetic animals treated with SB209670
(0.0015 ± 0.0001mm") was considerably lower than that of saline-treated animals of
the same sub-strain (0.13 ± 0.06mm''), the co-efficient of variation was close to 100%
in the saline-treated rats. In the diabetic rats, there was no difference between saline





































Volumes of striatal oligacmia (mm3) with blood flow between thresholds of 0-15, 15-35 and
0-35ml.l00g"1.min"1, in non-diabetic (DR) rats (top graph) with haematoma (50pl) treated with either
saline (0.5ml i.p. every 6h, starting 30min prior to induction of haematoma and continuing for 24h) or
SB209670 (lOmg.kg1 i.p. every 6h, starting 30min prior to induction of haematoma and continuing for
24h), and diabetic BB rats (bottom graph) with haematoma (50pl), treated with either saline or
SB209670 employing the same protocol used in the non-diabetic animals. Blood flow was measured with
quantitative [14C]-iodoantipyrine autoradiography, 24h after the induction of haematoma. Note the
differences in scale along Y axis of non-diabetic and diabetic animals (top and bottom graphs)
Data are presented as mean ± s.e.mean (n = 6 in SB209670-treated non-diabetic group, n = 5 in all other
groups)
#: significant difference between saline and SB209670-treated non-diabetic rats (P < 0.05)
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In diabetic animals, SB209670 treatment had no significant effect upon the volume of
striatal tissue with LCBF less than SSml.lOOg'Vmin"1 (5.14 ± 1.58mm3 5.11 ±
1.44mm following saline treatment). Interestingly, the non-diabetic animals treated
with SB209670 had a significantly smaller volume (0.10 ± 0.05mm3) compared to the
non-diabetic with saline treatment (0.80 ± 0.17mm3; Figure 29 & Table 20).
Striatal tissue with flow thresholds between 15 and 35ml. 100g"'.min"1 was
significantly larger in the non-diabetic animals with saline (0.67 ± 0.11mm3) compared
to non-diabetic animals with SB209670 (0.10 ± 0.06mrrf). In the diabetic animals,
SB209670 had no effect (2.85 ± 0.47 mm'1 in the group with saline and 3.85 ±
1.10mm" in the group with SB209670; Table 20 & Figure 29).
Similar patterns of differences between groups were observed in the blood flow
thresholds between 25 and 35ml.lOOg"1.min"1, and between 15 and 25ml.lOOg'Vmin"1
(Table 20).
These results show that the treatment with the non-peptide ETA/ETB receptor
antagonist SB209670 resulted in some haemodynamic improvement in the perilesional
area of non-diseased rats 24h after experimental ICH, whereas it had no effect in the
diabetic group.
3. 7. 3. Effects ofSB209670 upon LCBF remote from the haematoma
Blood flow in the contralateral to the haematoma striatum was significantly increased
(+41%) in the diabetic rats treated with SB209670 (121 ± 6ml.lOOg'Vmin"1)
compared to the diabetic animals with saline treatment (86 ± 7ml.l00g~1.min~1). In the
non-diabetic groups there was a small (-5%) non-significant decrease in flow (123 ±
3ml.lOOg'Vmin"1 in the SB209670-treated group and 129 ± 5ml.lOOg'Vmin"1 in the
saline-treated group).
In the contralateral globus pallidus, flow in the SB209670-treated diabetic rats was
non-significantly increased (+13%) compared to the saline-treated animals (70 ±
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5ml.l00g"1.min"1 and 62 ± 4ml.l00g'1.min"1 respectively). In the non-diabetic animals,
SB209670 treatment resulted in a +6% (non-significant) increase in flow (83 ±
4ml.l00g"I.min"1 vs 78 ± 2ml. lOOg'Vmin"1).
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3. 8. LCBF 24h after induction of experimental ICH in spontaneously
hypertensive and control animals
3. 8. 1. Physiological variables
The physiological variables of the animals used to assess the effect of the anaesthetic
during the induction of the haematoma are outlined in Table 21. There were no
pathological de-arrangements of arterial blood gases or MABP measurements in
either the WKY or SHR animals. Again, as found in the diabetic studies, MABP post-
induction of haematoma was elevated, not significantly though, in both groups,
compared to pre-induction of the mass lesion (Table 21).
As expected, MABP measured at the time of the iodoantipyrine experiment was
significantly higher in the hypertensive animals injected with blood or silicon oil,
compared to the normotensive animals injected with the same mass lesion (Table 22).
Heart rate in the SHR injected with blood was significantly higher compared to the
WKY injected with blood and also compared to the SHR injected with silicon oil
(Table 22).
3. 8. 2. Volume ofhaematoma/silicon oil
The volume occupied by the mass of blood or silicon oil, measured exclusively in the
striatum and estimated post mortem by planimetry, was not significantly different
between SHR and WKY groups. In WKY, 11 ± 3% of total striatal volume was
occupied by blood post mortem, compared to 10 ± 3% in SHR. In WKY rats injected
with silicon oil, 9 ± 3% of total striatal volume was occupied by the injectate,
compared to 7 ± 3% in SHR.
3. 8. 3. Volume ofstriatal oligaemia
The volume of striatal tissue with LCBF less than 15ml.l00g"1.min"1 was not
significantly different between groups. Its mean value was 1.25 ± 0.63mnY for the
hypertensive animals injected with blood, 1.48 ± 1.32mirf for the normotensive
animals with blood, 0.51 ± 0.24mm'' for the hypertensive animals injected with silicon
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oil and 1.57 ± 1.14mm3 for the normotensive animals injected with silicon oil (Table
23 & Figure 30).
The volume of striatal tissue with LCBF less than 35ml. lOOg'Vmin"1 was not
significantly different between groups. It was 3.14 ± 1.09mm3 in the hypertensive
animals injected with blood, 0.90 ± 0.24mm'' in the hypertensive animals injected with
silicon oil, 3.45 ± 1.97mm3 in the normotensive animals injected with blood and 2.99
± 2.24mm'' in the normotensive animals injected with silicon oil (Table 23 & Figure
30). Upon comparison of the iodoantipyrine autoradiograms with the
neuropathological slides from adjacent brain sections, it was evident that the areas
within the above stated blood flow threshold correlated closely with areas showing
evidence of tissue damage (pallor and cell loss).
Striatal tissue with flow thresholds between 15 and 35ml.lOOg'Vmin"1 was not
significantly different between hypertensive and normotensive animals injected with
blood (1.89 ± 0.50mm3 vs 1.96 ± 0.78mm'). The normotensive animals injected with
silicon oil had a similar volume of significant oligaemia (1.42 ± 1.11mm3), whereas the
hypertensive animals injected with the same agent had a volume almost significantly
smaller (0.40 ± 0.02mm3) compared to those injected with blood (Table 23 & Figure
30). There was invariably a degree of bleeding in the striatal parenchyma upon
injection of the silicon oil in the SFIR (Figure 31), so it is impossible to isolate the
cerebrovascular effects of the mass lesion from those of the blood itself.
Similar patterns of differences were observed in the blood flow threshold between 25
and 35ml. lOOg^.min"1 the volumes being 0.82 ± 0.18mm'' for the hypertensive animals
injected with blood, 0.82 ± 0.28mm3 for the normotensive animals injected with
blood, 0.19 ± 0.004mm'' for the hypertensives injected with oil and 0.65 ± 0.48mm''
for the normotensive animals injected with oil (Table 23). Again, at these flow
thresholds the hypertensive animals injected with silicon oil had an almost significantly
lower volume of oligaemia compared to those injected with blood, but for the same
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FIGURE 30






































Volumes of striatal oligacmia (mm3) with blood flow between thresholds of 0-15, 15-35 and
O-SSml.lOOg '.min1, in WKY rats with haematoma or silicon oil injection (50fd), top graph; and SHR
rats with hacmatoma or silicon oil injection (50pl) middle graph.The response of SHR and WKY to
haematoma alone is summarized in bottom graph. LCBF was measured with quantitative [14C]-
iodoantipyrine autoradiography, 24h after the induction of haematoma or silicon oil injection. Data are
presented as mean ± s.e.mean (n = 6 in groups with haematoma, n = 4 in groups with silicon oil injection)
No significant differences were found between groups
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Figure 31: Unstained coronal brain section from a hypertensive rat injected with 50pl silicon oil in
the right striatum. Note the presence of endogenous bleeding associated with the needle injection.
The appearance of the tissue surrounding the silicon oil cavity and the clot is different from the rest
of the brain, because during brain sectioning (see Methods), the silicon oil was smeared along the
direction of cutting.
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reasons outlined above this could not be verified. Similar patterns were observed in
flow threshold between 15 and 25ml.l00g"1.min~1 (Table 23).
These results indicate that the volume of perilesional striatal oligaemia, 24h after
experimental ICH, was probably influenced by the presence of intraparenchymal blood
in the hypertensive animals but not in the normotensive rats. The presence of chronic
hypertension did not exacerbate the extent of this oligaemia.
3. 8. 4. LCBF remote from the haematoma/silicon oil
LCBF was measured in structures contralateral to the mass lesion ^haematoma or
silicon oil). The blood flow in the striatum of the hypertensive animals injected with
blood was 100 ± 6ml. lOOg" .min"1, and in those injected with silicon oil was 112 ±
13ml.lOOg'Vmin"1. The normotensive animals injected with blood had a flow of 120 ±
4ml. 100g"I.min"1, almost significantly higher compared to the hypertensive rats with
the same mass lesion and the normotensive animals with silicon oil injection had a
flow of 139 ± 4ml. 100g"'.min"1, which was significantly increased compared to the
normotensive animals injected with blood. Upon comparison of these LCBF findings
with those observed in the studies of cerebrovascular physiology (Tables 12, 13 &
14), WKY rats subjected to ICH or silicon oil injection had higher LCBF values
compared to the non-lesioned animals of the same sub-strain. This was not the case in
the SHR rats, where LCBF values following ICH or silicon oil injection were similar
to those obtained in the studies of cerebrovascular physiology.
Blood flow in the globus pallidus of the hypertensive group injected with blood was
66 ± 3ml.100g"1.min~1 and in the normotensive group was 74 ± 3ml. 100g"1.min~1. In
the animals injected with silicon oil, blood flow was 66 ± 5ml.lOOg^.min"1. in the
hypertensives and 90 ± 2ml. lOOg'Vmin"1 in the normotensive animals which was
significantly increased compared to both the normotensives injected with blood and
the hypertensives injected with silicon oil. Again, WKY animals subjected to an
intracranial insult had higher LCBF values compared to non-lesioned animals of the
same sub-strain, whereas this was not the case with SHR.
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3. 9. Effects ofhaematoma upon BBB permeability
3. 9. I. Physiological variables and volume ofhaematoma
Arterial pH, plasma bicarbonate and base excess were significantly lower and MABP
significantly higher in the SHR compared to the WKY rats (Table 24). No other
significant differences in physiological parameters were observed between groups.
Haematoma volume lying exclusively in the striatum, and measured post mortem by
planimetry, was not significantly different between groups, (10.5 ± 2.5% of the total
striatal volume in both WKY and SHR groups) and was similar to that found in the
LCBF studies.
3. 9. 2. Unidirectional transfer constantfor AIB
There was intraparenchymal extravasation of the isotope, limited to the tissue
surrounding the haematoma. There were no significant differences in the intensity of
K, for AIB between WKY and SHR animals in the lesioned or contralateral striatum
(6.95 ± 0.64ml.g'1.min"1.10"3 in the WKY and 6.66 ± 0.82ml.g"1.min'1.10"3 in the SHR
animals in the lesioned side and 2.38 ± 0.36ml.g'1.min"1.10° in the WKY and 1.79 ±
0.34ml.g"1.min"1.10"3 in the SHR animals in the contralateral side).
3. 10. Haemodynamic effects of 7-NI
3. 10. 1. Physiological variables and volume ofhaematoma
MABP was significantly higher and heart rate significantly lower in the hypertensive
rats treated with 7-NI compared to the hypertensive animals with sesame oil (Table
25).
The volume occupied by the haematoma in the striatum, measured post mortem by
planimetry, was not significantly different between groups. It occupied 10 ± 2% of the
striatum in the SHR treated with sesame oil, 11 ± 2% in the WKY treated with
sesame oil, 8 ± 1.5% in the SHR treated with 7-NI and 10 ± 3% in the WKY treated
with 7-NI.
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3. JO. 2. Volume ofstriatal oligaemia
The volume of striatal tissue with LCBF less than 15ml. lOOg'Vmin"1 was not
significantly different between groups. Its mean value was 0.09 ± 0.05mm3 for the
hypertensive animals injected with 7-NI, 1.23 ± 0.75mm3 for the hypertensive animals
with sesame oil, 0.095 ± 0.058mm1 for the normotensive animals with 7-NI and 1.78
± 1.57mm"1 for the normotensive animals with sesame oil (Table 26 & Figure 32).
Presumably, the volume was smaller in the hypertensive animals with 7-NI compared
with the sesame oil-treated group partially because the mean volume of the
haematoma was smaller in the latter group.
The volume of striatal tissue with LCBF less than SSml.lOOg'Vmin"1 was smaller in the
hypertensive animals with 7-NI (1.41 ± 0.66mm3) compared to the hypertensive
animals with sesame oil (3.4 ± 1.3mm"1), although this difference was not significant.
Similarly, the normotensive animals treated with 7-NI had a non-significantly smaller
volume (0.71 ± 0.33mm3) compared to the normotensives with sesame oil treatment
(4.13 ± 2.26mm"1; Figure 32 & Table 26).
Striatal tissue with blood flow between 15 and 35ml.lOOg'Vmin"1 was significantly
larger in the normotensive animals with sesame oil (2.35 ± 0.83mm"1) compared to
normotensive animals with 7-NI (0.61 ± 0.28mm"1). In the hypertensive animals, 7-NI
had no significant effect (1.32 ± 0.62mm"1) compared to the group with sesame oil
treatment (2.17 ± 0.55mm3), although the volume of oligaemia was considerably
smaller in the 7-NI - treated group (Table 26 & Figure 32).
Similar patterns of differences between groups were observed in the blood flow
thresholds between 15 and 25ml.lOOg'Vmin'1 or between 25 and 35ml. 100g"1.min"1
(Table 26). However, the differences between WKY rats treated with 7-NI or sesame
oil did not reach statistical significance, probably as a result of the large variability
within treatment groups (Table 26).
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FIGURE 32











































Volumes of striatal oligaemia (mm3) with blood flow between thresholds of 0-15, 15-35 and
0-35ml.l00g"\min"\ in WKY rats (top graph) with haematoma (50pl) treated with either sesame oil
(0.5ml i.p. 30min after induction of haematoma) or 7-NI (25mg.kg"' i.p. 30min after induction of
haematoma), and SHR rats (bottom graph) with haematoma (50pl), treated with either sesame oil or 7-
NI employing the same protocol used in the WKY animals. Blood flow was measured with quantitative
[14C]-iodoantipyrine autoradiography, 24h after the induction of haematoma.
Data are presented as mean ± s.e.mean (n = 7 in 7-NI treated WKY group, n = 5 in all sesame oil-treated
groups, n = 4 in SHR group with 7-NI treatment)
#: significant difference between sesame oil and 7-NI treated WKY rats (P < 0.05)
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These results indicate that the treatment with the selective neuronal NOS inhibitor 7-
NI resulted in haemodynamic improvement in the perilesional area of normotensive
rats 24h after experimental ICH, whereas the same treatment had no significant effect
in the hypertensive animals.
3. 10. 3. LCBF remote from the haematoma
LCBF in striatum opposite the ICH was 100 ± dml.lOOg'Vmin"1 in SHR with 7-NI,
compared to S6 ± 6ml. lOOg'Vmin"1 in hypertensive animals with sesame oil treatment.
In the normotensive animals treated with the 7-NI there was a small (+5%) non¬
significant increase in blood flow (127 ± 5ml. 100g"!.min"' in the 7-NI - treated group
and 121 ± 5ml. lOOg'fmin"1 in the sesame oil-treated group). The 7-NI and sesame oil-
treated WKY rats had significantly higher striatal blood flow compared to the 7-NI
and sesame oil-treated SHR. The failure to observe reductions in LCBF associated
with 7-NI treatment was not surprising, in contrast to the findings of the studies of
cerebrovascular physiology (Table 13), because the time interval of 24h between 7-NI
administration and LCBF measurement would have obscured its direct
cerebrovascular effects.
In the contralateral globus pallidus, blood flow in the hypertensive rats with 7-NI
treatment was non-significantly decreased (-12%) compared to sesame oil-treated
SHR animals (58 ± 2ml.lOOg^ min"1 and 66 ± 4ml.lOOg^ min"1 respectively). In the
normotensive animals, 7-NI treatment had no effect in flow (77 ± 4ml. 100g'1.min"1 vs
75 ± 4ml. lOOg^ min"1 in the sesame oil-treated animals). Finally, the WKY animals




Following pharmacological manipulation in diabetic and non-diabetic BB rats, local
cerebral blood flow is compromised in a regionally heterogeneous manner in the
diabetic BB rats under physiological conditions, associated with reduced endothelial
NO bioactivity. This perturbation in the endothelial NO system does not result from
reduced substrate (L-arginine) availability or structural microvascular abnormalities,
and is possibly unrelated to development of subendothelial AGEs in the
cerebrovasculature. Increased whole blood viscosity was found in the diabetic
animals, but a fundamental role for chronic glycaemic control in association with the
observed phenomena was not established.
Following pharmacological manipulation in SHR and WKY rats, local cerebral blood
flow is not compromised in the SFIR under physiological conditions, but the NO-
dependent vasodilatory reserve appears to be attenuated, possibly associated with an
upregulated neuronal NO system.
Experimental ICH studies in the diabetic animals show that the volume of perilesional
striatal oligaemia, 24h after induction of ICH, is influenced by the presence of
intraparenchymal blood. The presence of diabetes mellitus exacerbated the extent of
this oligaemia, but not the extent of BBB disruption. Treatment with the non-peptide
ETa/ETb receptor antagonist SB209670 resulted in some haemodynamic
improvement in the perilesional area of non-diseased rats, whereas it had no effect in
the diabetic group.
Experimental ICH studies in the hypertensive animals indicate that the volume of
perilesional striatal oligaemia, 24h after induction of ICH, is probably influenced by
the presence of intraparenchymal blood in the hypertensive animals, but not in
normotensive controls. Chronic hypertension did not exacerbate the extent of this
oligaemia or the extent of BBB disruption. Treatment with the selective neuronal
NOS inhibitor 7-NI resulted in haemodynamic improvement in the perilesional area of
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normotensive rats, whereas the same treatment had no significant effect in the
hypertensive animals.
In conclusion, there is abnormal cerebrovascular homeostasis associated with IDDM
and chronic hypertension resulting in increased volume of delayed perilesional
oligaemia following experimental haemorrhagic stroke. This cerebrovascular
pathology results in resistance to neuroprotection with endothelin antagonists or
neuronal NOS inhibitors which are effective in otherwise healthy animals. These
results are of particular importance since stroke commonly occurs in patients with
assorted "risk" factors that can cause underlying alterations in cerebrovascular
regulation. Extrapolation of the neuroprotective strategies that have evolved from





4. 1. Physiological studies in the diabetic animals
4. I. 1. Basal LCBF
This is the first study of local cerebral blood flow in spontaneously diabetic insulin-
dependent BB rats. The global tendency towards reduced cerebral blood flow which
was observed in these animals parallels to some extent that found originally in human
diabetic patients (Kety et al., 1948). With the greater spatial resolution afforded by
the use of quantitative autoradiography, it has been feasible to identify a degree of
regional heterogeneity in the effects of diabetes upon cerebral blood flow. Whether
this apparent differential susceptibility to the disease processes in different parts of the
cerebrovascular bed reflects regional variations in vascular pathology, is a matter of
speculation. There is certainly evidence from published reports of a regional
heterogeneity in the mechanisms responsible for cerebrovascular dysfunction
associated with IDDM (Mayhan et al., 1991; Mayhan, 1992a). Regional differences in
LCBF have also been described recently in human diabetics when compared to healthy
control subjects (Grill et al., 1990; Macleod et al., 1994). In these human studies a
relative sparing of flow in ffonto-parietal cortex and large decreases in the caudate
nucleus show remarkable similarities to the results described here. However, even the
most sophisticated imaging techniques currently available in man do not have the
spatial resolution of animal brain autoradiography, nor can the experimental
conditions be as rigorously controlled. It may, therefore, be impossible to find exact
parallels between the effects of diabetes upon LCBF described in this study and those
in diabetic humans.
A number of studies have examined cerebral blood flow in untreated streptozotocin-
induced diabetic rats, with varying results (Duckrow et al., 1987; Harik & LaManna,
1988; Jakobsen et al., 1990; Pelligrino et al., 1991). Although in general terms
reductions in LCBF were found when streptozotocin diabetic rats were compared to
controls, the results were often too variable to reach statistical significance, and no
clear consensus emerged on the susceptibility of particular regions of the brain to the
condition. Interestingly however, if the rats were treated with insulin to normalize
glycaemia at the time of the measurement, any differences in LCBF between diabetics
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and controls were eliminated (Pelligrino et al., 1991). A similar effect has also been
described in peripheral nerve blood flow (Kihara & Low, 1995). In contrast, in the
present study of spontaneously diabetic insulin-dependent rats, significant decreases in
LCBF were evident despite the fact that there was no difference in plasma glucose
levels between diabetic and non-diabetic animals at the time of the study. This is not
to say, however, that the BB rats have not experienced periods of hyperglycaemia.
The measurement of LCBF in the diabetic animals was conducted around 4h after the
injection (s.c.) ofmedium-acting insulin, and the evidence from the physiological data
(Tables 1, 2 & 3) suggests that the exogenous hormone was acting to normalize
plasma glucose. Over a longer time scale, plasma glucose concentrations in BB/E rats
are quite unstable and fluctuate in the course of any 24h cycle between 54 and
460mg.dr1 (unpublished data). Glycosylated haemoglobin (HbAi) values are elevated
in the diabetic animals compared to non-diabetic controls in the Edinburgh BB colony
(Lindsay et al., 1997). There is no doubt therefore, that the diabetic animals used in
this study are hyperglycaemic for a large part of the time, but maximum plasma
glucose levels are unlikely to reach those found in streptozotocin-treated rats.
I chose throughout these studies to measure LCBF in conscious animals. Apart from
the fact that anaesthesia reduces cortical blood flow, there is also direct evidence that
it compromises the responsiveness of cerebral vessels (Edvinsson & McCulloch,
1981) in a rather unpredictable mode. It has also been shown that the type of
anaesthesia used during the induction of focal cerebral ischaemia (halothane or
barbiturate) influences the functional and pathological responses to the ischaemic
insult (Kawai et al., 1997), depending also on the species examined (Michenfelder &
Milde, 1975). On the other hand, the restrained animals used here may be stressed.
However, there was no evidence of stress in these animals. Plasma catecholamine
levels have been measured in previous experiments and no elevation was found (Bryan
et al., 1983; Seckl et al., 1991). Moreover, no evidence of hyperglycaemia was found
in any of the experimental groups presented in this thesis, or evidence of stress-
induced gastric ulcers in animals examined post mortem.
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4. I. 2. Influence ofchronic glycaemic control upon LCBF
Recent reports from human sufferers of IDDM show a fundamental influence of
glycaemic control upon the progress of extracranial complications (DCCT Research
Group, 1993). An attempt was made to improve glycaemic control in a subgroup of
diabetic animals, in order to establish whether glucose per se was directly responsible
for the observed LCBF perturbations. This exercise was rather complicated, with one
third of the animals treated by the continuous subcutaneous insulin infusion dying
prematurely, presumably due to hypoglycaemia. This is actually an equally important
complicating factor of treatment in intensively treated diabetics, where 3 times higher
incidence of severe hypoglycaemia is encountered (DCCT Research group, 1996),
associated with lack of preservation of higher brain function (Maran et a/., 1995).
In the animals that were used, this intensified insulin treatment protocol failed to alter
LCBF in the regions where significant flow reductions were found in rats subjected
only to a single daily dose of insulin. However, there was a trend (non-significant)
towards blood flow increase in some areas. Since the concentration of HbAi was
measured in this group, an attempt was made to correlate HbAi as a marker of long-
term glycaemic control and blood flow, but no influence could be found in this small
group of animals. Although HbAi was not measured in the conventionally treated rats,
the values obtained in the intensively treated rats were not different from those
reported from conventionally treated BB rats from the same colony (Lindsay et al.,
1997). Therefore, although a direct cause and effect relationship between level of
chronic glycaemic control and LCBF could not be established from these experiments,
this possibility cannot be discounted either.
4. 1. 3. Effects ofL-NAME and SB209670 upon LCBF
In the present study there appeared to be an attenuation of the effects of L-NAME
upon LCBF in diabetic rats. It is tempting to speculate that the decreases in LCBF
apparent in saline-treated diabetics may be the result of reduced dilatatory influence of
endogenous NO in determining basal cerebral blood flow. There is certainly evidence
from the peripheral circulation that endothelial NO systems are disrupted in diabetes
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(Cohen, 1993; Poston & Taylor, 1995; Steinberg & Baron, 1997), although there is
clear evidence of variation in the defect between different vascular beds (Kiff et al.,
1991a). In the cerebral circulation the data are equally complex. Indirect evidence for
reduced NO activity comes from studies of streptozotocin-induced diabetic rats where
a significant, but regionally variable, impairment of endothelium-dependent vascular
relaxation was observed following injection of a muscarinic receptor agonist
(Pelligrino et al., 1992). More direct evidence of an impairment of cerebrovascular
NO systems in this diabetic model are however lacking, in that the effects of L-
NAME upon cerebral blood flow (Pelligrino et al., 1992) and pial vessel diameter
(Mayhan et al., 1991) were reported to be similar in both non-dial: etic and diabetic
rats. Whilst in this study no difference in LCBF values between diabetic and non-
diabetic rats following L-NAME were found, with the exception of the hypothalamus,
this did not represent a significant decrease in flow from saline-treated diabetic rats in
which blood flow was already depressed. This could be interpreted as an attenuation
of the cerebrovascular response to L-NAME.
Since continuous production of NO from the endothelial cells inhibits the
vasoconstrictor effects of ET, as outlined in the Introduction, inhibition of NO
synthesis may unmask a continuous endothelin release in extracranial (Gardiner et al.,
1995; Richard et al., 1995) and intracranial (Kelly et al., 1995a) vessels. There is
certainly indirect evidence from in vitro studies in cultured bovine aortic endothelial
cells of an increased ET production associated with hyperglycaemia (Yamaguchi et
al., 1990). The possibility that an increased endogenous release of ET is responsible
for the observed LCBF in diabetes was tested with the administration of a potent non-
peptide ETA/ETB-antagonist (SB209670), but the finding of no alteration in LCBF in
the SB209760-treated diabetic rats is consistent with only a minor, if any, role of ET
in determining basal CBF in the diabetic rats. Flowever, the findings by others
(Haynes & Webb, 1994) and also in the haematoma studies presented in this thesis,
that during ET inhibition more than 20min drug exposure may be required for an
effect to be observed, raises also the possibility that ET may play a more substantial
role in the regulation of LCBF in the diabetic BB rats. Obviously, this possibility
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needs further clarification employing a longer therapeutic experimental design and is
outwith the basic hypothesis of this thesis. It is no doubt a starting point for further
studies. The experimental protocol, that only 20min elapsed from the i.v. injection of
SB209670 to the measurement of LCBF, was based on the report by Ohlstein and his
colleagues (1994) that this ET-antagonist has almost immediate effects following i.v.
administration. In fact, recent in vitro studies in support of no basal ET influence
upon LCBF in the diabetic rats, report that ET-1 and ETA receptors do not contribute
to the sustained hypertension induced by chronic NO synthesis blockade (Fujita et ai,
1995).
It is interesting that whilst reduced basal LCBF and an attenuated cerebrovascular
response to L-NAME were found in the diabetic rats, the saline-treated diabetic
animals were not hypertensive and L-NAME-treated diabetics displayed the normal
blood pressure response, i.e. hypertension (Table 1). This might suggest that the
disease process is more pronounced in the cerebral circulation than it is in other
vascular beds. However, the aortas of diabetic BB rats do develop morphological
defects in endothelial cells and abnormal endothelium-dependent responses to
acetylcholine (Meraji et al., 1987). Moreover, the hypertensive response to chronic L-
NAME administration is attenuated in diabetic BB/E rats (Lindsay et al., 1995). Thus
it is possible that the mechanisms ofNO dysfunction associated with diabetes develop
differentially in different vascular beds. In line with the finding of a preserved effect of
L-NAME upon peripheral resistance in the diabetic BB animals used in this study,
basal mesenteric blood flow and flow in response to L-NNA were also preserved in
STZ-diabetics compared to non-diabetic controls (Olbrich et al., 1996).
No significant differences were found in the physiological parameters between L-
NAME treated non-diabetic and diabetic animals, and the values of arterial blood
gases and pH were within normal range in all experimental groups (Table 1). No
effort was made to reduce MABP in the L-NAME treated rats to values similar to
those recorded in the saline-treated animals because, within the autoregulatory range,
LCBF is not dependent on MABP (Paulson et al., 1990; Strandgaard, 1978).
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Previous experimental paradigms have shown that reduction of MABP in L-NAME
treated animals with controlled haemorrhage had no effect upon LCBF (Yang, 1996).
Moreover, MABP in the L-NAME treated diabetic BB rats was within the
autoregulatory range reported for both normotensive and diabetic (Rubin & Bohlen,
1985) animals, the upper limit of which would have probably shifted to a higher level
following NOS inhibition (Kelly et al., 1994b). Recent studies have also reported that
endothelin release is enhanced during haemorrhagic hypotension, presumably as a
homeostatic mechanism (Zimmerman et al., 1994), so any effort to reduce MABP in
the L-NAME treated rats with controlled haemorrhage could have potentially
triggered compensatory mechanisms, including the release of endothelin.
4. 1. 4. Role ofL-arginine availability in cerebrovascular responses in IDDM
Although there is evidence that the effectiveness of endogenous NO in influencing
basal vascular tone may be altered by diabetes (Bucala & Cerami, 1992; Wascher et
al., 1994), it is not clear whether this represents a change in synthesis and release, or
in activity. There is evidence for reduced levels of L-arginine in the plasma of STZ-
induced diabetic rats (Mans et al., 1987) which might indirectly explain altered NO
synthesis due to reduction of substrate availability. Recent studies have also reported
that extracranial endothelial dysfunction associated with IDDM was corrected
following administration of L-arginine (Matsunaga et al., 1996; Pieper & Peltier,
1995; Wascher et al., 1996).
The possibility that L-arginine availability was inadequate in the diabetic BB rats was
therefore examined, but the plasma levels of L-arginine were found to be similar in
non-diabetic (DR) and diabetic animals. In support of this observation, and against a
pathogenetic role of reduced L-arginine availability in the diabetic cerebrovasculature,
Mayhan et al. recently (1996) reported that the impaired responsiveness of basilar
artery to acetylcholine and bradykinin was not altered following administration of
exogenous L-arginine in STZ-induced diabetic rats.
128
4. 1. 5. Effects of 7-NI upon LCBF
The cerebrovascular responsiveness to 7-NI was preserved in the diabetic BB rats, in
contrast to the L-NAME findings. This observation is consistent with a preserved
non-endothelial constitutive NO system in the brain associated with IDDM, and
suggests that the perturbed basal LCBF is not a result of an abnormal influence of the
neuronally derived NO.
It was surprising to find that L-NAME, although being a non-selective, and
presumably both endothelial and neuronal, NOS inhibitor had no effect upon LCBF in
the diabetic BB rats, whereas 7-NI, which is a selective neuronal NOS inhibitor, had
significant influences upon LCBF in the same group of animals. It has to be assumed
therefore that L-NAME acts predominantly as an inhibitor of endothelial NOS in the
cerebrovasculature, although this assumption is obviously speculative. The
development of a selective eNOS inhibitor would be ideal to test this possibility.
Aiiother observation that warrants consideration was that the percentage changes in
LCBF following 7-NI administration, and in comparison to the sesame oil-treated
rats, were significantly lower in the diabetic animals (median= -35.5%), compared to
the non-diabetic controls (median- -50%). This most probably occurred because of
the lower basal LCBF in diabetics. Since blood flow values were similar between
groups (non-diabetic and diabetic) following 7-NI treatment in all areas examined, a
nadir was possibly reached, beyond which any further reductions in LCBF might have
been detrimental to the brain, and which could therefore have triggered other
regulatory mechanisms.
A rather intriguing observation was that in one diabetic animal injected with 7-NI,
anomalous hyperaemia was observed unilaterally in the cortex, the thalamus and
hippocampus (Figures 5 & 6). It has been reported that L-NAME administration,
presumably effecting nNOS inhibition, results in paradoxical MABP reduction and
cortical microvascular vasodilation in eNOS knockout mice (Huang et a/., 1995 &
1996). The diabetic BB animals used in this study might be considered functionally
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analogous to the eNOS knockout mice, at least in the cerebrovasculature, and exhibit
a somehow similar paradoxical effect. It is attractive to hypothesize that neuronally
derived NO may possess vasoconstrictive functions, or that there is an interaction
between endothelial and neuronal NO for maintenance of vascular tone, the
disturbance of which may unmask an otherwise obscure NO-related vasoconstrictor
tone. To complicate interpretation of these observations further, similar unexplained
hyperaemia in response to much higher doses of 7-NI than the one used in this study,
has also been reported in normal animals (Kelly et al., 1994a; 1995b).
Local tissue glucose use was not measured in these studies for several reasons. As has
been reported previously (Kelly et al., 1994b & 1995b; Macrae et al., 1993), L-
NAME and 7-NI affect LCBF without any changes in metabolic rate for glucose.
Therefore, any changes in LCBF observed in the studies presented here were unlikely
to have been driven by metabolic alterations. An additional consideration that applies
to the diabetic animals is that diabetes mellitus and insulin treatment alter the density
of glucose transporters in the brain vessels in a rather unpredictable manner, as
outlined in the Introduction. Therefore, the methodology for autoradiographic studies
of metabolic rate for glucose would have had to be re-characterized.
A trend towards bradycardia in the diabetic BB rats compared to the non-diabetic
(DR) BB rats has also been reported by other groups using BB rats from other
colonies (Stevens et al., 1994). Physiological variables in the 7-NI treated animals
were within the normal range (Table 2). Heart rate in the 7-NI treated diabetics was
significantly lower (-40%) compared to the sesame oil treated rats, an observation
that has been reported previously in association to 7-NI treatment (Kelly et al.,
1995b). In the non-diabetic animals, the effect of 7-NI (-30% reduction in heart rate)
was not statistically significant. Heart rate was also significantly different between the
7-NI treated non-diabetic and diabetic groups (-29%), in part because heart rate was
also lower (-15%) -though not significantly- in the sesame oil-treated diabetic rats,
compared to the non-diabetics.
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4. 1. 6. Effects ofSIN-J upon LCBF
LCBF responses to i.v. SIN-1 infusion were modestly enhanced in the diabetic BB
animals compared to the non-diabetic controls, in most of the brain areas examined.
These results are consistent with the L-NAME and 7-NI findings in the same groups
of animals, because a reduced basal production of endothelial NO may be associated
with modestly increased sensitivity of VSMC to NO (Moncada et a/., 1991). Another
important consideration is that increased inactivation of endothelium-derived NO by
free radicals (Cameron & Cotter, 1995; Graier et al., 1996; Pieper et al., 1996) or
subendothelial advanced glycosylation end-products (Bucala et al., 1991; Cohen,
1993), or reduced responsiveness of the vascular smooth muscle associated with
diabetes, are not the principal determinants of the cerebrovascular dysfunction
associated with this model of IDDM. It is therefore possible that reduced EDNO
formation, as a result of NADPH depletion following overactivity of the polyol
pathway or protein kinase C associated with diabetes (Bredt et al., 1992; Cohen,
1993), or some other, as yet undefined, cause could play a pathogenetic role in the
evolution of cerebrovascular dysfunction associated with this disease process.
The autoradiographic blood flow findings are also supported by the electron
microscopic appearance of diabetic vessels. These did not show any thickening of the
sub-endothelial basement membrane (although deposition of advanced glycosylation
end-products can sometimes occur in the absence of any visible vascular wall
thickening), and the PAS staining that failed to reveal any excessive glucose
deposition in the brains of the diabetic animals. A time period of 8 weeks from the
onset of the disease is necessary for the deposition of AGE to occur, and the duration
of diabetes in all the animals used was over eight weeks in order to avoid the duration
of the disease being a confounding factor in this experimental design.
Finally, and although speculative, the observation that CBF in the striatum and globus
pallidus of the diabetic animals following SIN-1 administration was still significantly
lower than that of the non-diabetic rats with the same treatment (Table 7, Figures 33
& 34), whereas in the rest of the brain there were no similar differences between
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groups, may be associated with an increased clearance of EDNO in these particular
brain regions. However, there is no conclusive evidence from the rest of the studies in
support of this possibility.
The finding of an attenuated cerebrovascular response to L-NAME and preserved
response to SIN-1 in the diabetic BB rats is also in accordance with studies in human
sufferers of IDDM complicated by microalbuminuria, where the forearm vascular
response to L-NMMA was blunted but the response to sodium nitroprusside was
preserved (Elliott et al., 1993). Similar findings have also been reported in drug-
induced diabetic rats, where nerve blood flow was manipulated with L-NAME and
sodium nitroprusside (Omawari et al., 1996).
The physiological variables in the SIN-1 treated animals, as seen on Table 3, could
not have influenced the LCBF findings. Although body temperature was significantly
reduced in the diabetic animals, which could in theory reduce LCBF in response to
reduction in metabolic demand (Harper, 1990), this difference was very small in
absolute terms and if anything, the observed responsiveness of the diabetics to SIN-1
was higher compared to the non-diabetics. The same applies to the p02 in the
diabetics treated with SIN-1, which although significantly lower to that of the non-
diabetics, was still well within physiological range, and in the presence of a
physiological pC02 would not have affected LCBF (Harper, 1990) (Table 3).
4. I. 7. Plasma viscosity in diabetic rats and its role in LCBF
Although hyperglycaemia is considered to be an important factor contributing to
vascular dysfunction associated with diabetes, and would certainly account for
dysfunction in endothelial NO systems (Cohen, 1993; Poston & Taylor 1995), other
mechanisms may also be involved. Rheological problems such as an increase in plasma
viscosity (Barnes et al., 1977) and increased adhesion of platelets to endothelial cells
(MacMillan et al., 1978; Wautier et al., 1981) may contribute to cerebrovascular
dysfunction in diabetes. Alternatively, some aspects of diabetic vascular pathology,















Figure 33: Blood flow (IAP) autoradiogram from a non-diabetic animal with acute SIN-1 treatment
(1.8mg.kg"1.h"1 i.v. infusion). Grey scale on the right represents relative optical densities, which can
be used to calculate blood flow (see Methods).
Figure 34: Blood flow (IAP) autoradiogram from a diabetic animal with the same SIN-1 treatment as
above. Although cortex appears darker compared to the animal seen in Figure 35, striatum is lighter
compared to the same animal.
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associated with diabetes. Hypertension develops only at a later stage in BB rats and is
not therefore an issue in these studies, but increased blood viscosity was found indeed
in the diabetic BB rats. However, not only is the significance of blood viscosity in
determining LCBF contested (Brown & Marshall, 1985; Waschke et al., 1994), it is
also unlikely that increased viscosity can explain the heterogeneity in the reduction of
blood flow which was observed in the cerebrovasculature of these animals. There is
increasing evidence that diabetes adversely affects outcome in experimental models of
cerebral ischaemia (Nedergaard & Diemer, 1987; Sutherland et al., 1992) and in
human stroke victims (Jorgensen et al., 1994) and obviously, in brain areas with
critically compromised blood flow the presence of increased viscosivy could present
an important factor for worse outcome (Marshall, 1982).
134
4. 2. Physiological studies in the hypertensive animals
4. 2. 1. Basal LCBF
There was little evidence of any fundamental difference in basal LCBF between WKY
and STIR groups in these studies, although in one area of the brain, the nucleus
accumbens, blood flow was significantly higher in SHR. These observations are
largely in keeping with previous reports, where either similar quantitative
autoradiographic techniques were used to measure LCBF in conscious rats of these
two sub-strains (Wei et al., 1992), or where rats of a similar age to those used in this
study were examined using different measurement protocols (Grabowski &
Johansson, 1985). Moreover, the results of these physiological studies are in keeping
with morphological examination of cerebral capillary bed structure (Lin et a!., 1990a)
and precapillary arterioles on the pial surface (Harper & Bohlen, 1984) which show
no differences between SHR and WKY. Although structural changes have been
described in larger blood vessels of the cerebrovascular bed in SHR (Folkow, 1990),
it is not these vessels which regulate LCBF.
Age may be another factor to be considered as CBF reduces with advancing age
(Naritomi et al., 1979). All animals used for the studies presented in this thesis were
therefore young adults, and the DR and WKY controls were always age-matched to
the diabetic and SHR, so age was not a variable that could influence LCBF.
Physiological parameters, as seen on Tables 9, 10 and 11 were similar between groups
(with the exception of MABP, heart rate and haematocrit) and could not have
influenced the LCBF data. Although haematocrit was significantly elevated in the
SHR rats treated with saline, as compared to the WKY animals with the same
treatment (Table 9), it is unlikely that the actual difference (4%) could have had any
fundamental influence upon LCBF.
4. 2. 2. Effects ofL-NAME and SB209670 upon LCBF
Early in vitro investigations identified a decrease in NO-mediated activity in cerebral
blood vessels taken from SHR (Miyata et al., 1990; Malinski et al., 1993b).
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Subsequent examination of the basilar artery in situ showed that L-NAME induced
greater constriction in hypertensive rats (Kitazono et al., 1995). These authors
suggested that basal release ofNO might be somewhat enhanced in SHR over that in
WKY, and in vivo studies confirmed that the cerebrovascular response to NO
inhibition with L-NMMA was greater in SHR (Izuta et al., 1995), although no
significant difference in LCBF was found in SHR and WKY treated with L-NA. In the
studies presented in this thesis, acute treatment with L-NAME had broadly similar
effects upon LCBF in the WKY and SHR groups and were in keeping with previously
published results (Izuta et al., 1995; Yang, 1996). The dose of L-NAME used in the
present studies has previously been found in Sprague-Dawley (SD) rats to produce
significant reductions in LCBF at 15min post-injection (Kelly et al., 1994b) which are
maintained for at least 3h (Macrae et al., 1993), but in general it appears that L-
NAME is not as efficacious in reducing LCBF in WKY and SHR as it is in SD rats.
Although it was outwith the present experimental design to make such inter-strain
comparisons, it is also noteworthy that differences in vascular structure have been
found between normotensive WKY and SD in the cerebral capillary bed (Lin et al.,
1990a).
The pressor effect of L-NAME treatment was broadly similar in both groups (+27%
in WKY and +18% in SHR, Table 9), but MABP was within the autoregulatory range
reported previously (Barry et al., 1982; Kelly et al., 1994b). Moreover, the significant
reductions of LCBF that resulted from this treatment, would have been obscured if
the upper limit of autoregulation had been exceeded.
Treatment with SB209670 had no significant effects upon LCBF in the SHR. This
observation is in accordance to the general impression from previous studies in
humans and animals, that ET may have a more substantial role in fulminant forms or
stages of the disease (Rubanyi & Polokoff 1994) and also with reports where, in the
spontaneously hypertensive rats (SHR) chronic blockade of ET-1 did not alter MABP
(Li & Schiffrin, 1995).
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4. 2. 3. Effects of 7-NI upon LCBF
Whilst there was no evidence of any difference between WKY and SHR in the
response to the non-selective NOS inhibitor L-NAME, the response to the
intraperitoneal injection of 7-NI, which in vivo is a selective inhibitor of the neuronal
isoform of NOS (nNOS; Moore et al., 1993a & b), was significantly greater in the
majority of brain areas of hypertensive animals. Although previous studies have
suggested that there may be an upregulation of cerebrovascular NO systems in
hypertension (Kitazono et al., 1995), the current observations point to there being a
more specific upregulation of neuronal NOS. Studies specifically addressing the role
of neuronal NOS in the brains of SHRs are lacking, although it does seem that nNOS
expression is normal in the cerebellum and brain stem of 4-, 16-, and 24-week-old
SHR, compared to age-matched WKY (Iwai et al., 1995). It is interesting to note that
the activity of nNOS in cerebral ischaemia is potentially detrimental (Huang et al.,
1994) and although perhaps speculative at this stage, the current findings, consistent
with an upregulated nNOS system in hypertension, could offer one explanation for the
predisposition of hypertensives to ischaemia following stroke (Coyle, 1984). These
findings, of comparable cerebrovascular responses to L-NAME but enhanced
responses to 7-NI in the SHR could also be compatible with a down-regulation of
endothelial NOS in these animals together with an up-regulation of the neuronal NOS.
To test this hypothesis awaits the development of specific endothelial NOS inhibitors.
4. 2. 4. Effects ofSIN-J upon LCBF
There is growing evidence that endothelium-dependent vascular dilatation is
heterogeneously affected in hypertension (Nava et al., 1995) with both regional and
species differences (Deng et al., 1995). Studies in hypertensive humans and animals
have reported preserved dilatatory responses to sodium nitroprusside in peripheral
vascular beds (Taddei et al., 1993; Kiing & Ltischer, 1995). In contrast to the
qualitatively similar effects of SIN-1 upon blood pressure in both WKY and SHR
reported here, the effects of SIN-1 upon LCBF were attenuated in the SHR group
when compared with WKY. These apparent differences in the response to SIN-1
between vascular beds in the SHR group suggest that there may be regional
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perturbations ofNO-specific vasodilatator reserve, and would be consistent with an
up-regulation of endogenous cerebral NOS activity. In support of these observations,
L-arginine was found to have no effect upon LCBF in the contralateral hemisphere of
SHR subjected to MCA occlusion (Prado et al., 1996), and SIN-1 had no significant
effect upon cortical blood flow in SHR subjected to sham-occlusion of the MCA
(Zhang et al., 1994).
Contradictory results have also been reported using in situ methodology to measure
responsiveness of pial arteries, or the basilar artery, to superfusion of NO donors in
the stroke-prone substrain of the SHR (Kitazono et al., 1993; Mayhan et al., 1988;
Yang et al., 1991a & b; Yang et al., 1993) and also in stroke-resistant SHR (Mayhan
et al., 1987; Mayhan, 1991). There are several potential explanations for the apparent
differences between these results and the data reported in this thesis, including the fact
that the previous experiments were performed in anaesthetized animals, with the
potential influence of anaesthetic agents on cerebrovascular responsiveness
(Edvinsson & McCulloch, 1981); the possibility that NO bioactivity might differ
markedly between the stroke-prone substrain of SHR and the SHR used in the current
studies (Dominiczak & Bohr, 1995); the fact that the animals used for the current
studies were considerably younger than those used previously, and NO responsiveness
has been shown to change - at least in renovascular hypertension - as the duration of
hypertension progresses (Dubey et al., 1996); most importantly, neither the basilar
artery nor the pial vessels constitute the principal source of resistance to flow in the
cerebrovascular bed, and are therefore not responsible for the control of LCBF
(Harper, 1990). Recent investigations in conscious patients with arterial hypertension
have also confirmed impaired responsiveness to NO-donors (Preik et al., 1996),
although once again other, earlier reports have reached contradictory conclusions
(Creager & Roddy, 1994; Panza et al., 1995).
The vessels of the cerebrovascular bed are normally endowed with the ability to alter
their calibre in response to fluctuations in perfusion pressure. The resulting changes in
vascular resistance ensure the maintenance of constant cerebral blood flow over a
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wide range of arterial blood pressures, a phenomenon known as autoregulation
(Paulson et al., 1990). The lower limit of autoregulation below which the relationship
between cerebral blood flow and perfusion pressure becomes linear is not a fixed
point, and chronic hypertension is known to raise the arterial pressure threshold at the
lower limit of the autoregulatory range (Paulson et al., 1990; Strandgaard, 1978).
Although the levels ofMABP measured in the SHR in response to the higher dose of
SIN-1 (104mmHg) were above the lower limit of autoregulation (90mmHg) reported
for this strain (Barry et al., 1982; Harper & Bohlen, 1984), the observation that
LCBF was higher - though not significantly so - in most of the areas examined in the
SHR treated with the lower SIN-1 dose compared to those treated with the higher
dose, could be interpreted as indicating pressure-dependency in flow to some extent at
least. It is known that NO inhibition shifts the upper limit of cerebrovascular
autoregulation to higher pressure levels in normal animals (Kelly et al., 1994b) so it is
conceivable that NO could have a role in determining the lower limit of
autoregulation. A definitive conclusion regarding this possibility cannot be reached
however.
SIN-1 generates NO and superoxide, which can potentially react with NO to form
peroxynitrite (Moncada & Higgs, 1995; Plane et al., 1997). The dilator actions of
SIN-1 in extracranial tissues are also modulated by the basal production of
endothelium-derived NO (Plane et al., 1997). Studies performed in vitro with
endothelial cells from peripheral tissues of 5 week old SHR showed that superoxide
may be responsible for the decreased activity ofNO (Grunfeld et al., 1995). There is
also growing speculation of an enhanced oxidative stress in the pathogenesis of
hypertensive complications (Alexander, 1995). It is clearly possible that the effects of
SIN-1 upon LCBF could be related to generation of superoxide, complicated further
by the potential involvement of free radicals in the evolution of hypertensive
complications. The exact mechanism by which SIN-1 effects changes in cerebral
blood flow may therefore be quite complex, but whatever the underlying mechanism,
these studies clearly identify differences in the cerebrovascular response to SIN-1 in
WKY and SHR.
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4. 2. 5. General discussion of the LCBF data
Morphological analysis of those cerebral blood vessels which are largely responsible
for the control of LCBF, have revealed no structural differences between WKY and
SHR (Lin et al., 1990a). Whilst it is possible that subtle changes might go undetected
in these rather small vessels, the method of analysis did prove sufficiently sensitive to
detect differences between vessels from both WKY and SHR, when compared to
those from SD rats (Lin et al., 1990a). It has been argued that structural changes in
the vessel wall associated with chronic hypertension could explain altered responses
to vasoactive agents (constrictor and dilator) (Calver et al., 1992), but it might be
expected that the response to all vasoactive agents would be affected in a non-specific
manner (Folkow, 1990; Harper & Bohlen, 1984). It is possible that structural changes
might have been present in the relatively young (-14 weeks old) animals presented in
this thesis, particularly as structural changes appear even before frank hypertension
has been established (Folkow, 1990), but structural differences cannot readily provide
an explanation for the differential response to the two NOS inhibitors (L-NAME and
7-NI) and nor could they explain the attenuated vasodilatory response to SIN-1. Thus
the current results would appear to support the concept of hypertension-induced
functional changes (Winquist & Bohr, 1983) in the cerebrovasculature.
Cerebrovascular dysfunction associated with hypertension is most probably
multifactorial. Studies using pial arteries from hypertensive rats have identified altered
dilator responses which appear to involve vasoconstrictor prostanoids (Mayhan,
1992b; Yang et al., 1991a), and in situ studies have shown that the prostaglandin-
induced pial arterial vasodilatation is related to NO production (Armstead, 1995).
Interestingly, enhanced responses of the basilar artery to activation of ETb receptors
in hypertensive rats, independent of NO or prostanoid pathways, have also been
observed (Kitazono et al., 1995). The same group also found that the mechanisms
responsible for the impaired responses of the basilar artery in SHRs (Mayhan, 1990)
are not the same as those responsible for the attenuated responses of the pial vessels.
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The results of these studies provide further evidence for heterogeneous perturbation
of NO systems in the cerebrovasculature of the SHR strain, with a reduced
vasodilatory reserve and possibly an up-regulation of neuronally derived NO systems.
The importance of these findings may become pronounced in situations of cerebral
ischaemia, which is one of the commonest complications of chronic hypertension.
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4. 3. Haematoma studies in the diabetic animals
4. 3. 1. Consideration ofhaematoma model
The reproducibility of ICH models is variable, and this is reflected by the fact that
there are several models with certain particular advantages and disadvantages, as
outlined in the Introduction
Whenever blood is injected into the striatum, there is always variable reflux into the
white matter and subarachnoid space (Deinsberger et a/., 1996). The only model in
which reflux does not occur is that with the inflation of a microballoon (Kingman et
al., 1988; Nehls et al., 1990). It was not appropriate to use the microballoon model in
these experiments, because the principal hypothesis that blood is responsible for the
development of delayed perilesional ischaemia, and not the mass lesion itself, could
not have been tested with that particular model. The important issue is that the
volume of striata! blood load was measured post mortem in each animal with tissue
planimetry, so that any differences in ICH volume between different groups could be
detected. The volume of striatal blood or silicon oil load was similar in all groups
studied (-10% of whole caudate). Volume ofpurely striatal blood is of importance in
the LCBF studies, because the surrounding white matter has very low basal LCBF,
with values similar to the ischaemic levels in grey matter. Therefore, inclusion of this
area in the results would have resulted in overestimation of the actual ischaemic area.
The actual value of the ischaemic threshold (35ml. lOOg'Vmin'1), was selected for
reasons clearly defined in the Materials and Methods In addition, in models of focal
ischaemia studying MCAO with perivascular application of ET-1 in the rat, LCBF in
the ischaemic caudate nucleus had a mean value of 31ml.l00g~1.min"1, associated with
neuropathological evidence of ischaemic cell injury (Gartshore et al., 1996). In
addition, following MCA occlusion in SFIRSP, mean LCBF in the peripheral area of
the infarct was reported to be ~27ml.lOOg'Vmin"1 (Shima et al., 1994), whereas
following MCA occlusion in normotensive rats the ischaemic border had a CBF of
~30ml.l00g"1.min"1 (Nedergaard et al., 1986). Another point for consideration was
the reason for calculating blood flow between 15 and 35ml. lOOg'Vmin" . Since part of
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the tissue with LCBF less than 35ml.lOOg"1.min"1 is occupied by blood or silicon oil,
the threshold of 15ml. 100g"1.min"1 was selected, above which the tissue studied would
have most likely been perilesional.
The volume of blood that was injected is unlikely to have caused any significant
influence upon 1CP, which has been observed in association with volumes of lOOpl
(Kingman et al., 1987; 1988), where ICP has been found to raise sufficiently enough
to compromise CPP. In the pilot experiments that were performed in advance of the
rest of the studies, a very modest increase in ICP (never exceeding 16mmHg) was
observed, as has been reported previously (Jenkins et al., 1990; Kingman et al.,
1988). Observational studies in humans have identified volume of ICH of at least
40ml (equivalent to a 50pl clot in the rat brain) to be associated with delayed
neurological deterioration (Mayer et al., 1994).
Although it has been claimed that with slower infusion rates the rate of backflux is
lower (Yang et al., 1994), it was found in the preliminary experiments already
mentioned in the Materials and Methods section that if obvious backflux from the
burr-hole was present at the onset of the injection, this continued even if the rate of
the injection was reduced. It should also be mentioned that in the clinical setting,
active bleeding lasts for less than lmin in most ICHs (Kingman et al., 1988).
Therefore, a slower injection rate is more akin to an infusion of blood, where the
physical disruption of brain parenchyma by the blood may have rather different
characteristics.
Inbred rats are genetically very similar, so differences in immunological reaction to
donor blood as a factor for the autoradiographic findings is unlikely. In addition, there
were no differences in BBB permeability in any of the groups, excluding the
possibility that an exacerbated inflammatory reaction of the diabetic animals to the
blood was present. The blood that was injected was derived from non-diseased
animals, because the purpose of these studies, as outlined in the Materials and
Methods, was to study the responses of host cerebrovasculature to the presence of
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intraparenchymal blood, independent of the potential effects that diabetic blood may
have upon this responsiveness, in terms of clotting, white and red cell abnormalities,
as outlined in the Introduction. Other groups studying pressure autoregulation have
injected intravenously blood withdrawn from syngeneic animals with no ill-effects
(Barry et al., 1982). Another potential problem might have arisen if blood was
withdrawn from the animal's own femoral artery and then the vessel was to be ligated,
that is the ischaemic inflammatory sequelae in the limb could have induced secondary
cerebral responses (Bileviciute et al., 1995).
Extensive surgical manipulation and instrumentation for monitoring of physiological
parameters during the induction of the haematoma was avoided. An alternative
approach was followed, with the use of parallel groups of animals, in which arterial
blood gases, pH and MABP were monitored during induction of the haematoma, to
ensure that the anaesthetic regime (pentobarbitone) did not induce any cardiovascular
or respiratory effects that could account for the observed phenomena at 24h. It is of
note that other groups who study experimental intracerebral haematoma models
associated with animal recovery (Del Bigio et al., 1996; Lee et a/., 1997; Lyden et al.,
1997) acknowledge the difficulties and avoid cannulation of vessels for arterial blood
gases and pH monitoring at the time of haematoma induction.
Fully quantitative autoradiography was employed for measurements of LCBF and
BBB permeability, because it provides the gold standard for spatial measurements of
these parameters (Flossmann, 1994). This approach lacks the same advantages when
temporal evolution of the above mentioned processes are to be measured. Therefore,
the exact time point that was selected for the identification of the pathophysiological
events (24h post induction of the haematoma) corresponded to that reported by other
experimental groups to represent peak for oedema formation and blood flow decrease
(Yang et al., 1994). There is no doubt that an evolving phenomenon was studied and
therefore blood flow and permeability changes continue after 24h, together with the
possibility that diabetes and hypertension could alter the temporal characteristics of
these events. However, most groups who study experimental focal cerebral ischaemia
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use 24h as an acceptable endpoint for the study blood flow as well as
neuropathological evidence of stroke.
Detailed neuropathological analysis was not undertaken in these studies. The limited
histopathological data presented were used in support of the LCBF findings and
particularly the study of ischaemic thresholds. Since most of the histopathological
specimens were from frozen brains, which was inevitable because they had to be from
the same animals used for LCBF and BBB permeability studies, subtle
histopathological evidence of hypoxic-ischaemic damage could not be reliably
assessed (Brown and Brierley, 1968). However, a clearly demaicated area of
abnormality was always present in the striatum in sections stained with conventional
methods, the size of which could be compared to the size of striatal tissue within the
preset flow thresholds. For these reasons volumetric data of actual stroke are not
presented. However, in all groups the volume of tissue pallor corresponded closely to
the ischaemic regions, as defined.
4. 3. 2. Influence of blood constituents upon perilesional LCBF following
experimental ICH
The results of the silicon oil injections compared to the injection of blood, in both
non-diabetic and diabetic groups, support the hypothesis that factors released from
the blood influence LCBF regulation in the perilesional cerebrovasculature
(Mendelow, 1993). In addition, the presence of diabetes mellitus exacerbates the
oligaemic tendency in this animal model of the disease process. The presence of an
oligaemic area surrounding an intracerebral haematoma, analogous to the ischaemic
penumbra described in occlusive stroke, has also been demonstrated recently in
human sufferers of ICH using PET for measuring CBF (Villar-Cordova et at., 1997).
The small differences in baseline physiological variables in these experimental groups,
as shown on Table 16, should not have significantly influenced the LCBF or
histopathological findings. Although body temperature was significantly lower in the
diabetic animals injected with silicon oil, the actual difference was not great enough
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(less than 1°C) to have exerted any neuroprotective influence (Busto et al., 1989;
Zhang et al., 1993). The pH in the same group was lower than that of the non-
diabetic rats with silicon oil injection, but if anything, its effect would have been
detrimental, and again, the difference was very small in actual terms (-1.5%).
4. 3. 3. Haemodynamic compromise vs g/ucotoxicity
The effect of IDDM upon LCBF following experimental ICH has not been studied
before. Experimental information is available from studies of focal (Duverger &
MacKenzie, 1988; Nedergaard et al., 1988; Wagner et al., 1.992) or global
(Sutherland et al., 1992) cerebral ischaemia associated with either STZ-induced
diabetes or acute hyperglycaemia. There is substantial evidence that drug-induced
diabetes increases the volume of infarction following experimental focal ischaemia,
but whether this is related to altered haemodynamic responses or direct glucotoxicity
is not clear. Studies ofMCA occlusion in STZ-induced diabetic rats have revealed no
differences in the patterns of LCBF changes, measured with fully quantitative
autoradiography acutely after the onset of the occlusion, despite the larger final stroke
(Nedergaard & Diemer, 1987; Nedergaard et al., 1988). Other groups however, have
reported delayed cortical CBF recovery, measured with laser-doppler flow in cats
(Wagner et al., 1992) and more recently in rats (Kittaka et al., 1996), following
reperfusion.
It should be pointed out that all the above mentioned studies address purely the effect
of chronic hyperglycaemia, rather than diabetes per se in cerebral ischaemia, and that
insulin treatment reversed the deleterious effects of hyperglycaemia upon stroke
volume in one of the studies (Bomont & MacKenzie, 1995). In the experiments
reported in this thesis, due to insulin treatment, there were no significant differences in
plasma glucose between groups when LCBF was measured. The results obtained
therefore, represent more the effects of the total diabetic condition. There is obviously
substantial indirect evidence that chronic glucose control was far from optimal in the
diabetic animals used in this study. However, any potential influence of acute
hyperglycaemia upon CBF was eliminated. Previous studies addressing the
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vulnerability of the BB rat brain to ischaemia have not been performed. There is a
single published report of impaired metabolic recovery, measured with SPECT, at
reperfiision following transient forebrain ischaemia in diabetic BB rats (Sutherland et
al., 1992).
Although there is evidence for an alteration in cerebrovascular responsiveness
following occlusive stroke associated with diabetes (Kittaka et al., 1996), the
situation in relation to haemorrhagic stroke is rather more complicated. The presence
of intraparenchymal blood can potentially induce effects in the perilesional vasculature
by several mechanisms (Martin et al., 1986; Ohlstein et al., 1991; Sinar et al., 1988).
As evidenced by the differences in the volumes of striatal oligaemia following silicon
oil injections in both diabetic and non-diabetic animals, factors related to the presence
of blood do influence the extent of delayed perilesional haemodynamic compromise
following experimental ICH. Further indirect evidence that this is true was provided
with the appearance of fibrinoid necrosis in a perilesional striatal vessel from a
diabetic animal injected with blood (Figures 35 & 36). Such reactive small vessel
changes are a common finding around acute human ICH at autopsy, and may
represent a toxic effect of blood constituents, possibly mediating intense
vasoconstriction. Also of interest was the presence of extensive striatal ischaemia in a
diabetic animal in which the blood was lying exclusively in the white matter (Figures
37, 38, & 39), presumably as a result of significant vasoconstriction of the penetrating
vessels derived from the cortex and traversing the white matter to supply the striatum.
The presence of intermittent hyperglycaemia in the diabetic BB rats could have
additional confounding effects in terms of endothelin (Yamaguchi et al., 1990) and
adenosine (Hsu et al., 1991) production. Obviously, the presence of increased
viscosity found in the diabetic rats in line to that reported in humans (Barnes et al.,
1977), could have possibly created a further rheological burden, but whether it would
have directly influenced blood flow in the perilesional area is a matter of speculation
(Brown & Marshall, 1985; Waschke et al., 1994).
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Figure 35: Section from the caudate nucleus of a diabetic rat injected with 50pl blood, stained with
haematoxylin and eosin. This is a paraffin section, as opposed to the frozen sections shown in
previous figures, and was obtained from one of the animals used in the preliminary experiments
(section 2. 2. 1.). Note the presence of fibrinoid necrosis in the capillary shown in the centre of the
picture, which is adjacent to the haematoma, as evidenced by the presence of red cells in the
periphery of the picture. Magnification x600.
Figure 36: Immunohistochemistry for fibrinogen, from an adjacent section to that shown in Figure
35, shows positive staining (brown) in the neuropil around the capillary, confirming that breakdown
of BBB has occurred as a consequence of fibrinoid necrosis. Magnification x600. For Method see
page 193.
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Figure 37: Unstained coronal section from a diabetic rat brain. In this single animal, the blood was
confined exclusively to the white matter. Note that the tissue appearance of the caudate medial to the
blood is abnormal.
Figure 38: Blood flow (IAP) autoradiogram from a section adjacent to that shown in Figure 37. Note
extensive striatal ischaemia (white, pink and purple colour), possibly as a result of vasospasm in the
penetrating vessels arising from the pial surface, and traversing the white matter containing the
haematoma, to supply the infero-lateral area of the striatum.
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Figure 39: Coronal brain section from the same animal and adjacent to the section shown in Figure
38, stained with cresyl violet and luxol-fast blue. Note the presence of striatal tissue pallor sharply
demarcated from the surrounding normal parenchyma and corresponding closely to the area of
striatal ischaemia present in the IAP autoradiogram of Figure 38.
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As already mentioned, 15-20% of the diabetic animals died after regaining
consciousness from the anaesthesia used during haematoma induction but before the
LCBF experiment. A seizure, which was witnessed in one of these animals just before
it died, could have possibly resulted from hyperglycaemia at the time of the event,
since an association between hyperglycaemia and seizures has been reported
previously in experimental cerebral ischaemia (Warner et al., 1987).
The diabetic animals used in these studies were treated with insulin to prevent death.
Insulin administration is associated with improved outcome in experimental ischaemia
probably due to its anti-hyperglycaemic effects, together with its directly vasodilatory
influence (Fukuoka et al., 1989; LeMay et al., 1988). However, in this study although
its administration resulted in comparable plasma glucose levels between non-diabetic
and diabetic rats at the time of the final experiment, it did not affect the detrimental
influence of IDDM upon haemorrhagic stroke.
4. 3. 4. Volume ofstriatal oligaemiafollowing ICH
The volume of significant oligaemia was -4% of the striatum in the non-diabetic and
-17% of the striatum in the diabetic rats. The group from Glasgow has reported
significant oligaemia in 7.5% of the caudate nucleus at 4h post-injection of lOOpl
blood (Sinar el a!., 1988). Following injection of 25gl of blood, the same group
reported significant oligaemia in 12% of caudate nucleus at lmin, 5% at lOmin and
0.2% at 3h (Nath et al., 1987). The same group, using the microballoon model
reported significant oligaemia in -12% of caudate at 5min and -35% at 4h, together
with a haemodynamic improvement associated with temporary inflation of the
microballoon (Kingman et al., 1987; Nehls et al., 1988 & 1990). The microballoon
model has two fundamental differences in comparison to the model used in these
studies: the effects of blood could not be addressed with the microballoon, and the
volume of the actual striatal mass was much larger with the microballoon, because no
backflux along the white matter or the sub-arachnoid space could have occurred.
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The group from Michigan has also used a similar experimental ICH model, and has
addressed the temporal evolution of pathophysiological sequelae (Yang et al., 1994).
This group failed to identify any presence of striatal oligaemia at 24h, even with
volumes of blood double to that used in the studies presented in this thesis (Lee et al.,
1997; Yang et al., 1994). The most likely explanation is that, although quantitative
methodology was employed, it was actually global striatal blood flow rather than local
(including the perilesional area) CBF that was measured by the Michigan group.
Therefore, small areas of oligaemia would have been obscured, especially in the
presence of simultaneous hyperaemia in the lesioned striatum. It should however be
noted that, the temporal evolution of CBF changes reported by this group parallel
those described by the Glasgow group, with an immediate reduction in blood flow at
induction of the haematoma, which returns to baseline values at 4h and then starts
declining to reach a nadir at 24h.
Finally, Rosenberg reported dense striatal ischaemia at 24h in his collagenase ICH
model (Rosenberg et al., 1992). The volume of the haematoma is very large in this
model, occupying virtually the entire caudate nucleus. It is impossible to know
whether this ischaemia represents tissue occupied by the actual haemorrhagic lesion or
the perilesional area and therefore, direct comparisons with the findings of the current
studies cannot be made.
The manifestation of hyperaemia in the lesioned striatum peripheral to the oligaemic
zone in all experimental groups, including those injected with silicon oil, was a rather
interesting observation. It would have been attractive to hypothesize that it was a
manifestation of reactive hyperaemia, following reperfusion of a previously oligaemic
area, upon exhaustion of the vasospastic influences by the putative mediators in the
blood. However, the presence of similar striatal hyperaemia in the silicon oil injected
animals makes this possibility unlikely. The other potential explanation would have
been for this hyperaemia to manifest not regional cerebrovascular dysregulation, but a
homeostatic response in an attempt to increase flow in the inadequately perfused
perilesional tissue. This explanation is again inadequate, because it cannot provide an
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acceptable explanation for the hyperaemia observed in the cortex ipsilateral to the
haematoma in a minority of the diabetic animals (Figure 23). Whatever the cause of
this hyperaemia, it was not associated with evidence of histopathological abnormality
in any animal. Obviously, the pathogenetic mechanisms underlying this phenomenon
can only be studied adequately with methods, such as diffusion weighted MRI, that
can measure the temporal evolution of LCBF changes following experimental ICH.
Interestingly, Ackerman el al. (1983) reported the presence of increased cortical
blood flow, measured with PET, adjacent to the haematoma in a patienv with ICH.
Another study in human sufferers of ICH reported recently that, an initially oligaemic
zone (measured with SPECT) around an intracerebral haematoma may become
hyperaemic subacutely, resulting in reperfusion injury (Mayer et al., 1997).
4. 3. 5. BBB permeabilityfindings
Transport of AIB across the capillary endothelium is the rate-limiting step for the
accumulation of this inert, neutral amino acid in normal brain tissue. The back-flux of
AIB is minimized by active cellular uptake, and therefore unidirectional transport can
be quantified from tissue concentrations of radiolabeled AIB at the end of an
experiment (Blasberg et al., 1983). The degree of spatial resolution afforded by this
technique, when used in combination with quantitative autoradiography, makes it a
particularly useful approach for the study of cerebrovascular permeability following
experimental ICH.
No differences were observed in the blood-to-brain transfer constant {k\) to AIB, in
the tissue surrounding the experimental ICH or the contralateral caudate, between
non-diabetic and diabetic animals. The presence therefore, of increased oligaemia in
the diabetic BB rats in the area surrounding the experimental ICH was not associated
with an exacerbated disruption of BBB in the same region. Previous studies in
diabetic BB rats have also revealed a relative resistance of the brain to an increased
vascular permeability, which was present in extracranial tissues (Williamson et al.,
1987). Interestingly also, although acute hyperglycaemia is associated with increased
BBB permeability following experimental cerebral ischaemia (Dietrich et al., 1993;
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Warner et al., 1987), the presence of chronic hyperglycaemia is not (Sieber et al.,
1994).
The absence of any differences in BBB permeability between diabetic and non-diabetic
rats does not necessarily prove that there were no differences in oedema surrounding
the experimental ICH between those two groups of rats. Since oedema has vasogenic
and cytotoxic elements, it is quite possible that the cytotoxic element of oedema was
exacerbated in the diabetic animals subjected to ICH. Cell swelling can certainly occur
in the presence of hyperglycaemia, which is associated with increased intracellular
acidosis when blood flow reaches ischaemic levels to result in anaerobic glycolysis.
The reason for this phenomenon is that accumulation of intracellular H" activates the
membrane-bound Na+/H+ transporter. H+ is extruded but Na* accumulates inside the
cell in exchange. The sodium pump being out of energy cannot evacuate this excess
Na~ and the cell swells with osmotically attracted water (Siesjo, 1988). Ischaemic
blood flow levels were found in the surrounding the experimental ICH tissue in the
diabetic rats, and hyperglycaemia occurs frequently in the same animals. The
possibility therefore for an increased cellular oedema in the diabetic BB rats cannot be
excluded.
There are two methodological considerations applicable to the AIB method used for
estimating the intensity of BBB permeability in these studies. First, the k, of AIB
obtained in these studies is dependent upon the perfused capillary vessel surface area.
Whether differences were present between non-diabetic and diabetic animals in the
perfused surface area on the side of the haematoma could not be established directly.
There is certainly evidence arising from the studies of cerebrovascular physiology
presented earlier in this thesis that perfusion was lower in the striatum of the diabetic
BB rats under physiological conditions. However, perfusion was altered in the
lesioned side in both non-diabetic and diabetic rats, according to the results of the
LCBF experiments associated with ICH. Therefore, whether perfusion was different
in the lesioned side between groups at the area of k, estimation is not known. Second,
the tracer is trapped into functional cells, and this is the reason for no isotope uptake
154
in the core of the lesion. Whether differences in the intensity of ischaemic cell damage
were responsible for a reduced AIB uptake by cells in the diabetic animals is possible.
However, upon comparison of the AIB autoradiograms with the neuropathological
slides from adjacent sections, it was evident that the tracer accumulated mainly in the
border zone between the structurally abnormal area and the normal striatal tissue,
where the cells were expected to be equally functional in both groups.
4. 3. 6. The role of endothelin in the development of delayed ischaemia following
experimental ICH
ET is a potent vasoconstrictor of cerebral arteries both in vivo and in vitro, with long-
lasting effects (Robinson et al., 1991). Previously published studies reported that
factors released from blood promote the bioavailability of ET in a time-dependent
manner in vitro, reaching a peak at 24h (Ohlstein et al., 1991). This in vitro finding
was re-enforced by the current studies performed in vivo, where in both non-diabetic
and diabetic rats intrastriatal injection of blood resulted in an increased volume of
hypoperfusion when compared to intrastriatal silicon oil injection. Additional studies
in models of focal cerebral ischaemia found that endogenous tissue levels of ET
started to rise after 4 hours, and were significantly increased by 24 hours (Barone et
al., 1994), and the use of ET-antagonists reduced infarct volume following middle
cerebral artery occlusion in normal animals (Barone et al., 1995). These observations
led to the testing of the hypotheses that ET was involved in the evolution of the
observed delayed perilesional ischaemia following experimental ICH in the rat and
was also implicated in the potentiated ischaemic insult observed in the diabetic BB
animals. These hypotheses were tested using the potent non-peptide ET-antagonist
SB209670 (Ohlstein et al., 1994), employing a treatment protocol which was
associated with reduced infarct volume following middle cerebral artery occlusion in
normal animals (Barone et al., 1995).
The finding that treatment with SB209670 was associated with significant
haemodynamic improvement in the striatum of normal rats subjected to experimental
ICH was consistent with an important role for ET in the development of delayed
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ischaemia following haemorrhagic stroke. This compound has obviously
neuroprotective potential, the testing of which was outwith the purpose of the current
experimental design, in which potential mechanisms underlying the pathophysiological
sequelae following ICH were studied. In contrast, treatment with SB209670 failed to
alter the striatal oligaemia in the diabetic animals subjected to experimental ICH.
There are important implications associated with this observation. A large proportion
of patients that sustain strokes, both occlusive and haemorrhagic, suffer with diabetes
mellitus (Juvela, 1996). The outcome following stroke is also worse in these patients
(Jorgensen et al., 1994). Since human trials of potential neuroprotective agents have
failed to provide a single agent with proven therapeutic potential (Hsu, 1993), despite
the encouraging results obtained from various experimental models of stroke
conducted almost exclusively in young healthy animals without background
pathology, a potential explanation for this discrepancy may be based on the failure of
these experimental strategies to address the potential influence of host diseases upon
the pathophysiology of cerebral ischaemia.
There are two points that warrant further consideration in relation to the findings
associated with the SB209670 treatment in the diabetic BB rats subjected to
experimental ICH. First, MABP in the SB209670-treated diabetic rats at the time of
the LCBF experiment (98mmHg) was considerably lower than that of the diabetic
animals treated with saline (116mmHg). A similar trend towards MABP reduction
following SB209670 treatment was not evident in the non-diabetic rats (Table 19).
Although the differences in MABP were not significant, it is impossible to be certain
whether MABP had fluctuated during the 24h period from the induction of the
haematoma until the LCBF measurement to an extent which might have adversely
influenced the outcome. The recorded MABP value in the SB209670-treated rats
(98mmHg) was within the normal range but, in the presence of significant oligaemia,
cerebral blood flow becomes pressure dependent due to exhaustion of collateral
vasodilatory reserve. It is therefore conceivable that even this modest MABP
reduction was important in obscuring any beneficial haemodynamic effect of
SB209670 in the diabetic rats. Interestingly, in a recent study an endothelin antagonist
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failed to alter postischaemic cerebral hypoperfusion following experimental global
ischaemia, reportedly because it was associated with decreased MABP (Yasuma et
al., 1997). It is unlikely that the rest of the physiological variables (Table 19) could
have influenced the LCBF findings. Although pH was elevated in the non-diabetic
animals treated with SB209670 in relation to the saline-treated animals, both values
were within physiological range, and in addition, a trend of pH towards increase was
similarly evident in the diabetic animals, in which no significant effect was achieved
with SB209670 treatment upon striatal oligaemia.
The second point for consideration relates to the elevated LCBF in the hemisphere
opposite to the haematoma in the diabetic rats treated with SB209670, as compared
to the saline-treated animals. The same treatment had no significant effect upon LCBF
in the non-diabetic rats subjected to experimental ICFI. This finding could be
consistent with an increased basal production of ET in the diabetic brain, and
therefore, the dose of SB209670 used might have been insufficient to block its effect.
However, in view of the MABP findings, a higher dose of this ET-antagonist might
have resulted in further decrease in MABP and possibly masked any beneficial effect.
It should also be stressed that the acute SB209670 injection had no effect upon LCBF
in any of the brain areas examined in the diabetic animals during the pharmacological
manipulation of the cerebrovascular endothelium (section 4. 1. 3.), providing evidence
against an increased bioavailability of endothelin associated with diabetes mellitus.
However, firm conclusions in relation to the bioactivity of ET during IDDM cannot
be drawn with this experimental design.
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4. 4. Haematoma studies in the hypertensive animals
4. 4. 1. Influence of blood constituents upon perilesional LCBF following
experimental ICH
In keeping with the findings in the non-diabetic and diabetic animals, it appeared to be
the presence of blood and not the mass effect alone which was responsible for the
delayed striatal oligaemia in the SHR rats (Figure 30, Table 23). It is impossible to be
absolutely certain however, because invariably endogenous bleeding occurred in all
the SHR animals subjected to silicon oil injection (Figure 31) and it was therefore not
feasible to investigate adequately the isolated effect of the ICH mass. However, there
was a trend in the SHR animals injected with silicon oil to have smaller volumes of
striatal hypoperfusion, compared to the animals of the same sub-strain with ICH.
The finding in the WKY animals that silicon oil injections were associated with similar
haemodynamic compromise at 24h, compared to the experimental ICHs was rather
surprising, in relation to the rest of the experimental groups. An explanation other
than that in WKY the isolated mass effect of an ICH results in significant and long-
lasting oligaemia cannot be offered. It was surprising to observe that the blood itself
had probably no deleterious influences in WKY, contrary to what was found in the
SHR and the rest of the experimental groups. One important point that warrants
discussion is that the responses to the same insult (intrastriatal silicon oil injection)
can be variable between different experimental groups, even in animal strains derived
from the same species. Along the same lines, it is equally important to appreciate that
control animals (in our case WKY and DR rats of the BB strain) can differ widely
upon their vulnerability following an intracranial insult, such as experimental ICH. It is
therefore essential to employ the appropriate control animals for each rat strain used
for experimental purposes.
4. 4. 2. Influence ofchronic hypertension upon LCBFfollowing experimental ICH
The experiments with WKY and SHR rats did not provide evidence in favor of the
hypothesis that chronic hypeYension is associated with altered pathophysiolgy, in
terms of local cerebral perfusion, following experimental ICH. This was another
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surprising observation, since SHR rats have been reported to sustain an increased
ischaemic burden following experimental occlusive stroke (Coyle, 1984; Grabowski et
ai, 1988). The single experimental ICH study which was conducted in SHRs reported
that the hypertensive animals had greater mortality associated with the haematoma
(Gonzalez-Darder & Duran-Cabral, 1990), but the volume of blood injected into the
animals (400pl, equivalent to almost 25% of the rat's brain) makes it prohibitive for
any clinically applicable conclusions to be drawn from it. However, studies in human
sufferers of ICH have concluded that hypertensive patients do not have worse
outcome per se, but because the strokes they sustain are more extensive than in the
population at large, there is a misconception that chronic hypertension is associated
with worse outcome (Jorgensen et a/., 1995). Mizukami and Tawaza measured
regional CBF with intracarotid xenon-133 injections in 14 hypertensive patients with
ICH in 1983. In areas adjacent to the haematoma CBF was depressed in 13 out of the
14 patients, despite a normal ICP. Studies in human sufferers of ICH however, do not
provide clear information whether hypertension predisposes to a larger area of
ischaemia following haemorrhagic stroke or whether hypertensive subjects, as stated
earlier, have worse outcome because they have larger haemorrhages. Epidemiological
studies, in which diabetes mellitus but not chronic hypertension was associated with
poor outcome following ICH (Juvela, 1995), support the findings of these
experiments, in which delayed perilesional ischaemia following experimental ICH was
increased in spontaneously diabetic BB rats but not in spontaneously hypertensive
SHR rats.
The susceptibility to stroke in association with chronic hypertension has received
attention recently, especially in relation to a presence of a potential gene which is
responsible for this susceptibility to stroke (Jacewitz, 1992). The relevance of this
information is based upon claims that the susceptibility to infarction in SHR is
determined by an unidentified autosomal recessive gene, unrelated to the hypertension
itself and sometimes present in the minority of normotensive rats (Jacewitz, 1992). In
addition, recent studies from groups supporting this hypothesis, that a specific gene
specific for stroke cosegregates with that for hypertension, have shown that such a
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gene exists in the SHRSP but not in the SHR (Rubattu et al., 1997). It is also
suggested that the impaired endothelium-dependent vasorelaxation in stroke-prone
rats is genetically determined and again cosegregates with the stroke-prone phenotype
(Volpe et al., 1996). This information is obviously of peripheral importance to the
studies presented in this thesis, but might, nevertheless provide an indirect explanation
for the relatively large volumes of hypoperfusion in the WKY animals subjected to
ICH, as well as the reason that no differences in the LCBF findings were observed
between WKY and SHR animals with ICH.
The SHR rat was used as the model of chronic hypertension in these studies, in spite
of the above-mentioned genetic findings, since it is the most commonly used model of
the disease, and in the absence of a superior model. The SHRSP sub-strain was not
used for two reasons. First, the lesions developing in this model are occlusive rather
than haemorrhagic and second it would have been rather complicated to define an
appropriate control (SHR or WKY) for it. In fact, there are reports in which both the
WKY and SHR have been used as controls in the same study (Izuta et al., 1995), so a
similar design in the current studies would have been excessively complicated and
difficult to analyze statistically. Finally the genetic speculations discussed above would
have applied to any findings obtained with this model of hypertension.
4. 4. 3. BBB permeabilityfindings
BBB permeability to AIB was not increased in SHR following ICH. It should be
mentioned that, as was the case with the same experimental paradigm in the diabetic
groups, oedema per se was not addressed in these experiments. Certainly, in
experimentally induced occlusive stroke, hypertensive animals have been reported to
develop significantly more brain edema, as compared to normotensive ones (Olsson et
al., 1989). Whether this is the case following haemorrhagic stroke needs further
elucidation, but, it is clear that the vasogenic element of oedema certainly is not
different between WKY and SHR.
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4. 4. 4. Protective effects of 7-NI
There was clear evidence from the experimental ICH studies conducted in the diabetic
groups, that blood had deleterious effects upon the parenchymal cerebrovasculature,
in comparison to silicon oil. Similar definitive conclusions could not be reached in the
experiments performed in SHR and WKY rats. Although there was a trend in the
SHR group for the haematoma to be associated with increased striatal oligaemia, the
results obtained from the WKY animals were more inconclusive. There was therefore
no factual evidence upon which to base the same hypothesis, in relation to the role of
endothelin upon the evolution of ischaemia following ICH, because an equally
deleterious effect of blood was not observed. The striking observation during
pharmacological manipulation of the cerebrovascular control mechanisms in WKY
and SHR was the finding of an upregulated neuronal NO system in the SHR (section
4. 2. 3.). There is extensive recent speculation for a potentially detrimental role of
neuronally derived NO, linked to excitotoxicity, following various types of brain
insult, including ischaemia (Huang et al., 1994). The role of neuronally-derived NO is
rather complex, because following glutamate receptor activation its haemodynamic
vasodilatory influence is probably beneficial, whereas its effects upon non-vascular
cells are detrimental (Globus et al., 1995).
The experimental protocol with 7-NI treatment following ICH was selected after
consideration of the above mentioned aspects. The dose (25mg.kg"1) has been shown
to be neuroprotective in a model of photothrombotic stroke (Kelly et al., 1994a),
which has certain similarities with ICH in view of the presence of blood cell exudates
into the brain tissue in areas of thrombosis (Prado et al., 1996). The timing of the
administration was also based on the same protocol. In contrast to the findings with
the diabetic groups, the WKY (mainly) and the SHR exhibited vulnerability to the
mass effect of the haematoma, which obviously presents at the induction of the lesion
rather than as a maturation phenomenon, so it was felt that the timing of the injection
could be the same with those published protocols.
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This treatment protocol was associated with a significant reduction in the volume of
presumed perilesional oligaemia in the WKY, at 24h. This finding indirectly re-
enforces the observations with the silicon oil injections in the same sub-strain, where
the mass effect of the ICH induced hypoperfusion to the surrounding tissue, the onset
ofwhich coincides with the induction of the lesion.
The 7-NI treatment was associated with a trend towards haemodynamic improvement
in the SHR animals, but the response was less robust and more variable compared to
the WKY group. Several potential explanations can be offered for this observation.
As was discussed earlier, SHR rats responded to the ICH and silicon oil injections in a
way that was probably compatible with the blood per se being deleterious to the
cerebrovasculature. This influence of the blood upon the cerebrovasculature is a
delayed event on the basis of all available scientific information, and therefore the
timing of the 7-NI treatment would have been too early to have an effect. Secondly,
since nNO is probably overactive in the SHR, this dose of 7-NI might have been
ineffective. A higher dose was not used because, as discussed earlier, it had
detrimental effects in normal rats (Kelly et al., 1994a), and is sometimes associated
with bizarre cerebrovascular phenomena (Kelly et al., 1995b; Wang et al., 1995) so
appropriate controls for the SHR would have been difficult to obtain.
Finally, a point that applies to all the results of the ICH experiments is the variability
of both the haematoma volumes and the volumes of striatal hypoperfusion. In the
diabetic groups, the differences between the volumes of oligaemia in various groups
were so large, that despite the variability they were not obscured. Obviously, part of
the variability in the responses to the ICH in the diabetic animals can be attributed to
the apparent differences in the disease process between individual animals. Even in the
non-diabetic animals, where the volumes of hypoperfusion were rather small, a
significant difference with the SB209670 treatment was evident. However, in the
WKY and SHR groups, where the differences between groups were not so large, the
limitations of the model became more obvious.
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4. 5. Concluding remarks - Future studies
The results of these studies provided substantial evidence for the presence of
cerebrovascular dysfunction, in the form of regionally heterogeneous reduction of
basal LCBF linked to an attenuated eNOS activity, in the diabetic BB rats. This
alteration in cerebrovascular physiology was associated with increased haemodynamic
compromise in the tissue surrounding experimental ICH in this model of IDDM. This
information can provide the basis of future studies, in which treatment protocols for
correction of the eNOS dysfunction in the BB rats can be tested in relation to their
capability to alter basal LCBF and the pathophysiological response to an ICH.
Although the reproducibility of the ICH model was not optimal, the diabetic BB rats
bore an ischaemic burden more than 3 times larger compared to the non-diabetic DR
rats of the same strain. This difference is so large, that the therapeutic potential of
future strategies can be tested. Along these lines recent in vitro studies have located
the deficit in the eNOS activity in extracranial vessels of experimental IDDM, in
depletion of tetrahydrobiopterin, a cofactor of eNOS (Pieper, 1997). It will be very
interesting to study whether chronic treatment of the BB rats with an exogenous
cofactor can reverse in vivo the observed cerebrovascular dysfunction. Additionally, if
any improvement of this dysfunction was to be established, it would have been
possible to investigate whether this was associated with a reduction in the extent of
hypoperfusion following ICH. In relation to the perturbation of eNOS in diabetes,
chronic inhibition of NOS in the BB rats, similar to that investigated in normotensive
animals and in which a selective upregulation ofNOS was observed in the brain (Kelly
et a/., 1995c), could delineate further the extent of dysfunction in cerebrovascular
homeostatic reserve of the diabetic animals.
Along the same lines, further insight in a possible pathogenetic role of ET in the
vascular dysfunction associated with IDDM could be gained with a modified
SB209670 treatment protocol in the studies of cerebrovascular physiology, similar to
that used in the ICH studies. Caution ought to be exercised regarding the
neuroprotective potential of ET antagonists following haemorrhagic stroke in the rat
however. Although treatment with SB209670 was associated with significant
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reduction in striatal hypoperfusion in young healthy animals without background
pathology, certain points of concern were raised following its use in the diabetic
rodents, as discussed earlier. Additionally, other researchers in the field of cerebral
ischaemia have recently commented on the relative resistance of rats, in comparison to
other species, to the neuroprotective effects of ET antagonists (McCulloch et a/.,
1996).
The attempt to create a model of controlled diabetes with intensified insulin treatment
was not successful. It would have been interesting to ascertain whether such a
treatment reversed the observed perturbations in cerebrovascular physiology and
pathology. Unfortunately, the only indication provided from this experimental design
was that this treatment is associated with increased mortality in this rat model of
IDDM, probably resulting from insulin-induced hypoglycaemia.
There is considerable scope for further pathology studies. Firstly, the microvascular
neuropathology of the BB rat has not been documented. This requires clarification at
ultrastructural and light microscopic levels, using quantitative morphometric
techniques to assess thickening of cerebral small vessels. The use of specific
antibodies to advanced glycosylation end-products should extend the less specific,
traditional histochemical observations. Analysis of a variety of protein and mRNA
moieties (for example eNOS, endothelin and various markers of blood-brain barrier
integrity) by immunohistochemical and in-situ hybridization techniques, might provide
pathological substrates for the observed functional abnormalities of diabetic vessels.
Secondly, parallel pathology studies of perfusion-fixed brains in the ICH model are
required to better define the nature and extent of perilesional hypoxic-ischaemic brain
injury in each group. Traditional morphological criteria could usefully be
supplemented by newer methods of assessing early hypoxic-ischaemic neuronal
damage. Promising avenues would be analyzing heat-shock and immediate-early gene
expression in neurones, as well as loss of dendritic microtubule-associated protein 2
(MAP 2) immunoreactivity (Kitagawa et al., 1989).
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IDDM is a risk factor for haemorrhagic stroke, but occlusive strokes are even
commoner in diabetic individuals. Although it would require preliminary
characterization, a model of occlusive stroke in the BB rats would have been relevant
for the investigation of the mechanisms underlying the responses of the spontaneously
diabetic rats to focal ischaemia.
The studies of cerebrovascular physiology in the SHR rats provided evidence for
presence of cerebrovascular dysfunction in this animal model of chronic hypertension.
However, the perturbations were not of the same fundamental nature, as in the
diabetic BB rats, to cause alterations in basal LCBF. The likelihood of an upregulated
neuronally-derived NO system under physiological conditions having pathological
implications was investigated further with the ICH model, but considerable problems
were encountered. Endogenous bleeding was invariably present in the SHR rats as a
result of trauma from the needle used for the induction of the haematoma. The
haemodynamic responses of the control WKY rats were rather surprising for reasons
already discussed. Finally, problems associated with variability in both the burden of
haemorrhagic insult and the responses to ICH in WKY and SHR became more
obvious. It is appreciated that chronic hypertension is the commonest risk factor for
ICH, but the limitations of this model of haemorrhagic stroke that were outlined





Physiological variables of non-diabetic and diabetic rats treated acutely with saline (0.5ml i.v.). L-
NAME (30mg.kg"', i.v.) or SB209670 (lOmg.kg1, i.v.), just before the LCBF measurement (20min
after the injection)
Non-diabetic Diabetic
Saline L-NAME Saline L-NAME SB209670
pC02 (mmHg) 41.1 ±0.7 35.3 ± 1.7 42.9 ±0.6 40.8 ±0.9 43.2 ± 1.7
pCL (mmHg) 88.5 ±2.5 100.1 ± 1.9 88.5 ± 1.4 92.1 ±4.4 90.9 ±0.8
pH 7.425 ±0.005 7.379 ±0.018 7.413 ±0.026 7.393 ±0.009 7.462 ± 0.005
MABP (mmHg) 115 ± 5 142 ±3 # 109 ± 3 149 ±4 # 118 ± 4
Heart Rate (bpm) 395 ± 29 293 ±8 315 ± 25 255 ± 15 350 ± 26
Plasma glucose (mg.df ') 144 ±8 251 ±87 284 ± 65 131 ±56 222 ± 40
Temperature (°C) 36.9 ±0.4 36.5 ±0.2 36.6 ±0.3 36.4 ±0.2 36.0 ±0.3
Haematocrit (%) n.d. 49 ± 1.7 n.d. 52.5 ± 1.0 54.7 ± 1.3
Plasma bicarbonate 27.0 ±0.3 21.0 ± 1.0 27.3 ± 1.4 25.0 ±0.8 29.4 ±0.6
Base excess 3.0 ±0.2 -3.1 ± 1.1 2.8 ± 1.8 0.3 ±0.8 5.5 ±0.7
Data are presented as mean ± s.e.mean (n = 6 in saline-treated groups, n = 4 in L-NAME and
SB209670-treated groups)
n.d.: not determined




Physiological variables in non-diabetic and diabetic rats injected acutely with sesame oil (0.6ml, i.p.)













Plasma glucose (mg.df ) 152 ± 9
Temperature (°C) 37.2 ± 0.5
Haematocrit (%) n.d.
Plasma bicarbonate 26.8 ±0.5



































Data are presented as mean ± s.e.mean (n = 4 in each group)
n.d.: not determined
#: significant difference between sesame oil and 7-NI-treated rats of the same sub-strain.
*: significant difference between non-diabetic and diabetic rats with the same treatment
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Table 3
Physiological variables in non-diabetic and diabetic rats treated acutely with saline (40gl.min"', i.v.
infusion) or SIN-1 (l.Smg.kg"1 h"1, i.v. infusion), just before the LCBF experiment (20min after the
onset of the infusion)
Non-diabetic Diabetic
Saline SIN-1 Saline SIN-1
pCO; (mmHg) 41.4 ± 1.0 41.5 ± 1.9 44.0 ± 0.5 38.1 ±0.7 #
pO; (mmHg) 88.8 ± 4.2 98.6 ±3.5 88.0 ± 1.8 80.1 ±3.1 *
pH 7.424 ± 0.008 7.425 ±0.012 7.396 ±0.038 7.557 ±0.016 #*
MABP (nunHg) 125 ±9 100 ±5 115 ± 7 97 ±4
Heart Rate (bpm) 383 ± 23 389 ±33 319 ± 36 377 ±27
Plasma glucose (mg.df1) 198 ±58 204 ± 19 252 ±61 512 ± 101
Temperature (°C) 36.6 ±0.1 37.5 ±0.2 # 36.6 ±0.4 35.8 ±0.3 *
Haematocrit (%) n.d. 50.2 ±0.2 n.d. 51.8 ± 0.7
Plasma bicarbonate 27.2 ±0.4 26.6 ± 0.7 26.9 ±2.1 34.3 ± 1.1 *
Base excess 3.0 ±0.4 2.6 ±0.4 2.0 ±2.7 11.8 ± 1.3 #*
Data are presented as mean ± s.e.mean (n = 4 in each group)
n.d.: not determined
#: significant difference between saline and SIN-1-treated animals of the same sub-strain.
*: significant difference between non-diabetic and diabetic animals with the same treatment.
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Table 4
Physiological variables in conventionally treated diabetic rats (with a single subcutaneous injection of
insulin) and in rats with implanted insulin rods, providing continuous subcutaneous insulin delivery,
just before the LCBF measurement
Conventional insulin treatment CSII
pC02 (mmHg) 42.7 ±0.9 44.0 ± 1.2
pO; (mmHg) 88.8 ± 1.6 89.4 ±2.1
pH 7.414 ±0.027 7.404 ± 0.030
MABP (mmHg) 109 ± 1 112 ± 4
Heart Rate (bpm) 323 ±33 327 ± 20
Plasma glucose (mg.dl1) 284 ± 92 285 ± 65
Temperature (°C) 36.8 ±0.3 36.4 ±0.3
Haematocrit (%) n.d. 51.3 ± 1.2
Plasma bicarbonate 27.4 ± 1.4 27.3 ± 1.4
Base excess 3.0 ± 1.8 2.3 ± 1.8
Glvcosvlated Hb n.d. 8.8 ±0.6




LCBF (ml.lOOg'.min1) data in non-diabetic and diabetic rats treated acutely with saline (0.5ml.



































27 ±1 # 32 ±1 *
93 ± 2 # 86 ± 3 *
50 ±2 # 53 ±1 *
107 ±6














54 ± 5 # 79 ± 9
84 ±2 # 106 ±4 * 86 ±10 110 ±11
60 ± 3 # 72 ± 6 * 66 ± 9 82 ± 6
59 ± 2 # 69 ± 4 * 67 ± 10 72 ± 5
Data are presented as mean ± s.e.mean (n = 6 in each saline-treated group, n = 4 in L-NAME and
SB209670-treated groups)
*: significant difference between non-diabetic and diabetic animals treated with saline




LCBF (ml.lOOg'.min1) data in non-diabetic and diabetic rats injected acutely with sesame oil
(0.6ml, i.p.) or 7-NI (25mg.kg"' i.p.)
Non-diabetic Diabetic
Sesame oil 7-NI Sesame oil 7-NI
Neocortex
Parietal 164 ±8 110 ± 5 # 137 ± 11 106 ±5
Cingulate 150 ±10 72 ±4 # 131 ± 15 77 ±5 #
Corpus Callosum 41 ±3 19 ± 3 # 33 ± 1 22 ±2 #
Basal Ganglia
Striatum 129 ±4 72 ±3 # 91 ± 1 * 69 ±4 #
Globus Pallidus 73 ± 1 45 ±4 # 56 ± 1 * 42 ±4 #
Accumbens 135 ± 13 64 ± 5 # 110 ± 4 60 ±4 #
Thalamus
Hypothalamus 92 ±3 41 ±3 # 81 ±6 38 ±2 #
Lateral geniculate 146 ±6 73 ±6 # 111 ± 6 * 72 ± 5 #
Hippocampus
CA 2,3 91 ±5 46 ±5 # 74 ±7 46 ±3 #
Dentate Hilus 90 ±4 49 ±5 # 73 ± 3 * 47 ±2 #
Data are presented as mean ± s.e.mean (n = 4 in each group)
*: significant difference between diabetic and non-diabetic treated with sesame oil
#: significant difference betw een sesame oil and 7-NI-treated animals of the same sub-strain
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Table 7
LCBF (ml.lOOg'.min1) data in non-diabetic and diabetic rats treated acutely with saline (40gl.min"',
i.v. infusion) or SIN-1 (1.8mg.kg"' .h~\ i.v. infusion)
Non-diabetic Diabetic
Saline SIN-1 Saline SIN-1
Neocortex
Parietal 149 ±7 211 ± 13 # 134 ±5 269 ±3 #*
Cingulate 135 ±7 164 ± 14 121 ± 7 159 ± 1 #
Corpus Callosum 40 ± 3 40 ±5 32 ± 1 42 ±4
Basal Ganglia
Striatum 120 ±3 130 ±4 82 ±3 * 107 ±4 #*
Globus Pallidus 73 ±2 80 ±5 51 ±3 * 63 ±2 #*
Accumbens 117 ± 2 156 ± 12 # 103 ±5 143 ± 1 #
Thalamus
Hypothalamus 92 ±5 111 ± 15 80 ± 3 78 ±4
Lateral geniculate 133 ±3 160 ±8 # 108 ±7 * 148 ±7 #
Hippocampus
CA 2,3 91 ±4 103 ±2 70 ±6 91 ±5
Dentate Hilus 84 ±4 106 ±2 # 65 ±4 * 99 ±4 #
Data are presented as mean ± s.e.mean (n = 4 in each group)
*: significant difference between non-diabetic and diabetic rats infused with i.v. saline or SIN-1
#: significant difference between saline and SIN-1-treated animals of the same sub-strain
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Table 8
LCBF (ml.lOOg'Vmin"1) data in conventionally treated diabetic rats (with a single daily subcutaneous
injection of insulin) and in rats with implanted insulin rods, providing continuous subcutaneous
insulin delivery
Conventional insulin treatment CSII
Basal Ganglia
Striatum 87 ± 3 102 ± 9
Globus Pallidus 54 ± 3 59 ± 3
Thalamus
Lateral geniculate 109 ±6 122 ± 8
Hippocampus
CA 2,3 74 ± 7 72 ± 4
Dentate Hilus 72 ± 4 70 ± 3




Physiological variables of WKY and SHR rats treated acutely with saline (0.5ml i.v.), L-NAME
(30mg.kg_1, i.v.) or SB209670 (lOmg.kg1, i.v.), just before the LCBF measurement (20min after the
injection)
WKY SHR
Saline L-NAME Saline L-NAME SB209670
pCO; (inmHg) 41.6 ± 1.8 4 0.3 ± 1.3 39.3 ± 1.8 37.7 ± 1.5 41.0 ±0.4
pCL (mmHg) 89.3 ±3.4 90.6 ±4.2 91.4 ± 2.1 86.8 ± 1.0 88.1 ± 1.6
pH 7.487 ±0.010 7.465 ±0.001 7.475 ± 0.006 7.463 ± 0.006 7.444 ± 0.0C
MABP (mmHg) 120 ±3 152 ±3 # 175 ±6 * 207 ± 1 #* 171 ±8
Heart Rate (bpm) 289 ±8 210 ± 12 # 382 ±19 * 323 ±23 * 355 ± 17
Plasma glucose (mg.df ') 142 ±10 135 ±9 140 ± 13 109 ±4 126 ±6
Temperature (°C) 36.4 ±0.2 36.6 ±0.4 36.7 ±0.2 36.7 ±0.0 37.4 ±0.1
Haematocrit (%) 49.4 ±0.6 50.9 ± 1.5 51.6 ±0.4 * 51.5 ± 0.9 52.5 ±0.8
Plasma bicarbonate 30.5 ±0.7 28.3 ±0.7 28.5 ±0.9 26.8 ±0.6 27.3 ±0.5
Base excess 6.6 ±0.7 4.2 ±0.8 4.4 ± 1.0 2.7 ±0.6 3.2 ±0.5
Data are presented as mean ± s.e.mean (n = 6 in WKY and n = 5 in SHR saline groups, n = 4 in each
other group)
*: significantly different between WKY and SHR with the same treatment
#: significant difference between saline and L-NAME or SB209670 treatment in the same sub-strain
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Table 10
Physiological variables in WKY and SHR rats injected acutely with sesame oil (0.6ml. i.p.) or 7-NI
(25mg.kg_1 i.p.), just before the LCBF experiment (40min after the injection)
WKY SHR
Sesame oil 7-NI Sesame oil 7-NI
pC02 (mmHg) 41.5 ±2.3 40.0 ±0.7 38.6 ±2.1 36.7 ±0.4
p02 (mmHg) 91.5 ±3.2 97.8 ±3 .8 91.1 ±2.6 89.2 ±0.7
pH 7.490 ±0.011 7.479 ± 0.007 7.481 ±0.001 7.462 ± 0.009
MABP (mmHg) 119 ± 3 123 ±3 173 ±8 * 180 ±6
Heart Rate (bpm) 287 ± 10 280 ±7 377 ±24 * 300 ± 11
Plasma glucose (mg.df1) 142 ± 12 170 ± 12 130 ± 10 146 ± 13
Temperature (°C) 36.5 ±0.1 37.1 ±0.2 36.9 ±0.2 36.5 ±0.1
Haematocrit (%) 49.3 ±0.7 50.9 ± 1.5 51.4 ± 0.3 52.2 ±2.2
Plasma bicarbonate 30.8 ±0.8 29.2 ±0.7 28.6 ± 1.2 26.3 ±0.6
Base excess 6.9 ±0.8 5.2 ±0.7 4.5 ± 1.3 2.1 ±0.7
Data are presented as mean ± s.e.mean (n = 5 in the WKY rats treated with sesame oil. n = 4 in each
other group)
*: significant difference between WKY and SHR with the same treatment
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Table 11
Physiological variables in WKY and SHR rats treated acutely with saline (TOgl mini.v. infusion)
low SIN-1 (0.54mg.kg"l.h1, i.v. infusion) or high SIN-1 (1.8mg.kg"'.h'1, i.v. infusion) dose, just
before the measurement of LCBF (20min after the onset of the infusion)
WKY SHR
Saline low SIN-1 high SIN-1 Saline low SIN-1 high SIN-1
pC02 (mmHg) 41.1 ±2.2 38.4 ±2.0 37.9 ±1.1 41.0 ± 0.6 37.9 ± 1.0 40.4 ± 1.3
p02 (mmHg) 90.1 ±4.1 85.5 ± 1.0 94.6 ±2.7 90.1 ±2.1 90.2 ±3.0 97.4 ± 1.0
PH 7.488 ±0.012 7.476 ± 0.007 7.478 ± 0.005 7.474 ± 0.008 7.461 ±0.007 7.443 ± 0.004
MABP (mmHg) 120 ±4 96 ±8 95 ±6 # 179 ±6 * 147 ±2 #* 104 ± 5 #
Heart Rate (bpm) 291 ±9 287 ±20 303 ± 3 370 ± 20* 410 ±24 * 338 ± 16
Plasma glucose (mg.df ') 146 ± 11 219 ± 46 219 ± 26 144 ± 16 146 ±7 175 ± 17
Temperature (°C) 36.3 ±0.2 35.8 ±0.2 37.0 ±0.2 36.7 ±0.2 37.4 ±0.1 37.3 ± 0.3
Haematocrit (%) 49.3 ±0.7 49.7 ±0.3 49.9 ± 1.1 51.6 ±0.4 50.9 ± 0.5 52.3 ± 1.5
Plasma bicarbonate 30.3 ±0.9 27.9 ±0.6 28.0 ±0.9 29.3 ±0.4 26.9 ±0.5 27.0 ± 0.8
Base excess 6.5 ±0.9 3.8 ±0.7 3.9 ± 1.0 5.4 ±0.5 2.7 ±0.6 2.8 ± 0.8
Data are presented as mean ± s.e.mean (n = 5 in saline-treated WKY, n = 4 in all other groups)
*: significant difference between WKY and SHR following tire same treatment
#: significant difference between saline and SIN-1 treatment in animals of the same sub-strain
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Table 12
LCBF (ml.lOOg'Vmin"') data in WKY and SHR rats treated acutely with saline (0.5ml, i.v.), L-
NAME (30mg.kg"', i.v.) or SB209670 (lOmg.kg"1, i.v.)
WKY SHR
Saline L-NAME Saline L-NAME SB209670
Neocortex
Parietal 141 ±6 124 ±7 132 ±8 105 ±6 158 ±5
Cingulate 98 ±4 99 ±5 117 ± 6 91 ±6 # 127 ±23
Corpus Callosum 37 ±2 20 ± 1 # 32 ±2 29 ±2 * 34 ±6
Basal Ganglia
Striatum 99 ±4 87 ±4 94 ± 5 83 ± 5 110 ± 14
Globus Pallidus 64 ±4 53 ±3 68 ±8 54 ±3 78 ± 12
Accumbens 98 ±4 78 ±5 # 116 ± 3 * 82 ±5 # 117 ± 13
Thalamus
Hypothalamus 75 ±4 49 ±3 # 83 ±5 45 ±3 a 65 ±3
Lateral geniculate 106 ± 5 89 ±6 116 ±9 93 ±5 126 ±9
Hippocampus
CA 3 76 ±4 60 ± 1 # 85 ± 3 63 ±4 # 84 ±2
CA 2 71 ±3 56 ±2 # 83 ±4 59 ± 5 # 82 ±8
CA 1 68 ±5 56 ± 1 74 ± 3 61 ±3 90 ± 11
Molecular layer 73 ±4 57 ± 1 # 85 ± 2 61 ±5 # 87 ± 5
Dentate Hilus 76 ±4 61 ± 1 # 93 ±6 62 ±5 # 85 ± 9
Data are presented as mean ± s.e.mean (n = 6 in WKY and n = 5 in SHR saline-treated groups, n = 4 in
L-NAME and SB209670-treated groups)
*: significant difference between WKY and SHR
#: significant difference between saline and L-NAME or SB209670
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Table 13
LCBF (ml.lOOg '.min1) data in WKY and SHR rats injected acutely with sesame oil (0.6ml, i.p.) or
7-NI (25mg.kg"' i.p.)
WKY SHR
Sesame oil 7-NI Sesame oil 7-NI
Neocortex
Parietal 143 ±7 121 ±5 138 ±7 78 ±4 #*
Cingulate 98 ±5 82 ± 1 120 ±7 64 ±6 #
Corpus Callosum 38 ±2 21 ± 1 # 33 ±3 21 ± 1 #
Basal Ganglia
Striatum 100 ±4 78 ±3 # 97 ± 5 59 ±5 #*
Globus Pallidus 66 ±3 49 ±2 # 72 ±9 38 ± 1 #*
Accumbens 99 ±4 77 ±5 # 119 ± 2 * 56 ± 1 #*
Thalamus
Hypothalamus 77 ±4 50 ±3 # 87 ±4 36 ±3 #*
Lateral geniculate 110 ±4 87 ±3 # 123 ±8 69 ±2 #*
Hippocampus
CA 3 78 ±4 57 ±2 # 88 ±2 49 ±3 #
CA 2 72 ±4 51 ± 1 # 85 ±4 45 ±2 #
CA 1 71 ±4 49 ±2 # 76 ±2 44 ±2 #
Molecular layer 75 ±4 55 ±3 # 87 ±2 45 ±2 #
Dentate Hilus 78 ±5 58 ± 3 # 96 ±7 46 ± 1 #*
Data are presented as mean ± s.e.mean. (n = 5 in WKY treated with sesame oil, n = 4 in all other
groups)
*: significantly different between WKY and SHR with the same treatment
#: significant difference between sesame oil and 7-NI - treated rats of the same sub-strain
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Table 14
LCBF (ml.lOOg'.min"1) data in WKY and SHR rats treated acutely with saline (40pl.min"', i.v.
infusion) low SIN-1 (0.54mg.kg'1.h"1, i.v. infusion) or high SIN-1 (1.8mg.kg'l.h"1, i.v. infusion) dose.


































low SIN-1 high SIN-1 Saline
139 ± 12 206 ±9 # 127 ±9
152 ± 7 # 171 ±6 # 112 ± 5
29 ± 3 36 ± 3 32 ±3
117 ±5 # 129 ±6 # 90 ±4
90 ±2 # 80 ±4 61 ±4
136 ± 7 # 153 ± 4 # 114 ± 4
79 ± 5 89 ± 4 80 ± 4
138 ± 6 # 164±7 # 111 ± 10
98 ±4 # 104 ± 3# 83 ±3
82 ± 7 92 ±5 # 80 ±3
80 ±6 100 ±5 # 73 ±3
95 ±4 # 103 ±3 # 84 ±2
94 ±5 # 112 ±6 # 90 ±5
low SIN-1 high SIN-1
142 ±10 148 ±11*








109 ±8 107 ±9
82 ±4 # 66 ±4
138 ±11 130 ± 8
75 ± 7 70 ± 5






Data are presented as mean ± s.e.mean (n = 5, in WKY rats treated with saline, n = 4 in all other groups)
*. significant difference between WKY and SHR animals given the same treatment
#. significantly different from saline-treated rats of the same sub-strain
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Table 15
Physiological variables during induction of experimental ICH in animals anaesthetized with
pentobarbitone (30-45mg.kg"' i.p.), placed on a thermal blanket and receiving supplementary oxygen
(41t.min"') through a face mask (see also section 2. 16.)
Non-diabetic Diabetic
15 min 15 min 15 min 15 min
pre-induction post-induction pre-induction post-inductioi
pCO; (mmHg) 44.5 ± 1.3 44.1 ± 1.3 44.4 ±2.6 44.7 ±3.0
pO; (mmHg) 80.3 ±2.8 80.7 ±2.6 80.2 ± 1.6 80.4 ±2.5
pH 7.354 ±0.021 7.353 ±0.030 7.419 ±0.016 7.419 ±0.015
MABP (mmHg) 102 ±4 112 ± 7 100 ±4 110 ± 4
Heart Rate (bpm) n.d. n.d. n.d. n.d.
Plasma glucose (mg.df') 142 ± 10 141 ±6 230 ±49 225 ± 74
Temperature (°C) 36.1 ±0.1 36.2 ±0.4 36.0 ±0.2 36.1 ±0.2
Haematocrit (%) n.d. n.d. n.d. n.d.
Plasma bicarbonate 25.8 ± 1.4 25.4 ± 1.3 28.8 ±0.5 29.5 ± 1.0
Base excess -1.2 ± 1.4 -1.5 ± 1.7 3.5 ± 1.5 3.5 ± 1.0




Physiological variables in non-diabetic and diabetic rats subjected to intrastriatal injection of blood or























































21.7 ± 0.8 *
-4.7 ±1.0 *
Data are presented as mean ± s.e.mean (n = 6 in each haematoma and n = 5 in each silicon oil
group)
*: significant difference between non-diabetic and diabetic groups receiving the same treatment
#: significant difference between haematoma and silicon oil groups in animals of the same sub-strain.
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Table 17
Volumes of striatal oligaemia (in mm3) in non-diabetic and diabetic animals injected with blood or
silicon oil (50pl), measured 24h after the injection
Nort diabetic Diabetic
LCBF (ml. lOOg'.min1) Haematoma Silicon oil Haematoma Silicon oil
less than 15 0.11 ±0.05 0.57 ±0.37 1.91 ±0.90 0.12 ±0.04
between 15 and 25 0.24 ±0.07 0.07 ±0.02 1.44 ±0.24 * 0.05 ± 0.02 #
less than 25 0.35 ±0.12 0.64 ±0.38 3.35 ± 1.05 * 0.17 ±0.05
between 25 and 35 0.40 ±0.03 0.11 ±0.03 # 1.20 ±0.25 * 0.14 ±0.06 #
between 15 and 35 0.64 ±0.10 0.18 ±0.06 # 2.64 ±0.44 * 0.19 ±0.06 #
less than 35 0.75 ±0.15 0.75 ±0.41 4.55 ± 1.30 * 0.31 ±0.08 #
Data are presented as mean ± s.e.mean (n = 6 in each haematoma and n = 5 for each silicon oil
group)
*: significant difference between non diabetic and diabetic groups with the same injection (blood or
silicon oil)
#: significant difference between haematoma and silicon oil groups in animals of the same sub-strain.
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Table 18
Physiological variables in non-diabetic and diabetic rats subjected to intrastriatal injection of blood
(50gl). at the time of the AIB experiment (24h after the blood injection)
Non diabetic Diabetic
Haematoma Haematoma
pC02 (mmHg) 38.7 ± 1.4 39.9 ± 1.7
p02 (mmHg) 86.3 ±2.9 85.1 ±4.0
pH 7.353 ±0.021 7.362 ±0.018
MABP (mmHg) 113 ± 3 112 ± 2
Heart Rate (bpm) 414 ±30 334 ±32
Plasma glucose (mg.df1) 138 ±9 207 ± 64
Temperature (°C) 37.0 ±0.2 36.2 ±0.2 *
Haematocrit (%) 47.7 ± 1.8 49.5 ± 1.2
Plasma bicarbonate 21.6 ± 1.4 22.9 ±0.6
Base excess -3.1 ± 1.6 -2.3 ±0.7
Data are presented as mean ± s.e.mean (n = 5 in each group)
*: significant difference between non diabetic and diabetic groups
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Table 19
Physiological variables in non-diabetic and diabetic rats subjected to intrastriatal injection of blood
(50pl). and treated with either saline (i.p.) or SB209670 (lOmg.kg"' i.p. every 6h, starting 30min
prior to injection of blood and continuing for 24h) at the time of the LCBF experiment (24h after the
blood injection)
Non diabetic haematoma Diabetic haematoma
Saline SB209670 Saline SB209670
pCCT (mmHg) 39.2 ± 1.1 41.3 ±0.9 40.1 ±2.3 44.6 ± 1.4
pCK (mmHg) 89.7 ±2.3 91.3 ± 1.9 90.2 ± 1.8 88.1 ±2.5
PH 7.376 ±0.011 7.453 ±0.011 # 7.363 ±0.047 7.469 ± 0.007
MABP (mmHg) 117 ± 2 115 ± 4 116 ± 9 98 ±6
Heart Rate (bprn) 425 ± 13 425 ±9 291 ± 12 285 ± 19
Plasma glucose (mg.df1) 161 ±6 169 ± 18 158 ± 10 72 ± 10
Temperature (°C) 37.3 ±0.3 37.0 ±0.2 37.0 ±0.2 36.6 ±0.4
Haematocrit (%) 47.8 ± 1.4 45.4 ± 1.3 48.4 ± 1.0 46.5 ± 1.4
Plasma bicarbonate 23.0 ± 1.3 28.0 ±0.9 # 23.0 ±2.3 32.5 ±0.8 i
Base excess -1.3 ± 1.6 4.0 ±1.0 # -2.0 ±2.7 8.4 ±0.5 i
Data are presented as mean ± s.e.mean (n = 6 in non diabetics treated with SB209670. n = 5 in each
other group)
#: significant difference between saline and SB209670-treated animals of the same sub-strain
185
Table 20
Volumes of striatal oligaemia (in mm3) in non-diabetic and diabetic animals injected with blood
(50pl) and treated with saline or SB209670 (lOmg.kg"1 i.p. every 6h. starting 30min prior to the
injection of blood and continuing for 24h)
Non-diabetic haematoma Diabetic haematoma
LCBF (ml. lOOg'.min') Saline SB209670 Saline SB209670
less than 15 0.13 ±0.06 0.0015 ±0.0001 2.27 ± 1.03 1.30 ±0.53
between 15 and 25 0.24 ±0.08 0.013 ±0.007 # 1.50 ±0.26 2.10 ±0.66
less than 25 0.37 ±0.15 0.01 ±0.006 # 3.77 ± 1.20 3.40 ± 1.17
between 25 and 35 0.43 ± 0.02 0.08 ±0.05 # 1.34 ±0.26 1.74 ±0.48
between 15 and 35 0.67 ±0.11 0.10 ±0.06 # 2.85 ±0.47 3.85 ± 1.10
less than 35 0.80 ±0.17 0.10 ±0.05 # 5.11 ± 1.44 5.14 ± 1.58
Data are presented as mean ± s.e.mean (n = 6 in non-diabetics treated with SB209670, n = 5 in each
other group)
#: significant difference between saline and SB209670-treated animals of the same sub-strain
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Table 21
Physiological variables during induction of experimental ICH in animals anaesthetized with
pentobarbitone (30-45mg.kg"' i.p ), placed on a thermal blanket and receiving supplementary oxygen
(41t/min) through a face mask (see also section 2. 16.)
WKY SHR
15min 15 min 15min 15 min
pre-induction post-induction pre-induction post-inductioi
pCO; (mrnHg) 45.5 ±0.5 44.7 ±2.1 44.9 ± 1.9 44.7 ±2.0
pO; (mmHg) 79.5 ± 1.6 81.5 ± 1.2 80.1 ± 1.2 80.9 ± 1.9
pH 7.455 ±0.020 7.457 ±0.030 7.447 ±0.016 7.462 ±0.015
MABP (mmHg) 105 ±5 115 ± 6 143 ±7 159 ±6
Heart Rate (bpm) n.d. n.d. n.d. n.d.
Plasma glucose (mg.dl1) 159 ± 11 170 ± 12 168 ±9 175 ±6
Temperature (°C) 35.9 ±0.3 36.1 ±0.3 36.0 ±0.3 36.2 ±0.4
Haematocrit (%) n.d. n.d. n.d. n.d.
Plasma bicarbonate 29.3 ±0.6 29.2 ±0.7 26.6 ± 1.5 26.3 ± 1.2
Base excess 5.4 ±0.4 5.2 ±0.7 2.6 ± 1.1 2.3 ± 1.0




Physiological variables in WKY and SHR rats subjected to intrastriatal injection of blood or silicon
oil (50pl), at the time of the LCBF experiment (24h after the blood or silicon oil injection)
WKY SHR
Haemcitoma Silicon Oil Haematoma Silicon Oil
pC02(mmHg) 38.2 ± 1.2 42.3 ± 0.6 42.3 ±0.9 41.2 ±0.9
p02 (mmHg) 84.7 ±2.9 80.8 ± 2.0 85.4 ± 1.0 89.1 ±2.8
pH 7.456 ±0.011 7.461 ±0.008 7.325 ±0.012 7.372 ±0.021
MABP(mmHg) 122 ±2 122 ±5 171 ±5 * 176 ±9
Heart Rate (bpm) 315 ± 3 334 ±23 422 ± 14 * 351 ± 19
Plasma glucose (mg.dr1) 149 ±19 138 ±16 158 ± 14 119 ±5
Temperature (°C) 36.4 ±0.1 36.4 ±0.2 36.7 ±0.2 37.6 ±0.4
Haematocrit (%) 48.9 ± 1.6 48.9± 2.0 52.6±0.6 51.3 ±1.8
Plasma bicarbonate 26.8 ± 0.8 29.0 ± 0.8 22.1 ± 0.8 23.7 ± 0.7
Base excess 2.6 ±0.9 5.0 ±0.8 -3.7 ± 0.9 -0.8 ±1.2
Data are presented as mean ± s.e.mean (n = 6 in the haematoma groups, n = 4 in the silicon oil
groups)
#: significant difference between haematoma and silicon oil in animals of the same sub-strain.
*: significant difference between WKY and SHR following the same treatment.
188
Table 23
Volumes of striatal oligaemia (in mm3) in WKY and SHR animals injected with blood or silicon oil
(50gl), measured 24h after the injection
WKY SHR
LCBF (ml.lOOg'.min1) Haematoma Silicon oil Haematoma Silicon oil
less than 15 1.48 ± 1.32 1.57 ± 1.14 1.25 ±0.63 0.51 ±0.24
between 15 and 25 1.15 ± 0.59 0.77 ± 0.64 1.07 ±0.33 0.19 ±0.02
less than 25 2.63 ± 1.88 2.34 ± 1.77 2.32 ±0.94 0.71 ±0.25
between 25 and 35 0.82 ±0.28 0.65 ± 0.48 0.82 ±0.18 0.19 ±0.004
between 15 and 35 1.96 ±0.78 1.42 ± 1.11 1.89 ±0.50 0.40 ±0.02
less than 35 3.45 ± 1.97 2.99 ±2.24 3.14 ± 1.09 0.90 ± 0.24
Data are presented as mean ± s.e.mean (n = 6 in the haematoma groups, n = 4 in the silicon oil
groups)
No significant differences found between groups
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Table 24
Physiological variables in WKY and SHR rats subjected to intrastriatal injection of blood (50gl). at
the time of the AIB experiment (24h after the blood injection)
WKY SHR
Haematoma Haematoma
pCO; (mmHg) 33.1 ±3.6 38.6 ± 1.4
pO: (mmHg) 84.7 ±3.3 86.9 ±2.3
pH 7.503 ±0.008 7.373 ±0.013
MABP (inmHg) 120 ±8 172 ±7
Heart Rate (bpm) 313 ± 38 390 ±21
Plasma glucose (mg.df1) 188 ±51 139 ±5
Temperature (°C) 36.3 ±0.3 37.3 ±0.4
Haematocrit (%) n.d. 51.0 ±0.7
Plasma bicarbonate 28.2 ± 1.9 22.3 ±0.4
Base excess 4.1 ±2.1 -2.0 ±0.4
Data presented as mean ± s.e.mean (n = 8 in SHR and n = 4 in WKY group)




Physiological variables in WKY and SHR rats subjected to intrastriatal injection of blood (50pl), and
treated with either sesame oil (i.p.) or 7-NI (25mg.kg_1 i.p. 30min after the injection of blood) at the
time of the LCBF experiment (24h after the blood injection)
WKY SHR
Sesame oil 7-NI(25mg.kg') Sesame oil 7-NI(25mg. kg'1)
pC02 (mmHg) 37.9 ± 1.5 38.7 ±0.8 42.1 ± 1.1 36.6 ± 1.8
pO; (mmHg) 84.8 ±3.6 85.5 ± 1.6 86.2 ±0.5 88.5 ±2.6
pH 7.459 ±0.013 7.455 ±0.007 7.318 ±0.012 7.492 ±0.011
MABP (mmHg) 122 ±3 120 ±5 168 ±5 192 ±5 #
Heart Rate (bpm) 318 ± 2 337 ±22 418 ± 16 346 ±10 #
Plasma glucose (mg.dl') 157 ±21 139 ± 5 156 ± 17 158 ± 3
Temperature (°C) 36.5 ±0.1 36.5 ±0.1 36.8 ±0.3 37.1 ±0.2
Haematocrit (%) 48.5 ± 1.9 50.9 ±0.9 52.4 ±0.6 55.0 ± 1.5
Plasma bicarbonate 26.6 ± 1.0 26.8 ±0.6 21.6 ±0.7 28.2 ±0.7
Base excess 2.4 ± 1.1 2.6 ±0.7 -4.2 ±0.9 4.2 ±0.7
Data presented as mean ± s.e.inean (n = 7 in the WKY animals treated with 7-NI. n = 4 in SHR
treated with 7-NI and n = 5 in SHR and WKY groups treated with sesame oil)
#: significant difference between sesame oil and 7-NI treatment.
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Table 26
Volumes of striatal oligaemia (in mm3) in WKY and SHR animals injected with blood (50gl) and
treated with sesame oil or 7-NI (25mg.kg"' i.p., 30min after the injection of blood), measured 24h
after the injection of blood
WKY Haematoma SHR Haematoma
LCBF (ml. lOOg'.min1) Sesame oil 7-NI Sesame oil 7-NI
less than 15 1.78 ± 1.57 0.10 ±0.06 1.23 ±0.75 0.09 ±0.05
between 15 and 25 1.38 ±0.67 0.29 ±0.15 1.20 ±0.37 0.55 ±0.28
less than 25 3.16 ±2.21 0.38 ±0.21 2.43 ± 1.13 0.65 ±0.31
between 25 and 35 0.97 ±0.29 0.33 ±0.14 0.97 ±0.20 0.76 ±0.34
between 15 and 35 2.35 ±0.83 0.61 ±0.28 # 2.17 ±0.55 1.32 ±0.62
less than 35 4.13 ±2.26 0.71 ±0.33 3.40 ± 1.30 1.41 ±0.66
Data presented as mean ± s.e.mean (n = 7 in the WKY animals treated with 7-NI, n = 4 in SHR
treated with 7-NI and n = 5 in SHR and WKY groups treated with sesame oil)
#: significant difference between sesame oil and 7-NI treatment.
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Methods for Fibrinogen Immunohistochemistry
The brain sections were immersed in xylene (100%) for 5min to remove the paraffin
wax, then dehydrated in alcohol (70%) for 2min and afterwards in alcohol (100%) for
2min, placed in picric acid for 15min and cleared with water for 20min.
Sections were afterwards treated with trypsin (trypsin 0.1% with 0.1% CaCl2 in Tris-
Buffered Saline TBS - pH 7.6) for 20min at 37°C and washed in water for 5min. They
were treated with 3% hydrogen peroxide for 5min and washed again in water. They
were afterwards washed in TBS for 5min and treated with normal swine serum (NSS)
for 20min (Dilution 1:5 NSS/TBS). Excess serum was drained from the sections.
The sections were then incubated in primary antibody for 30min (Primary antibody
diluted in 1:5 NSS/TBS). Rabbit anti-human fibrinogen (DAKO) was the primary
antibody used. It was dissolved in 0.1M NaCl and 15mM NaN3 during storage. The
antibody titre was 6000mg.r'. It reacts with native human fibrinogen as well as with
the fibrinogen fragments D, E, X and Y and was used in dilution of 1:5000.
The sections were afterwards washed in TBS for 5min twice.
They were then incubated in polyclonal swine anti-rabbit antibody (secondary
antibody) for 30min (Dilution 1:200 in 1:5 NSS/TBS). They were washed in TBS for
5min twice and incubated in ABC Elite reagent (DAKO) for 30min. They were
washed again in TBS for 5min twice and treated with DAB solution for lOmin.
They were washed in water for 5min, counterstained in Mayer's haematoxylin for
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Cerebrovascular effects of nitric oxide manipulation in
spontaneously hypertensive rats
Ioannis P. Fouyas, 'Paul A.T. Kelly, Isobel M. Ritchie & Ian R. Whittle
Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh
EH4 2XU
1 Evidence that nitric oxide (NO) bioactivity is altered in chronic hypertension is conflicting, possibly
> as a result of heterogeneity in both the nature of the dysfunction and in the disease process itself. The
brain is particularly vulnerable to the vascular complications of chronic hypertension, and the aim of this
study was to assess whether differences in the cerebrovascular responsiveness to the NO synthase (NOS)
i inhibitors, NG-nitro-L-arginine methyl ester (l-NAME) and 7-nitroindazole (7-NI), and to the NO donor
3-morpholinosydnonimine (SIN-1) might indicate one possible source of these complications.
2 Conscious spontaneously hypertensive (SHR) and WKY rats, were treated with l-NAME
(30 mg kg-1, i.v.), 7-NI (25 mg kg"1, i.p.), SIN-1 (0.54 or 1.8 mg kg"' h~', continuous i.v. infusion)
or saline (i.v.), 20 min before the measurement of local cerebral blood flow (LCBF) by the fully
quantitative [l4C]-iodoantipyrine autoradiographic technique.
3 With the exception of mean arterial blood pressure (MABP), there were no significant differences in
physiological parameters between SHR and WKY rats within any of the treatment groups, or between
treatment groups. l-NAME treatment increased MABP by 27% in WKY and 18% in SHR groups,
whilst 7-NI had no significant effect in either group. Following the lower dose of SIN-1 infusion, MABP
was decreased to a similar extent in both groups (around —20%). There was no significant difference in
MABP between groups following the higher dose of SIN-1, but this represented a decrease of —41% in
SHR and -21% in WKY rats.
4 With the exception of one brain region (nucleus accumbens), there were no significant differences in
basal LCBF between WKY and SHR. l-NAME produced similar decreases in LCBF in both groups,
ranging between —10 and —40%. The effect of 7-NI upon LCBF was more pronounced in the SFIR
(ranging from —34 to —57%) compared with the WKY (ranging from —14 to —43%), and in seven
out of the thirteen brain areas examined there were significant differences in LCBF.
5 Following the lower dose of SIN-1, in the WKY 8 out of the 13 brain areas examined showed
significant increases in blood flow compared to the saline treated animals. In contrast, only 2 brain areas
showed significant increases in flow in the SHR. In the rest of the brain areas examined the effects of
SIN-1 upon LCBF were less marked than in the WKY.
6 Infusion of the higher dose of SIN-1 resulted in further significant increases in LCBF in the WKY
group (ranging between + 30% and + 74% compared to saline-treated animals), but no significant
effects upon LCBF were found in the SHR. As a result, there were significant differences in LCBF
between SIN-l-treated WKY and SHR in six brain areas. In most brain areas examined, cerebral blood
flow in SHR following the higher dose of SIN-1 was less than that measured with the lower dose of
SIN-1.
7 Despite comparable reductions in MABP (~20%) in both groups, calculated cerebrovascular
resistance (CVR) confirmed that the vasodilator effects of the lower dose of SIN-1 were significantly
more pronounced throughout the brain in the WKY (ranging between —3% and —50%;
median=— 38%) when compared to the SHR (ranging between —10% and —36%; median =—26%).
In the animals treated with the higher dose of SIN-1, CVR changes were broadly similar in both groups
(median= —45% in WKY and —42% in SHR), but with the reduction in MABP in SHR being twice
that found in WKY, this is in keeping with an attenuated blood flow response to SIN-1 in the SHR.
8 The results of this study indicate that NO-dependent vasodilator capacity is reduced in the
cerebrovasculature of SHR. In addition, the equal responsiveness to a non-specific NOS inhibitor but an
' enhanced effectiveness of a specific neuronal NO inhibitor upon LCBF in the SHR could be consistent
with an upregulation of the neuronal NO system.
Keywords: Cerebral blood flow; hypertension; SHR; nitric oxide; l-NAME; 7-nitroindazole; 3-morpholinosydnonimine
* (SIN-1); quantitative autoradiography
Introduction
Although it has been proposed that an impaired release of
endothelial vascular relaxing factors might underlie the pa¬
thogenesis of hypertension (Liischer & Vanhoutte, 1986), the
involvement of nitric oxide in the aetiology of the disease
process remains controversial. Studies in hypertensive human
1 Author for correspondence.
subjects have shown that there is abnormal nitric oxide (NO)
activity associated with hypertension (Calver et al., 1992), but
divergent results have also emerged (Cockroft et al., 1994). In
experimental animal models of chronic hypertension, there is
increasing evidence that endothelium-dependent relaxation is
heterogeneously affected (Ltischer, 1992), with normal func¬
tion maintained in the renal and coronary arteries (Tschudi et
al., 1991), but impaired function in aorta, mesenteric, carotid
and cerebral circulation (Liischer & Vanhoutte, 1986; Dohi et
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al., 1990; Cuevas et al., 1996). These observations could ex¬
plain not only contradictory experimental observations, but
also the selective vulnerability of certain tissues, such as the
brain, to hypertensive complications.
The brain is particularly vulnerable to complications as¬
sociated with hypertension and both the incidence (Whisnant,
1996) and severity of cerebrovascular ischaemia (Coyle, 1984)
are increased in hypertension. Studied performed in vitro
have raised the possibility that cerebrovascular NO systems
are altered in hypertensive rats (Miyata et al., 1990; Malinski
et al., 1993), and perturbations in endothelium-dependent
relaxation have been identified in pial arteries examined in
situ (Yang et al., 1991a; Mayhan, 1992). In contrast, cere¬
brovascular responsiveness to NO inhibition is preserved in
vivo (Izuta et al., 1995), and basal local cerebral blood flow
(LCBF) appears to be unaffected by hypertension (Wei et al.,
1992).
Whilst it might appear from these observations that there
may be no functional basis to the increased susceptibility to
ischaemia in chronic hypertensives, this cannot be discounted
in favour of structural dysfunction without first examining the
integrity of NO-dependent cerebrovascular dilator reserve and
the role of perivascular neuronal NO systems in cerebrovas¬
cular control (Kelly et al,. 1995). The fact that NO donors
reduce infarct size in spontaneously hypertensive rats (SHR)
subjected to middle cerebral artery (MCA) occlusion (Zhang et
al., 1994), is consistent with a reduced NO-dependent dilator
capacity of the hypertensive brain. In the present studies, we
have measured local cerebral blood flow (LCBF) in SHR and
normotensive WKY controls following treatment with an
exogenous NO donor 3-morpholinosydnonimine (SIN-1) and
7-nitro indazole, which shows in vivo selectivity for neuronal
nitric oxide synthase (NOS) inhibition (Moore et al., 1993a,b).
We have also re-examined the effects of the non-selective NOS
inhibition NG-nitro-l-arginine methyl ester (l-NAME) to
allow comparisons with 7-N1.
Methods
These studies were performed with a total of 25 SHR and 27
WKY adult male rats between 14 and 16 weeks of age (Charles
River, U.K.). Animals were held under normal animal house
conditions with free access to food and water.
Measurement of local cerebral blood flow
On the day of the experiment the animals were anaesthetized
with halothane (1.5% in a gas mixture of 70% nitrous oxide
and 30% oxygen) and prepared for the measurement of
LCBF as described previously (Kelly et al., 1994). Following
surgery, general anaesthesia was withdrawn and 2 h allowed
to elapse before any further experimental manipulation. Ap¬
proximately equal numbers of SHR and WKY rats were
treated with either l-NAME (30 mg kg-1 in saline, i.v. over
60 s; n = 4 from each group), 7-NI (25 mg kg"' in sesame oil,
i.p. over 5 s; n = 4 from each group), SIN-1 (0.54 or
1.8 mg kg-1 h~' in saline, continuous i.v. infusion; n = 4
from each group). In previous studies from this laboratory
we have found no difference in LCBF between control ani¬
mals injected with oil (i.p.) or saline (i.v.), or between saline
infusion or bolus injection. In this study, control animals
were injected with saline. (1.0 ml i.v.; n = 5 SHR and n = 6
WKY). The doses of l-NAME and 7-NI were chosen on the
basis of previously published work from this and other la¬
boratories (Macrae et al., 1993; Moore et al., 1993a,b; Kelly
et al., 1994; 1995). Doses of 7-NI higher than that used in
this study, have been shown to produce further reductions in
cerebral blood flow in normal rats (Kelly et al., 1995; Wang
et al., 1995) but they may also produce anomalous focal
hyperaemia (Kelly et al., 1995).
In a series of preliminary studies, two doses of SIN-1
were identified which produced either similar magnitude of
reduction in MABP in WKY and SHR (lower dose,
0.54 mg kg"' h"1), or which reduced MABP to comparable
absolute values in both groups (higher dose,
1.8 mg kg"1 h"1). In these studies, we also found that an
1.v. infusion of SIN-1 at 1.8 mg kg"1 h"1 for 20 to 30 min
completely blocked the expected cardiovascular and cere¬
brovascular effects of subsequent i.v. injection of l-NAME
(30 mg kg"1).
The measurement of LCBF was initiated 20 min after the
start of l-NAME, 7-NI, SIN-1 or saline treatments by use of
the fully quantitative [l4C]-iodoantipyrine autoradiographic
technique. As far as possible, control (saline) experiments
were performed contemporaneously to the various drug
treatments. The protocols were in complete accordance with 1
the methodology as originally published (Sakurada et al.,
1978) and as described previously from this laboratory (Kelly
et al., 1994). Autoradiographic images were analysed by t
quantitative densitometry relative to 14C-containing standards
and LCBF was calculated by use of the appropriate opera¬
tional equation for the technique (Sakurada et al., 1978).
Areas of interest were chosen to represent brain areas in the
vascular territories of the anterior, middle and posterior
cerebral arteries. Arterial blood pressure and rectal tem¬
perature were monitored continuously in each animal
throughout the experiments and heart rate was measured
intermittently. Samples of arterial blood were withdrawn
before and after treatments, for the measurement of pH,
Pco2, and Po2.
Calculation of cerebrovascular resistance
Cerebrovascular resistances (CVR) were calculated in animals
treated with SIN-1 and the relevant saline-treated rats by di¬
viding mean arterial blood pressure (mmHg) by LCBF values
(ml 100 g"1 min"') for each brain area in each individual
animal.
Drugs
With the exception of SIN-1 which was a gift from Cassella
AG, Frankfurt, Germany, all drugs were purchased from the
Sigma Chemical Co.
Statistical analysis
Physiological and LCBF data (presented as mean±s.e.mean)
were analysed by Student's t test with Bonferroni correction
applied to allow multiple pair-wise comparisons between ap¬
propriate groups (maximum number of comparisons = 3).
Differences in the CVR response to SIN-1 treatment between
the two rat strains were analysed by Mann-Whitney U-test.




With the exception ofmean arterial blood pressure, there were
no significant differences in physiological parameters between
SHR and WKY rats within any of the treatment groups, or
between treatment groups (Table 1). As expected, mean ar¬
terial blood pressure (MABP) was 46% greater in SHR com¬
pared to WKY rats before any treatment, and saline injection
had no effect. Not withstanding the initial difference in blood
pressure, l-NAME treatment increased MABP to a similar
extent in both groups of rats, whilst 7-NI had no significant
effect in either group. Following treatment with the lower SIN-
1 dose MABP decreased by —21% in the SHR and by —20%
in the WKY (Table 2). However, following the higher dose of
SIN-1, MABP was decreased by —41% in SHR but by only
— 21% in WKY rats, so that after treatment there was no
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Data are presented as mean±s.e.mean. "Significant difference between WKY
*Significantly different from saline-treated rats of the same sub-strain (P<0.05).
and SHR given the same treatment (P<0.05).
Table 3 Local cerebral blood flow in normotensive (WKY) and spontaneously hypertensive (SHR) rats treated with saline, L-NAME
or 7-NI
Saline l-NAME 7-NI
WKY SHR WKY SHR WKY SHR
Neocortex
Parietal 141+6 132± 8 124 + 7 105 + 6 121+5 78 + 4*"
Cingulate 98±4 117 ± 6 99 + 5 91+6 82+1 64 + 6*
Corpus callosum 37±2 32 ±2 20± 1* 29 ±2" 21 ± 1 * 21 ± 1 *
Basal ganglia
59 + 5*"Striatum 99 + 4 94 + 5 87 + 4 83 ±5 78 + 3*
Globus pallidus 64+ 4 68 + 8 53 + 3 54+ 3 49 + 2 38 ±1"
Accumbens 98 ±4 116 ±3" 78 ±5 82 ±5* 77 ±5 56 ± 1*"
Thalamus
Hypothalamus 75±4 83 ±5 49 + 3* 45 + 3* 50 ±3* 36 + 3*"
Lateral geniculate 106 ±5 116± 9 89 ±6 93 ±5 87 ±3 69 ±2*"
Hippocampus
CA3 76+ 4 85 + 3 60+1 63 + 4* 57 + 2* 49 ±3*
CA2 71 + 3 83 + 4 56 ±2* 59 + 5* 51 + 1* 45 + 2*
CA1 68 + 5 74+ 3 56 ± 1 61 ±3 49 + 2 44 + 2*
Molecular layer 73±4 85 + 2 57+1 61+5* 55 + 3 45 + 2*
Dentate hilus 76 + 4 93 + 6 61 + 1 62 + 5* 58 + 3 46+1*"
Group n 6 5 4 4 4 4
Data are presented as mean local cerebral blood flow (ml lOOg 1 min ')±s.e.mean. "Significant difference between WKY and SHR
animals given the same treatment (P<0.05). *Significantly different from saline-treated rats of the same sub-strain (P<0.05).
significant difference in MABP between these two groups
(Table 2).
Local cerebral blood flow following l-NAME
Significant differences in basal LCBF between WKY and SHR
were found in only of one of the thirteen brain regions ex¬
amined (nucleus accumbens) (Table 3). Following injection of
l-NAME, LCBF in the WKY group was significantly reduced
(compared to saline treated animals) in the corpus callosum
(— 46%), the hypothalamus (— 35%) and the CA2 layer of the
hippocampus ( — 21%). Elsewhere in the brain there was a
tendency towards decreases in LCBF (with the exception of
cingulate cortex) ranging between — 12 and —22%, but these
differences were not significant. Similarly, in the l-NAME-
treated SHR group there was a global trend towards reduc¬
tions in LCBF ranging between —12 and —22%, which
reached acceptable levels of significance in the nucleus ac¬
cumbens (— 29%), hypothalamus (— 46%), hippocampal fields
CA2 and CA3 ( — 29% and —26%), and in the molecular layer
(— 28%) and hilus of the dentate gyrus (— 33%). There were
no significant differences in the LCBF between l-NAME
treated WKY and SHR, apart from in the corpus callosum
(Table 3).
Local cerebral blood flow following 7-NI
Following the intraperitoneal injection of SHR with 7-NI,
significant reductions in LCBF (ranging between —34 and
— 57%) were found in 12 of the 13 areas examined when
compared to the appropriate saline treated group (Table 3).
Although the response to 7-NI in the WKY group was qua¬
litatively similar, significant reductions in LCBF were limited
to the corpus callosum ( — 43%), striatum (— 21%), hypotha¬
lamus (— 33%), and CA2 (— 28%) and CA3 (— 25%) fields of
the hippocampus. However, throughout the brain, the re-
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Table 4 Local cerebral blood flow in normotensive (WKY) and spontaneously hypertensive (SHR) rats treated with saline or SIN-1
Saline Low SIN-1 High SIN-1
WKY SHR WKY SHR WKY SHR
Neocortex
148+11"Parietal 138 + 6 127 + 9 139+12 142+10 206 + 9*
Cingulate 95 + 3 112 + 5 152 + 7* 143 + 5* 171+6* 138 + 5"
Corpus callosum 35 + 2 32 + 3 29 + 3 29+1 36 + 3 41+2
Basal ganglia
Striatum 96 + 3 90 + 4 117 + 5* 109 + 8 129 + 6* 107 + 9
Globus pallidus 62 + 4 61+4 90 + 2* 82 + 4* 80 + 4 66 + 4
Accumbens 96 ±4 114 + 4 136 + 7* 138 + 11 153 + 4* 130 + 8
Thalamus
Hypothalamus 71 + 3 80 + 4 79 + 5 75 + 7 89 + 4 70 + 5
Lateral geniculate 103 + 5 111 + 10 138 + 6* 139+14 164+ 7* 118 + 8"
Hippocampus
CA3 74 + 4 83 + 3 98 + 4* 100 + 8 104+ 3* 81+9
CA2 68 + 3 80 + 3 82 + 7 81+9 92 + 5* 82 + 5
CA1 65 + 4 73 + 3 80 + 6 81+6 100 + 5* 76 + 5"
Molecular layer 71+4 84 + 2 95 + 4* 88 + 8 103 + 3* 82 + 4"
Dentate hilus 73 + 5 90 + 5 94 + 5* 89 + 9 112 + 6* 87 + 4"
Group n 5 4 4 4 4 4
Data are presented as mean local cerebral blood flow (ml lOOg 1 min ')±s.e.mean. "Significant difference between WKY and SHR
animals given the same treatment (P<0.05). *Significantly different from saline-treated rats of the same sub-strain (P<0.05).
Table 5 Calculated cerebrovascular resistance in normotensive (WKY) and hypertensive (SHR) animals, treated with saline or SIN-1
WKY SHR
Low % High % Low % High %
Saline SIN-1 change SIN-1 change Saline SIN-1 change SIN-1 change
Neocortex
Parietal 0.87 + 0.02 0.69 + 0.05 -21 0.46 + 0.03 -46 1.43 + 0.11 1.06 + 0.08 -26 0.71+0.06 -48
Cingulate 1.27 + 0.05 0.63 + 0.05 -50 0.56 + 0.02 -55 1.58 + 0.08 1.04 + 0.05 -34 0.76 + 0.06 -50
Corpus callosum 3.37 + 0.21 3.28 + 0.10 -3 2.66 + 0.23 -19 5.85 + 0.79 5.17 + 0.31 -12 2.55 + 0.22 -54
Basal ganglia
Striatum 1.24+ 0.05 0.82 + 0.05 -34 0.74+ 0.04 -39 1.99 + 0.09 1.38 + 0.11 -31 0.99 + 0.11 -48
Globus pallidus 1.95 + 0.12 1.06 + 0.08 -46 1.19 + 0.40 -37 2.85 + 0.24 1.82 + 0.12 -36 1.59 + 0.09 -40
Accumbens 1.26 + 0.03 0.72 + 0.03 -43 0.62+ 0.02 -50 1.54 + 0.11 1.10 + 0.10 -29 0.81+0.06 -47
Thalamus
Hypothalamus 1.68 + 0.10 1.21+0.04 -28 1.08 + 0.09 -34 2.26 + 0.16 2.02 + 0.21 -11 1.52+ 0.14 -29
Lateral geniculate 1.17 + 0.08 0.69 + 0.05 -41 0.58 + 0.02 -49 1.66 + 0.20 1.10 + 0.13 -34 0.89 + 0.08 -43
Hippocampus
CA3 1.64 + 0.08 0.97 + 0.07 -41 0.92 + 0.06 -43 2.17 + 0.13 1.51+0.15 -30 1.33 + 0.14 -36
CA2 1.76 + 0.08 1.18 + 0.09 -33 1.04 + 0.03 -39 2.13 + 0.12 1.91+0.27 -10 1.25 + 0.09 -41
CA1 1.86 + 0.13 1.19 + 0.04 -36 0.95 + 0.02 -47 2.36 + 0.16 1.87 + 0.19 -21 1.39 + 0.12 -42
Molecular layer 1.71+0.08 1.02 + 0.09 -40 0.92 + 0.04 -45 2.03 + 0.09 1.74 + 0.21 -14 1.27 + 0.08 -38
Dentate gyrus 1.65 + 0.09 1.03 + 0.10 -38 0.85 + 0.01 -47 1.92 + 0.10 1.73 + 0.23 -10 1.21+0.10 -36
Median effect - - -38 - -45 - - — 26§ - -42
Group n 5 4 4 4 4 4 .
Cerebrovascular resistances were calculated by dividing mean arterial blood pressure (mmHg) by LCBF values (ml 100g~'min ') for
each individual animal and are presented as mean + s.e.mean. The effects of SIN-1 treatments (percentage change) were compared
between rat strains by Mann-Whitney U-test. §SignificantIy different from similarly-treated WKY group (P<0.01).
sponse to 7-NI was less marked in the WKY group (ranging
between —14 and —43%) when compared to SHR, and in
seven brain areas (parietal cortex, striatum, globus pallidus,
nucleus accumbens, hypothalamus, lateral geniculate and hilus
of the hippocampal dentate gyrus) the decreases in LCBF were
significantly greater in the SHR group (Table 3).
Local cerebral blood flow following SIN-1
Following treatment with the lower dose of SIN-1 there were
significant increases in LCBF in all but five brain areas (par¬
ietal cortex, corpus callosum, hypothalamus, CA1 and CA2
layers of the hippocampus) in the WKY group (Table 4).
Significant effects ranged from +22% in striatum, to +60% in
cingulate cortex. In contrast, in the SHR group, there were
significant effects upon LCBF in only two brain regions (cin¬
gulate cortex and globus pallidus) (Table 4). In the rest of the
brain areas examined, the effects of this lower dose of SIN-1
upon LCBF were less marked than in the WKY.
Following intravenous infusion of the higher dose of SIN-1
there were significant increases in LCBF in all but three brain
areas (corpus callosum, globus pallidus and hypothalamus) in
the WKY group (Table 4). Significant effects ranged from ■
+ 30% in hippocampal field CA2 and striatum, to + 74% in
cingulate cortex. The CBF values in most of the brain areas
examined were higher compared to those obtained following
treatment with the lower dose of SIN-1. In contrast, in the
SHR group, there were no significant effects of this higher
dose of SIN-1 upon LCBF in any region of the brain. In this
group, LCBF in grey matter areas ranged from —16% in
hypothalamus to +18% in cingulate cortex (Table 4). A
comparison of LCBF between WKY and SHR groups trea¬
ted with the higher dose of SIN-1 revealed significant dif¬
ferences in six of the thirteen brain areas examined (parietal
cortex, cingulate cortex, lateral geniculate, hippocampal field
CA1, and molecular layer and hilus of the dentate gyrus)
(Table 4). Although there were no significant differences be¬
tween the effects upon LCBF of the two doses of SIN-1 in
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SHR, the values obtained following treatment with the higher
dose of SIN-1 were generally lower in most of the areas
examined (Table 4).
Cerebrovascular resistance (CVR)
Despite comparable reductions in MABP (~20%) in both
groups, calculated CVR confirmed that the vasodilator effects
of the lower dose of SIN-1 were significantly more pronounced
(P<0.01, Mann-Whitney U-test) throughout the brain in the
WKY (ranging between —3% and —50%; median=— 38%)
when compared to the SHR (ranging between —10% and
— 36%; median = —26%) (Table 5). In the groups treated with
the higher dose of SIN-1, CVR changes were broadly similar in
both groups (median = —45% in WKY and —42% in SHR),
but with the reduction in MABP in SHR being twice that
found in WKY, this is in keeping with an attenuated blood
flow response to SIN-1 in the SHR (Table 5).
Discussion
In the present study we found little evidence of any funda¬
mental difference in basal LCBF between WKY and SHR
groups, although in one area of the brain, the nucleus ac-
cumbens, blood flow in SHR was significantly higher. These
observations are largely in keeping with previous data, where
either similar quantitative autoradiographic techniques were
used to measure LCBF in conscious rats of these two strains
(Wei et al., 1992), or where rats of a similar age to those used in
this study were examined with different measurement protocols
(Grabowski & Johansson, 1985). Moreover, our physiological
studies are in keeping with morphological studies of cerebral
capillary bed structure (Lin et al., 1990) and precapillary ar¬
terioles on the pial surface (Harper & Bohlen, 1984) which
show no differences between SHR and WKY. Although
structural changes have been described in larger blood vessels
of the cerebrovascular bed in SHR (Folkow, 1990), it is not
these vessels which regulate LCBF.
Early in vitro investigations identified a decrease in NO-
mediated activity in cerebral blood vessels taken from SHR
(Miyata et al., 1990; Malinski et al., 1993). Subsequent ex¬
amination of the basilar artery in situ showed that l-NAME
induced greater constriction in hypertensive rats (Kitazono et
al., 1995). These authors suggested that basal release of NO
might be somewhat enhanced in SHR over that in WKY, and
in vivo studies confirmed that the cerebrovascular response to
NO inhibition with NG-monomethyl-l-arginine (l-NMMA)
was greater in SHR (Izuta et al., 1995), although no significant
difference in LCBF was found in SHR and WKY treated with
NG-nitro-l-arginine (l-NOARG). In our studies, acute treat¬
ment with l-NAME had broadly similar effects upon LCBF in
the WKY and SHR groups and were in keeping with pre¬
viously published results (Izuta et al., 1995; Yang, 1996). The
dose of l-NAME used in the present study has previously been
found in Sprague-Dawley (SD) rats to produce significant re¬
ductions in LCBF at 15 min post-injection (Kelly et al., 1994)
which are maintained for at least 3 h (Macrae et al., 1993), but
in general it appears from our study that l-NAME is not as
efficacious in reducing LCBF in WKY and SHR as it is in
Sprague-Dawley (SD) rats. Although it was outwith the pre¬
sent experimental design to make such inter-strain compari¬
sons, it is also noteworthy that differences in vascular structure
have been found between normotensive WKY and SD in the
cerebral capillary bed (Lin et al., 1990).
Whilst there was no evidence of any difference between
WKY and SHR in the response to the non-selective NOS in¬
hibitor l-NAME, the response to the intraperitoneal injection
of 7-NI, which in vivo is a selective inhibitor of the neuronal
isoform of NOS (nNOS; Moore et al., 1993a,b), was signifi¬
cantly greater in the majority of brain areas of hypertensive
animals. Although previous studies have suggested that there
may be an upregulation of cerebrovascular NO systems in
hypertension (Kitazono et al. 1995), our observations point to
there being a more specific upregulation of neuronal NOS.
Studies specifically addressing the role of neuronal NOS in the
brains of SHRs are lacking, although it does seem that nNOS
expression is normal in the cerebellum and brain stem of 4-, 16-
and 24-week-old SHR, compared to age-matched WKY (Iwai
et al., 1995). It is interesting to note that the activity of nNOS
in cerebral ischaemia is potentially detrimental (Huang et al.,
1994) and although perhaps speculative at this stage our
findings, consistent with an upregulated nNOS system in hy¬
pertension, could offer one explanation for the predisposition
of hypertensives to ischaemia following stroke (Coyle, 1984).
Our findings of comparable cerebrovascular responses to l-
NAME but enhanced responses to 7-NI in the SHR could also
be compatible with a down-regulation of endothelial NOS in
these animals together with an up-regulation of the neuronal
NOS. Testing of this hypothesis awaits the development of
specific endothelial NOS inhibitors.
There is growing evidence that endothelium-dependent
vascular dilatation is heterogeneously affected in hypertension
(Nava et al., 1995) with both regional and species differences
(Deng el al., 1995). Studies in hypertensive humans and ani¬
mals have demonstrated preserved dilatator responses to so¬
dium nitroprusside in peripheral vascular beds (Taddei et al.,
1993; Kiing & Liischer, 1995). In contrast to the qualitatively
similar effects of SIN-1 upon blood pressure in both WKY and
SHR, the effects of SIN-1 upon LCBF were attenuated in our
SHR group when compared with WKY. These apparent dif¬
ferences in the response to SIN-1 between vascular beds in the
SHR group suggest that they may be regional perturbations of
NO-specific vasodilator reserve, and would be consistent with
an up-regulation of endogenous cerebral NOS activity. In
support of our observations, l-arginine was found to have no
effect upon LCBF in the contralateral hemisphere of SHR
subjected to middle cerebral artery (MCA) occlusion (Prado et
al., 1996), and SIN-1 had no significant effect upon cortical
blood flow in SHR subjected to sham-occlusion of the MCA
(Zhang et al., 1994). Contradictory results have also been
obtained with in situ methodology to measure responsiveness
of pial arteries, or the basilar artery, to superfusion of NO
donors in the stroke-prone substrain of the SHR (Mayhan et
al., 1988; Yang et al., 1991a,b; 1993; Kitazono et al., 1993) and
also in stroke-resistant SHR (Mayhan et al., 1987; Mayhan,
1991). There are several potential explanations for the appar¬
ent differences between these results and the data presented in
this paper, including the fact that the previous experiments
were performed under the influence of anaesthetics, with their
potential influence on cerebrovascular responsiveness (Ed-
vinsson & McCulloch, 1981); the possibility that NO bioac-
tivity might differ markedly between the stroke-prone
substrain of SHR and the SHR used in our study (Dominiczak
& Bohr, 1995); the fact that our animals were considerably
younger than those used previously, and NO responsiveness
has been shown to change-at least in renovascular hyperten¬
sion-as the duration of hypertension progresses (Dubey et al.,
1996); most importantly, neither the basilar artery nor the pial
vessels constitute the principal source of resistance to flow in
the cerebrovascular bed, and are therefore not responsible for
the control of LCBF. Recent investigations in conscious pa¬
tients with arterial hypertension have also confirmed impaired
responsiveness to NO-donors (Preik et al., 1996), although
once again other, earlier studies have reached contradictory
conclusions (Creager & Roddy, 1994; Panza et al., 1995).
Cerebrovascular resistance (CVR), calculated from LCBF
and MABP values measured from each individual rat, was
found to decrease to a greater extent in WKY (median ef¬
fect =—38%) treated with the lower dose of SIN-1 when
compared to SHR (median effect = —26%). Since the reduc¬
tion in MABP following this treatment was similar in both
WKY and SHR, these differences in CVR directly reflect blood
flow changes between the two groups. In the rats treated with a
higher dose of SIN-1, CVR changes were broadly similar in
both groups, but with the reduction in MABP in SHR
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( — 41%) being twice that found in WKY ( — 20%), this is in
keeping with an attenuated blood flow response to SIN-1 in
the SHR. However, the vessels of the cerebrovascular bed are
normally endowed with the ability to alter their calibre in re¬
sponse to fluctuations in perfusion pressure. The resulting
changes in vascular resistance ensure the maintenance of
constant cerebral blood flow over a wide range of arterial
blood pressure, a phenomenon known as autoregulation
(Paulson et al., 1990). The lower limit of autoregulation below
which the relationship between cerebral blood flow and per¬
fusion pressure becomes linear is not a fixed point, and chronic-
hypertension is known to raise the arterial pressure threshold
at the lower limit of the autoregulatory range (Strandgaard,
1978; Paulson et al., 1990). Although the levels of MABP
measured in our SHR in response to the higher dose of SIN-1
(104 mmHg) were above the lower limit of autoregulation re¬
ported for this strain (90 mmHg) (Barry et al., 1982; Harper &
Bohlen, 1984), the observation that LCBF was higher-though
not significantly-in most of the areas examined in the SHR
treated with the lower SIN-1 dose compared to those treated
with the higher dose, could be interpreted as indicating pres¬
sure-dependency in flow to some extent at least. It is known
that NO inhibition shifts the upper limit of cerebrovascular
autoregulation to higher pressure levels in normal animals
(Kelly et al., 1994), so it is conceivable that NO could have a
role in determining the lower limit of autoregulation. A defi¬
nitive conclusion regarding this possibility cannot be derived
simply by calculating CVR.
SIN-1 generates NO and superoxide, which can potentially
react with NO to form peroxynitrite (Moncada & Higgs, 1995;
Plane et al., 1997). The dilator actions of SIN-1 in extracranial
tissues are also modulated by the basal production of endo-
thelium-derived NO (Plane et al., 1997). Studies performed in
vitro with endothelial cells from peripheral tissues of 5 week
old SHR showed that superoxide may be responsible for the
decreased activity of NO (Grunfeld et al., 1995). There is also
growing speculation of an enhanced oxidative stress in the
pathogenesis of hypertensive complications (Alexander, 1995).
It is clearly possible that the effects of SIN-1 upon LCBF could
be related to generation of superoxide, complicated further by
the potential involvement of free radicals in the evolution of
hypertensive complications. The exact mechanism by which
SIN-1 effects changes in cerebral blood flow may therefore be
quite complex, but whatever the underlying mechanism there
are differences in the cerebrovascular response to SIN-1 in
WKY and SHR.
Morphological analysis of those cerebral blood vessels
which are largely responsible for the control of LCBF found
no structural differences between WKY and SHR (Lin et al.,
1990). Whilst it is possible that subtle changes might go un¬
detected in these rather small vessels, the method of analysis
did prove sufficiently sensitive to detect differences between
vessels from both WKY and SHR. when compared to those
from SD rats (Lin et al., 1990). It has been argued that
structural changes in the vessel wall associated with chronic
hypertension could explain altered responses to vasoactive
agents (constrictor and dilator) (Calver et al., 1992), but it
might be expected that the response to all vasoactive agents
would be affected in a non-specific manner (Harper & Bohlen,
1984; Folkow, 1990). It is possible that structural changes
might have been present in our relatively young (14 weeks old)
animals, particularly as structural changes appear even before
frank hypertension has been established (Folkow, 1990), but
structural differences cannot readily provide an explanation
for the differential response to the two NOS inhibitors (L-
NAME and 7-NI) and nor could it explain the attenuated
vasodilator response to SIN-1. Thus our results would appear
to support the concept of hypertension-induced functional
changes (Winquist & Bohr, 1983) in the cerebrovasculature.
Cerebrovascular dysfunction associated with hypertension
is most probably multifactorial. Studies with pial arteries from
hypertensive rats have identified altered dilator responses
which appear to involve vasoconstrictor prostanoids (Yang et
al., 1991a; Mayhan, 1992), and in situ studies have shown that
the prostaglandin-induced pial arterial vasodilatation is related
to NO production (Armstead, 1995). Interestingly, enhanced
responses of the basilar artery to activation of endothelinB
(ETb) receptors in hypertensive rats, independent of NO or
prostanoid pathways, have also been observed (Kitazono et
al., 1995). The same group also found that the mechanisms
responsible for the impaired responses of the basilar artery in
SHRs (Mayhan, 1990) are not the same as those responsible
for the attenuated responses of the pial vessels.
This present study provides further evidence for hetero¬
geneous perturbation of NO systems in the cerebrovasculature
of the SHR strain, with a reduced vasodilator capacity and
possibly an up-regulation of neuronally derived NO systems.
The importance of these findings may become pronounced in
situations of cerebral ischaemia, which is one of the com¬
monest complications of hypertension.
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Cerebrovascular responsiveness to N -nitro-L-arginine methyl
ester in spontaneously diabetic rats
Ioannis P. Fouyas, 'Paul A.T. Kelly, Isobel M. Ritchie & Ian R. Whittle
Department of Clinical Neurosciences, University of Edinburgh, Edinburgh EH4 2XU
1 There is evidence that endothelial dysfunction is associated with diabetes mellitus. The purpose of the
present study was to assess local cerebral blood flow (LCBF) and cerebrovascular responsiveness to the
NOS inhibitor NG-nitro-l-arginine methyl ester (l-NAME) in spontaneously diabetic insulin-dependent
BioBred (BB) rats.
2 Diabetic rats, and non-diabetic controls, were treated with l-NAME (30mgkg~', i.v.) or saline,
20 min prior to the measurement of LCBF by the fully quantitative [14C]-iodoantipyrine autoradio¬
graphic technique.
• 3 There were no significant differences in physiological parameters (blood pH, Pco2, and Po2, rectal
temperature, arterial blood pressure, or plasma glucose) between any of the groups of rats, and no
difference in either the extent or the temporal characteristics of the hypertensive response to l-NAME
i between diabetic and non-diabetic rats.
4 In diabetic rats, a global reduction in basal LCBF was observed, although significant reductions
(between —20 and —30%) were found in only 5 (mainly subcortical) out of the 13 brain regions
measured. Following l-NAME injection, significant reductions in LCBF (between —20 and —40%)
were found in the non-diabetic animals. In diabetic animals treated with l-NAME, a significant
reduction in LCBF was measured only in the hypothalamus ( — 33%).
5 The cerebrovascular response to acute L-NAME is attenuated in spontaneously diabetic insulin-
dependent BB rats. This would be consistent with the endothelial dysfunction in cerebral vessels, known
to be associated with diabetes mellitus and it is possible that a loss of NO-induced dilator tone, amongst
other factors, may underlie the observed reductions of basal LCBF in these animals.
Keywords: Cerebral blood flow; diabetes mellitus; l-NAME; nitric oxide; nitric oxide synthase inhibition; quantitative
autoradiography
Introduction
Diabetes mellitus is a metabolic disorder associated with
functional and structural abnormalities in a variety of organs
and systems of the body. In the cardiovascular system, diabetes
is associated with the development of hypertension, accelerated
atherogenesis, thrombosis and ischaemia, which are associated
with both macro- and microvascular changes (Colwell, 1991).
These cardiovascular complications were thought to be largely
independent of the degree of diabetic control (Kannel &
McGee, 1979), suggesting that it was the disease process itself
which was responsible and not exposure to hyperglycaemia or
insulin treatment. However, more recent work (Reichard et al.,
1993) suggests a more complex causal relationship between the
disease process and therapeutic intervention.
Although the cerebral circulation has been found to be
subject to vascular pathology similar to that found in the
periphery (Aronson, 1973; Grunnet, 1963), the effects upon
cerebrovascular physiology were previously thought to be ra¬
ther subtle, and often went unrecognised. More recently
however, it has become apparent that neither the brain nor its
vasculature are spared from the effects of diabetic pathology
(Mooradian, 1988; McCall, 1992), and altered blood/brain
transport, cerebral blood flow, and brain metabolism, as well
as effects on neurones and glia, are all associated with the
disease process. Pathophysiological effects of the disease upon
the cerebral circulation are manifest in an impaired auto-
regulatory response to alterations in systemic blood pressure
(Kastrup et al., 1986), and altered CCL reactivity (Griffith et
al., 1987).
In the streptozotocin-induced animal model of diabetes
1 Author for correspondence.
there is clear evidence, from both in vitro and in situ (cranial
window) studies, of impaired cerebrovascular responsiveness
to a variety of vasoactive compounds including ADP (May-
han, 1989), 5-hydroxytryptamine (Rosenblum & Levasseur,
1984; Mayhan, 1989), /J-adrenoceptor agonists (Mayhan,
1994), and acetylcholine (Mayhan et al., 1991). Studies per¬
formed in vivo showed a reduced effect of muscarinic agonists
upon blood flow (Pelligrino et al., 1992). Interestingly, how¬
ever, the streptozotocin rat model does not appear to display
the same reduced cerebrovascular C02 reactivity found in
human subjects (Pelligrino & Albrecht, 1991). Further in vivo
studies of peripheral vascular beds in streptozotocin-treated
rats have revealed a complex endothelial dysfunction with the
pressor response to l-NAME being attenuated (Kiff et al.,
1991a) whilst vasodilator responses to acetylcholine remained
intact (Kiff et al., 1991b).
The BioBred (BB) rat strain provides a useful model for the
study of insulin-dependent diabetes mellitus (IDDM). The
involvement of genetic and immune aetiological factors in the
pathogenesis of the disease, together with the dependence on
exogenous insulin for prevention of ketoacidosis and the de¬
velopment of diabetic complications in a variety of organs
(Marliss et al., 1982), represent a condition more akin to the
human disease process than that afforded by models of drug-
induced diabetes (Eizirik et al., 1994). Pathological changes in
the retina, kidneys and peripheral nerves have been observed
as early as 3 weeks following the onset of diabetes (Baird,
1989).
The purpose of this study was to measure the local cerebral
blood flow (LCBF) in insulin-dependent diabetic BB rats to
determine whether the decreases in CBF evident in human
diabetes were paralleled in this animal model. Given the im¬
portance of NO in the regulation of normal cerebral blood
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flow (Faraci & Brian, 1994; Kimura et al., 1994) and the fact
that diabetes mellitus is associated with alterations of NO
production and release in the extracerebral tissues (Bucala et
al., 1991; Corbett et al., 1992; Cohen, 1993), diabetic rats were
challenged with the nitric oxide synthase (NOS) inhibitor NG-
nitro-l-arginine methyl ester (l-NAME), to assess the in¬




All rats were supplied from the British Diabetic Association
BB (Edinburgh) U.K. Resource Unit. The BB/E colony con¬
sists of two lines created by selectively breeding for and against
diabetes. In the high-incidence diabetes-prone (DP) main line,
the incidence of IDDM is 50-60%, and the age at onset of
diabetes is 96+ 18 days (mean + s.d.). In the diabetes-resistant
(DR) subline, the incidence of diabetes is < 1%.
All rats were maintained at 20°C on a 12 h light/dark cycle
and fed rat and mouse Number 1 Expanded Feed (Special Diet
Services, Witham, U.K.). Animals were weighed twice weekly
from 40 days of age. Failure to gain weight, or loss of weight,
was taken as an indication of the possible onset of diabetes,
and such rats were tested for glycosuria. If glycosuria was
detected, the blood glucose concentration was measured from
a sample obtained by tail-tipping. A blood glucose con¬
centration >18 mmol 1~1 is invariably associated with keto-
nuria, weight loss and the requirement for daily injection of
insulin to survive. These variables constituted our criteria for
classifying an animal as having IDDM.
A total of 16 adult male BB rats (weight: 348-495 g) were
used in this study from both the DP (n = 8) and DR (n = 8)
sublines. At the time of the study all rats in the DP group were
diabetic, and had been so for between 8 to 20 weeks. These
animals had been treated since the onset of diabetes with a
single daily subcutaneous injection of medium-acting insulin
(2.4-4.0 iu) given at 09 h 00 min each day. Experiments were
performed 4 h after the last insulin injection in the diabetic
animals. Animals in the DR group were age-matched to those
in DP group and served as controls for the effects of the disease
processes.
Measurement of local cerebral blood flow
On the day of the experiment the animals were anaesthetized
with halothane (1.5% in a gas mixture of 70% nitrous oxide
and 30% oxygen) and prepared for the measurement of LCBF
as described previously (Kelly et al., 1994). Following surgery,
general anaesthesia was withdrawn and 2 h allowed to elapse
before any further experimental manipulation.
Equal numbers of non-diabetic and diabetic rats were in¬
jected (i.v.) with either l-NAME (30 mg kg-1; n = 4 from each
group) or an equal volume of saline (1.0 ml; n = 4 from each
group) over 60 s via a femoral venous cannula. At this dose, l-
NAME reduces LCBF significantly by 15 min post-injection
and the effect is maintained stable for at least 3 h (Macrae et
al., 1993). The measurement of LCBF was started 20 min after
the injection of l-NAME or saline by the fully quantitative
[14C]-iodoantipyrine autoradiographic technique. The proto¬
cols were in complete accordance with the methodology as
originally published (Sakurada et al., 1978) and as described
previously from this laboratory (Kelly et al., 1994). Auto¬
radiographic images were analyzed by quantitative densito¬
metry relative to 14C-containing standards, and LCBF was
calculated by the appropriate operational equation for the
technique (Sakurada et al., 1978). Areas of interest were cho¬
sen to represent brain areas in the vascular territories of the
anterior, middle and posterior cerebral arteries. Arterial blood
pressure and rectal temperature were monitored continuously
in every animal throughout the experiments and heart rate was <
measured intermittently. Samples of arterial blood were with¬
drawn before and after l-NAME or saline injection, for the
measurement of pH, Pc02, Po2, plasma glucose and haema- t
tocrit.
Data (presented as mean+ s.e.mean) were analyzed by
Student's t test with Bonferroni correction applied to allow
multiple pair-wise comparisons between appropriate groups.
Acceptable levels of significance were set at P< 0.05.
Results
Physiological variables
Prior to the injection of either l-NAME or saline there were
no significant differences in blood gas tensions, pH, rectal
temperature or mean arterial blood pressure (MABP) be¬
tween non-diabetic and diabetic rats, although heart rate was
significantly lower (— 22%) in the diabetic group (Table 1).
Abnormally high base excess in the diabetic animals con¬
firmed the chronic metabolic disturbances of diabetes, but
prior to any drug treatment there were no significant differ¬
ences in either plasma glucose or body weight between un¬
treated non-diabetic and insulin-treated diabetic rats. There
was, however, considerable variation in plasma glucose in
both non-diabetic and diabetic rats (coefficient of varia¬
tion =58 and 71% respectively). Whilst this possibly indicates
a more variable glucose metabolism in the non-diabetic BB
subline than would normally be expected, it must be stressed
that plasma glucose in all animals was within the normal
physiological range (Table 1). Although there was a trend
towards increased haematocrit in diabetic rats, this was not
significant.
Following the injection of l-NAME, MABP increased to a
similar extent in both non-diabetic ( + 21%) and diabetic rats
Table 1 The effects of l-NAME upon physiological variables in non-diabetic and diabetic rats
Non-diabetic Diabetic
Pre l-NAME Post l-NAME Pre l-NAME Post l-NAME
pH 7.38 + 0.02 7.38 + 0.02 7.40+ 0.01 7.39 + 0.01
Pco2 (mmHg) 42.5 + 1.5 35.3 + 1.8 45.2+1.8 40.8 + 0.9
Pco2 (mmHg) 89.6 + 2.7 100.1 + 1.9 85.9 + 0.9 92.1+4.4
Base excess -0.13 + 0.7 — 3.1 ± 1 2.9 + 0.7 0.3 + 0.8
Haematocrit (%) 47.8 + 0.5 50.5+1.0 52.5+1.0 54.9+1.0
Plasma glucose (mmolF1) 15 + 4.5 14 + 5 9.5 + 3.5 7.5 + 3.5
Heart rate (beats min-1) 405 + 15 293 + 8# 315+15* 255+15
MABP (mmHg) 117 + 3 142 ± 2# 121 ±3 149 + 4#
Temperature (°C) 36.0 + 0.1 36.5 + 0.1 36.4 + 0.3 36.4 + 0.2
Data are presented as mean+ s.e.mean (n = 4 in each group). There were no differences in the values obtained from the saline-treated
animals (diabetic and non-diabetic) and those measured prior to injection of l-NAME. *Significant difference between diabetic and
non-diabetic animals; #significant difference between pre- and post l-NAME.
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( + 23%), but the heart rate was reduced significantly only in
the non-diabetic group ( — 28%) (Table 1). In diabetic rats,
where heart rate was already significantly lower prior to
treatment ( — 22% compared to non-diabetics), the effect of l-
NAME (—19%) was not significant. As a result, heart rates
were similar in the two l-NAME-treated groups (diabetic and
non-diabetic) following l-NAME (see Table 1).
Local cerebral blood flow
In saline-treated, diabetic rats, mean LCBF was reduced in all
13 brain areas when compared to non-diabetic controls (Table
2). However, the extent of these reductions in LCBF were re¬
gionally heterogenous, ranging from —8% in parietal cortex
(not significant) to —32% in piriform cortex (P<0.05). Using
the conservative statistics required for multiple comparisons,
the reductions were statistically significant in only five of the
areas examined, and these were predominantly sub-cortical
(Table 2). Taking each diabetic animal individually, there was
no correlation between the extent of LCBF reduction and ei¬
ther duration of diabetes or plasma glucose status at the time
of the experiment.
In keeping with previous observations, l-NAME treatment
produced reductions in LCBF throughout the brain in non-
diabetic animals (Table 2). Only in parietal (—10%) and cin-
gulate areas of cortex (—19%) and in nucleus accumbens
( — 21%) did the effects of l-NAME fail to reach statistical
significance. Elsewhere, significant (/><0.05) reductions in
LCBF were measured, ranging from —21% in the molecular
layer of the hippocampus to —44% in piriform cortex (Table
2). In contrast, l-NAME treatment had no significant effect
upon LCBF in diabetic rats, when compared to the appro¬
priate saline-treated (diabetic) group. The one exception to this
was the hypothalamus, where a significant ( — 33%) decrease in
LCBF was observed (Table 2). In contrast to the significant
differences in flow between the saline-treated non-diabetic and
diabetic groups, there were no significant differences in LCBF
between the groups treated with l-NAME (Table 2).
The cerebrovascular response to l-NAME will be influ¬
enced not only by the direct inhibition of NOS in the blood
vessels of the brain, but also indirectly via autoregulatory re¬
sponses to peripheral hypertension. Following l-NAME
Table 2 Local cerebral blood flow in diabetic and non-diabetic animals, treated with saline or l-NAME
Saline l-NAME
Non-diabetic Diabetic Non-diabetic Diabetic
Neocortex
Parietal 146 + 5 134+12 131+7 115 + 6
Cingulate 148 + 9 127+16 120 + 8 113 + 13
Occipital 133 + 2 99+11 83 + 9# 84+13
Piriform 111+6 76 + 6* 62 + 6# 66 + 6
Corpus callosum 39 + 2 32+1 27+1# 25 + 4
Basal ganglia
Striatum 125 + 5 87 + 3* 93 + 2# 84 + 9
Globus pallidus 73 + 1 54 + 3* 50 + 2# 47 + 5
Accumbens 124+10 107 + 6 98 + 4 89+10
Thalamus
Hypothalamus 95 + 3 80 + 6 59 + 5# 54 + 5#
Lateral geniculate 142 + 7 109 + 6* 84 + 2# 86+10
Hippocampus
CA 2,3 94 + 5 74 + 7 60 + 3# 66 + 9
Molecular layer 90 + 2 68 + 8 70+11# 61+6
Dentate gyrus 92 + 4 12 +A* 59 + 2# 67 + 10
Data are presented as mean local cerebral blood flow (ml lOOg 1 min ')±s.e.mean (n = 4 in each group). *Significant difference
between diabetic and non-diabetic animals; #significant difference between saline and l-NAME-treated animals.
Table 3 Cerebrovascular resistance in diabetic and non-diabetic animals, treated with saline or l-NAME
Non-diabetic Diabetic
Saline l-NAME % change Saline l-NAME % char,
Neocortex
Parietal 0.76 + 0.05 1.10 + 0.08# 45 0.84 + 0.08 1.32 + 0.10# 57
Cingulate 0.76 + 0.07 1.20+1.10# 58 0.90 + 0.12 1.37 + 0.16 52
Occipital 0.82 + 0.04 1.79 + 0.23# 118 1.15 + 0.15 1.93 + 0.37 67
Piriform 1.00 + 0.10 2.35 + 0.27# 135 1.46 + 0.15 2.33 + 0.30 60
Corpus callosum 2.86 + 0.13 5.34 + 0.26# 87 3.40 + 0.17 6.28 + 0.93 85
Basal ganglia
Striatum 0.88 + 0.05 1.53 + 0.05# 74 1.26 + 0.07* 1.84 + 0.22 46
Globus pallidus 1.51+0.07 2.84 + 0.12# 88 2.03 + 0.12* 3.33 + 0.30# 64
Accumbens 0.91+0.10 1.47 + 0.07# 62 1.03 + 0.06 1.76 + 0.24 71
Thalamus
Hypothalamus 1.16 + 0.07 2.49 + 0.24# 115 1.39 + 0.13 2.85 + 0.37# 105
Lateral geniculate 0.77 + 0.04 1.70+ 0.05# 121 1.05 + 0.05* 1.83 + 0.25 74
Hippocampus
CA 2,3 1.16 + 0.01 2.40 + 0.08# 107 1.52 + 0.15 2.42 + 0.39 59
Molecular layer 1.22 + 0.05 2.37 + 0.24# 94 1.68 + 0.23 2.36 + 0.52 40
Dentate gyrus 1.20 + 0.05 2.43 + 0.10# 103 1.52 + 0.10* 2.43 + 0.40 60
Cerebrovascular resistances were calculated by dividing mean arterial blood pressure (mmHg) by LCBF values (ml lOOg 'min-1) for
each individual animal and are presented as mean ±s.e.mean (n = 4 in each group). *Significant difference between diabetic and non-
diabetic animals; #significant difference between saline and l-NAME-treated animals.
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treatment, calculated mean vascular resistance values were
increased in all brain regions in both non-diabetic and diabetic
rats (Table 3). In non-diabetic rats, these increases in resistance
paralleled a decrease in LCBF in the majority of brain regions
(Table 2), but in diabetic rats, whilst there was only moderate
change in LCBF (with the exception of the hypothalamus),
ranging between —3% and —21% (Table 2), cerebrovascular
resistance increased by between 40 and 74% (Table 3). This
increased resistance, with no change in flow, is likely to be the
result of autoregulatory cerebrovascular constriction in re¬
sponse to peripheral hypertension.
Discussion
This is, to our knowledge, the first study of local cerebral blood
flow in sponanteously diabetic insulin-dependent BB rats. The
global tendency towards reduced cerebral blood flow which we
have observed in these animals parallels to some extent that
found originally in human diabetic patients (Kety et al., 1948),
but with the greater spatial resolution afforded by the use of
quantitative autoradiography in our studies, we have been able
to identify a degree of regional heterogeneity in the effects of
diabetes upon cerebral blood flow. Whether this apparent
differential susceptibility to the disease processes in different
parts of the cerebrovascular bed reflects regional variations in
vascular pathology, remains to be determined. Regional dif¬
ferences in LCBF have also been described recently in human
diabetics when compared to healthy control subjects (Grill et
al., 1990; Macleod et al., 1994). In these human studies a re¬
lative sparing of flow in fronto-parietal cortex and large de¬
creases in the caudate nucleus show remarkable similarities to
the results described here. However, even the most sophisti¬
cated imaging techniques currently availabe in man do not
have the spatial resolution of animal brain autoradiography,
nor can the experimental conditions be as rigorously con¬
trolled. It may, therefore, be impossible to find exact parallels
between the effects of diabetes upon LCBF described in this
study and those in diabetic humans.
A number of studies have examined cerebral blood flow in
untreated streptozotocin-induced diabetic rats, with varying
results (Duckrow et al., 1987; Harik & LaManna, 1988; Ja-
kobsen et al., 1990; Pelligrino & Albrecht, 1991). Although in
general terms reductions in LCBF were found when strepto-
zotocin diabetic rats were compared to controls, the results
were often too variable to reach statistical significance, and no
clear consensus emerges on the susceptibility of particular re¬
gions of the brain to the condition. Interestingly however, if
the rats were treated with insulin to normalize glycaemia at the
time of the measurement, any differences in LCBF between
diabetics and controls were eliminated (Pelligrino & Albrecht,
1991). A similar effect has also been described in peripheral
nerve blood flow (Kihara & Low, 1995). In contrast, in the
present study of spontaneously diabetic, insulin-dependent
rats, significant decreases in LCBF were evident despite the
fact that there was no difference in plasma glucose levels be¬
tween diabetic and non-diabetic animals at the time of the
study. This is not to say, however, that the BB rats have not
experienced periods of hyperglycaemia. The measurement of
LCBF in the diabetic animals was conducted around 4 h after
the injection (s.c.) of medium-acting insulin, and the evidence
from the physiological data suggests that the hormone was
acting to normalize plasma glucose. Over a longer time scale,
plasma glucose concentrations in BB/E rats are quite unstable
and fluctuate in the course of any 24 h cycle between 3 and
22 mmol 1_I. In a parallel study using groups of rats from the
same colony, we have found (unpublished observations) that
glycosylated haemoglobin (HbA,) values were elevated
(7.46 + 0.87%) compared to non-diabetic controls
(3.13 + 0.24%). There is no doubt, therefore, that our diabetic
animals are hyperglycaemic for a large part of the time, al¬
though maximum plasma glucose levels are unlikely to reach
those found in streptozotocin-treated rats.
In the present study there appeared to be an attenuation of
the effects of l-NAME upon LCBF in diabetic rats. It is
tempting to speculate that the decreases in LCBF apparent in
saline-treated diabetics may be the result of reduced dilatator
influence of endogenous NO in determining basal cerebral
blood flow, possibly mediated via disinhibition of endothelin
release (Gardiner et al., 1995; Kelly et al., 1995; Richard et al.,
1995). There is certainly evidence from the peripheral circula¬
tion that endothelial NO systems are disrupted in diabetes
(Cohen, 1993; Poston & Taylor, 1995), although there is clear
evidence of variation in the defect between different vascular
beds (Kiff et al., 1991a). In the cerebral circulation the data are
equally complex. Indirect evidence for reduced NO activity
comes from studies of streptozotocin-induced diabetic rats
where a significant, but regionally variable, impairment of
endothelium-dependent vascular relaxation was observed fol¬
lowing injection of a muscarinic receptor agonist. More direct
evidence of an impairment of cerebrovascular NO systems in
this diabetic model are however lacking, in that the effects of l- 1
NAME upon cerebral blood flow (Pelligrino et al., 1992) and
pial vessel diameter (Mayhan et al., 1991) were reported to be
similar in both non-diabetic and diabetic rats. Whilst we si- i
milarly found no difference in LCBF values between diabetic
and non-diabetic rats following l-NAME, with the exception
of the hypothalamus, this did not represent a significant de¬
crease in flow from saline-treated diabetic rats in which blood
flow was already depressed. This we interpret as an attenuation
of the cerebrovascular response to l-NAME.
It is interesting that whilst we found reduced basal LCBF
and an attenuated cerebrovascular response to l-NAME in
our diabetic rats, the saline-treated diabetic animals were not
hypertensive and l-NAME-treated diabetics displayed the
normal blood pressure response, i.e. hypertension. This might
suggest that the disease process is more pronounced in the
cerebral circulation than it is in other vascular beds. However,
the aortae of diabetic BB rats do develop morphological de¬
fects in endothelial cells and abnormal endothelium-dependent
responses to acetylcholine (Meraji et al., 1987). Moreover, the
hypertensive response to chronic L-NAME administration is
attenuated in diabetic BB/E rats (Lindsay et al., 1995). Thus it
is possible that the mechanisms of NO dysfunction associated
with diabetes develop differentially in different vascular beds.
Although there is evidence that the effectiveness of en¬
dogenous NO in influencing basal vascular tone may be altered
by diabetes (Bucala & Cerami, 1992; Wascher et al., 1994), it is
not clear whether this represents a change in synthesis and
release, or in activity. There is evidence for reduced levels of l-
arginine in the plasma of diabetic rats (Mans et al., 1987)
which might reduce NO synthesis, although there is also in
vitro evidence that hyperglycaemia may actually increase NO
production (Wascher et al., 1994). However, in vivo, elevated
intracellular glucose is converted to sorbitol via the polyol ,
pathway in the endothelium with resultant depletion of cellular
NADPH and reduced NOS activity (Cohen, 1993). The same
pathway increases the formation of free radicals that inactivate
endogenous NO (Cameron & Cotter, 1995). Finally, increased
formation of subendothelial advanced glycosylation end pro¬
ducts by elevated glucose may quench and inactivate NO
(Bucala et al., 1991; Cohen, 1993).
Although hyperglycaemia is believed to be an important
factor contributing to vascular dysfunction associated with
diabetes, and would certainly account for dysfunction in en¬
dothelial NO systems (Cohen, 1993; Poston & Taylor, 1995),
other mechanisms may also be involved. Rheological problems
such as an increase in plasma viscosity (Barnes et al., 1977) and
increased adhesion of platelets to endothelial cells (MacMillan
et al., 1978; Wautier et al., 1981) may contribute to cere¬
brovascular dysfunction in diabetes, and some aspects of dia¬
betic vascular pathology, notably arteriosclerosis (Grunnet,
1963), may be related to the hypertension often associated with
diabetes. Hypertension develops only at a later stage in BB rats
and is not therefore an issue in these studies, but in a parallel
study using groups of rats from the same colony, we have
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indeed found increased blood viscosity in BB diabetic animals.
However not only is the significance of blood viscosity in de¬
termining LCBF contested (Brown & Marshall, 1985;
Waschke et al., 1994), it is also unlikely that increased viscosity
can explain the heterogeneity in the reduction of blood flow
which we observed.
There is increasing evidence that diabetes adversely affects
the outcome in experimental models of cerebral ischaemia
(Nedergaard & Diemer, 1987; Sutherland et al., 1992) and in
human occlusive stroke (Jorgensen et al., 1994). Although the
crucial role of elevated plasma glucose in situations of cerebral
ischaemia cannot be over-emphasized (Smith et al., 1986),
evidence from the present study that there may also be an
already perturbed basal blood flow and reduced endothelial
NO activity, could represent an important additional factor
contributing to the morbidity of stroke in diabetic patients.
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